QUARTERLY REPORT

H1 FY2024 — Results booklet

H1 FY2024PDF · 105 pages3.2 MB
and cash dividend declaration
for the six months ended 31 December 2023
Unaudited
Interim Results

-- 1 of 105 --

DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
CONTENTS
A. Notes to the summarised financial statements
15 	A.1. Segment information
24 	A.2. Normalised profit from operations
25 	A.3. Earnings, headline earnings and normalised headline earnings
27 	A.4. Revenue from non-insurance activities
27 	A.5. Borrowings at amortised cost
29 	A.6. Fair value hierarchy of financial instruments
B. Other significant items in these results
33 	B.1. Exchange rates to South African Rand used in the preparation of
these results
33 	B.2. Capital management, financial leverage ratio and covenants
35 	B.3. Impact of and volatility in long-term interest rates in
the SA and UK markets
35 	B.4. Change in hedge strategy – VitalityLife business
36 	B.5. Consolidation of Discovery Unit Trusts
36 	B.6. Material transactions with related parties
36 	B.7. Major customers and other Discovery entities not part
of Discovery Group
37 	B.8. Changes in directorate
37 	B.9. Dividend declaration in respect of the six months ended
31 December 2023
C. 	Accounting policies
39 	C.1. 	New Accounting Standards and amendments to published
Accounting Standards not yet effective
39 	C.2. 	Normalised headline earnings
39 	C.3. 	Basis of preparation
01 	Results commentary
08 	Group statement of financial position
09 	Group income statement
10 	Group statement of other comprehensive income
11 	Group statement of cash flows
12 	Group statement of changes in equity
D. 	New standards and interpretations
and restatements
41 	D.1.1. IFRS 17 Insurance Contracts (IFRS 17)
45 	D.1.2. Restatement as a result of prior period errors
45 	D.1.3. Changes in presentation of specified line items
on the statement of financial position
46 	D.1.4. Reconciliation of restated Group statement
of financial position
48 	D.2. 	IFRS 17 Accounting policies
58 	D.3. 	Critical estimates and judgements
60 	D.4. 	Insurance and reinsurance contract notes
E. 	Review opinion
110 	External review and comparative information
Embedded value statement
113 	Table 1: Group embedded value
115 	Table 2: Value of in-force covered business
116 	Table 3: Group embedded value earnings
116 	Table 4: Components of Group embedded value earnings
117 	Table 5: Experience variances
118 	Table 6: Methodology and assumption changes
119 	Table 7: Embedded value of new business
120 	Table 8: Embedded value economic assumptions
122 	Table 9: Embedded value sensitivity
122 	Table 10: Value of new business sensitivity
Annexure A
125 	New business annualised premium income
126 	Income from non-insurance business lines
ibc 	Administration

-- 2 of 105 --

1
Results commentary
GROUP OVERVIEW AND SALIENT GROUP RESULTS
The period under review was characterised by continued macroeconomic complexities. Global inflation rates declined from the prior-
period highs, but remained elevated, and cumulative interest rate increases heightened consumer pressures in many regions constraining
economic growth. Many markets in Asia experienced post-COVID-19 relief, however, China continued to face significant macroeconomic
and growth constraints.
Discovery Group delivered a robust performance for the period ended 31 December 2023, demonstrating
resilience and strong underlying growth dynamics in a complex operating environment. At a Group level,
normalised operating profit increased 13% to R5 622 million; headline earnings were largely unchanged at
R3 260 million; normalised headline earnings increased 11% to R3 320 million; and new business annual
premium income (API) increased 28% to R14 197 million.
Salient Group results
for the period ended 31 December 2023 (IFRS 17 reporting)
Unit
December
2023
December
2022 	% Change
Group earnings
Normalised profit from operations 	R million 	5 622 	4 973 	13%
Normalised headline earnings 	R million 	3 320 	3 004 	11%
Headline earnings 	R million 	3 260 	3 276 	0%
Basic earnings per share 	Cents 	492.9 	487.9 	1%
Basic headline earnings per share 	Cents 	493.8 	498.4 	-1%
Basic normalised headline earnings per share 	Cents 	502.8 	457.0 	10%
Group net asset value and embedded value
Net asset value 	R million 	52 206 	43 524 	20%
Embedded value 	R million 	103 480 	92 459 	12%
Annualised RoEV 	% 	12.1% 	14.4%
Basic embedded value per share 	R 	156.29 	140.43 	11%
Financial leverage and capital management
Financial leverage ratio (FLR) 1 	% 	19.7% 	22.1%
Shareholder free cash increase, before ordinary dividend 	R million 	350 	(62)
Dividend per share 	Cents 	65 	n/a
Business volume
Total income from non-insurance lines2 	R million 	2 942 	2 554 	15%
New business annualised premium income 	R million 	14 197 	11 106 	28%
1 FLR allowing for the inclusion of 50% of the contractual service margin (CSM) net of reinsurance and net of tax.
2 Not included in new business API.
Delivering strong
growth, cash
generation and capital
resilience across all
three composites.
01
The Group’s focus in the period centred on the following:
Establishing platforms to
accelerate future growth
by scaling Discovery Bank
and Vitality Global
through evolving the Vitality
Shared-value Insurance model.
Transitioning to
the new IFRS 17
Insurance Contracts
accounting standard.
02 	03

-- 3 of 105 --

2	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Results commentary continued
01 Delivering strong growth, cash generation and capital resilience across all
three composites
The Group generated normalised operating profit growth of 13% with positive contributions from each composite, as South Africa (SA)
increased 9%, United Kingdom (UK) increased 13%, and Vitality Global (VG) increased 71%. The UK and VG results benefitted from a weaker
rand compared with the prior period. New business API for the Group increased by 28% as a result of robust growth across the composites,
with Discovery Health’s new business augmented by the successful take-on of Sasolmed closed medical scheme. Excluding Discovery Health,
new business for the Group increased 11%, with particularly pleasing trends for Discovery Individual Life business, Ping An Health Insurance
and VitalityHealth; while VitalityLife’s growth was modest in sterling and Group Life declined.
Normalised headline earnings grew 11% while headline earnings were largely unchanged. The difference is explained by the considerable
prior period fair value gain from the UK interest rate swaption. The swaption was realised towards the end of the prior financial year, with
no profit impact in the current period. Consistent with prior reporting, headline earnings are normalised for this.
The Group demonstrated continued financial resilience over the period. Organic cash generation increased with cash conversion now at 66%
of after-tax normalised operating profit and central liquidity remained strong. The financial leverage ratio (FLR) improved to 19.7% and
capital ratios remained strong across each business.
The Group’s embedded value increased to R103.5 billion, which represents an 12.1% annualised return on embedded value (RoEV), with a
positive contribution from experience variances over the period, reflecting the positive dynamics of the Vitality Shared-value Insurance model.
02 Establishing platforms to accelerate future growth by scaling Discovery Bank and
Vitality Global through evolving the Vitality Shared-value Insurance model
The strong operating performance reflects the continued investment and focus on delivering growth and ensuring financial discipline. This
was enabled through diligent capital allocation, growing cash generation, and balance sheet strength. Growth in core businesses remained
robust over the period, and the focused investment in Discovery Bank and Vitality Global manifested in exceptional performance, with these
businesses being positioned as strong platforms for continued growth.
Discovery Bank achieved its stated target of monthly operational break-even before acquisition costs during the period, ahead of plan, and
is growing rapidly through the acquisition of quality clients on a scalable platform. The Bank’s rapid scaling and exceptional customer
engagement position it to play a central role in advancing the SA Composite through integrated ecosystems.
Vitality Global delivered exceptional growth over the period. Ping An Health Insurance has emerged as a specialist health insurer of scale in
China, delivering high-quality operating metrics, with a robust balance sheet. Vitality Network’s strong growth demonstrates the global
adoption of the Vitality Shared-value Insurance model with key partners. The results also demonstrate the emerging operational leverage
inherent within the business, with the evolving model creating opportunities for further growth and even greater impact and global
relevance.
Summary of the earnings and new business performance by composite:
Normalised
profit from
operations
(Current period,
in ZAR million)
% change
(Current
period vs
prior period)
New
business API
(Current
period, in
ZAR million)
% change
(Current
period vs
prior period)
Discovery Health 	1 874 	+7% 	6 835 	+52%
Discovery Life 	2 267 	+6% 	1 519 	+2%
Discovery Invest 	620 	+11% 	1 629 	+8%
Discovery Insure 	20 	>100% 	666 	+8%
Discovery Bank 	(339) 	-15%
Other initiatives and central costs1 	(87) 	12% 	451 	-13%
SA Composite1 	4 355 	+9% 	11 100 	+29%
VitalityHealth 	527 	(20%) 	1 135 	+28%
VitalityLife 	390 	97% 	935 	+17%
Closure costs of VitalityInvest 	(57) 	(48%)
Other initiatives and central costs 	(48) 	85%
UK Composite 	812 	13% 	2 070 	+22%
Vitality Network 	296 	+49%
VHI – Ping An Health Insurance (PAHI) 	344 	>100% 	1 027 	+28%
VHI – Other 	(173) 	>100%
Other initiatives and central costs 	(12) 	+33%
Vitality Global 	455 	+71%
Normalised profit from operations 	5 622 	13%
Normalised headline earnings 	3 320 	11%
Core new business API 	14 197 	28%
1 FLR allowing for the inclusion of 50% of the contractual service margin (CSM) net of reinsurance and net of tax, consistent with key credit rating agencies.

-- 4 of 105 --

3
BUSINESS-SPECIFIC PERFORMANCE
South Africa, including new initiatives
The SA Composite’s normalised operating profit increased by 9% to R4 355 million and new business by 29% to R11 100 million. Discovery
Bank in particular continued to show excellent progress across all metrics, with the acquisition of quality clients accelerating, and the Bank
reaching monthly operational break-even before acquisition costs during the period. Discovery Health’s growth demonstrates the
consistent performance across the business with new business increasing 52%, including the take-on of Sasolmed closed medical scheme.
Discovery Individual Life delivered strong earnings growth with improving new business margins, while Group Life declined from the prior
year’s exceptional performance. Discovery Invest’s performance was robust with revenues and profit benefitting from higher market levels.
Discovery Insure recorded pleasing revenue growth, however, its profit recovery was constrained by two severe weather events.
Unit
December
2023
December
2022 	% Change
Net non-interest revenue (NIR) 	R million 	567 	438 	29%
Net interest income (NII) 	R million 	366 	268 	37%
Operating loss before new business acquisition costs 	R million 	154 	256 	(40%)
Normalised loss from operations 	R million 	339 	398 	(15%)
Retail deposits 	R billion 	16.7 	12.7 	31%
Advances 	R billion 	5.7 	4.8 	19%
Average interest-earnings assets (IEA) 	R billion 	15 811 	12 585 	26%
Credit loss ratio (CLR) 	% 	3.7 	2.1 	74%
Number of accounts 	Number 	1 933 839 	1 312 970 	47%
Number of clients 	Number 	825 069 	581 457 	42%
Discovery Bank’s (DB) operating loss, before new business acquisition costs, improved by 40%, and the overall loss was 15% better than
the prior year. Growth remains high with DB exceeding 825,000 clients in December 2023 and the total client base growing by 42%
compared with the prior year. This momentum is indicative of DB’s accelerated pace towards achieving its ambition of one million
clients by 2026, which the Bank is well ahead of target to achieve.
In light of challenging macroeconomic conditions, DB has remained focused on high-quality growth with the Bank’s shared-value
behavioural banking model proving its efficacy. Deposits grew by 31%, reflecting that clients are increasingly using Discovery Bank as
their primary account. Advances have grown steadily by 19% since December 2022, with the Bank maintaining materially lower credit
loss ratios than the market, for equivalent products. Average interest-earnings assets increased by 26% and the net interest margin
increased by 7% over the period, while NII grew by 37%.
Non-interest revenue continued to grow steadily, by 29% year-on-year, driven by the growth in interchange income and fee income per
client. In line with the Bank’s growth trajectory, client engagement levels grew, with a 56% increase in payment volumes and a 37%
increase in spend values in December 2023 compared to the prior year.
DB expanded its lending suite by launching a Revolving Credit Facility in December 2023, which offers clients more flexibility. A
revolutionary new home loan proposition will imminently be launched to the market, featuring a unique Shared-value interest rate
reduction mechanism. Discovery Bank clients have c. R280 billion in existing home loan balances, which DB is well-positioned to cater
for. The Bank is well-funded and positioned to continue to prudently grow advances in these target segments.
Discovery Bank
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	R million 	1 874 	1 748 	7%
New business API 	R million 	6 835 	4 487 	52%
Revenue 	R million 	5 334 	4 924 	8%
Non-scheme revenue as % of total revenue 	% 	14.7% 	14.4% 	2%
Lives under administration 	R billion 	3.84 	3.81 	1%
* Including VHI Africa.
Discovery Health (DH) maintained its solid revenue and profit delivery record, notwithstanding further investment in enhancing systems
infrastructure and the digital health ecosystem, including the new Discovery Health app. The successful take-on of Sasolmed closed
medical scheme administration significantly increased new business API, with c. 78,000 lives to be added.
Non-medical scheme products – Flexicare, Gap Cover and Healthy Company – continued to perform well with total non-scheme
revenue now representing almost 15% of total DH revenue, validating the strategy to grow revenue and profits through adjacent
opportunities. DH has fully incorporated Vitality Health International (VHI) Africa, which will continue to support the corporate
membership base of DH’s South African clients and more broadly.
Discovery Health Medical Scheme (DHMS) remains resilient, maintaining membership levels despite a relatively flat open medical
scheme market and challenging macroeconomic environment. DHMS maintains its market share of 57.8% in the open medical scheme
market and solvency remains strong at 30.6%, significantly higher than the 25% regulatory requirement.
Discovery Health*

-- 5 of 105 --

4	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Results commentary continued
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	R million 	2 267 	2 145 	6%
New business API 	R million 	1 519 	1 485 	2%
Premium income 	R million 	18 211 	16 824 	8%
Solvency ratio1 	% 	180% 	177%
RoEV (annualised)1 	R million 	11.9% 	13.7%
Total VNB margin 	% 	4.3% 	4.5%
1 Including Invest.
Discovery Individual Life delivered 12% earnings growth and 7% new business growth for the period. The growth rates were diluted by
a reduction in Group Life, following an exceptional result in the prior period. Individual life claims experience improved significantly
over the period, being offset by an elevated claims experience in Group Life. The improvement in Discovery Individual Life earnings was
driven by strong underlying premium growth, improving claims experience and higher interest income.
Lapse experience remained ahead of expectation, but policy alterations were negatively impacted by consumer pressure due to
elevated levels of inflation and interest rates. Overall non-economic experience variances were positive and the embedded value for
Discovery Life (including Invest) delivered an annualised RoEV of 11.9%, despite negative economic variances from higher real yields.
The VNB margin for Discovery Individual Life has shown a significant increase to 5.6% at December 2023, primarily due to efficient
expense controls and improved business mix over the last six months. Discovery Life maintained its leading position in the affluent
retail protection market with an increase in market share to 27.5% for the 12 months to December 2023, with growth across all key
retail distribution channels. The strong improvement in the Discovery Individual Life VNB margin was partially offset by weaker
performance in Group Life, due to lower new business volumes versus the prior period.
Discovery Life’s resilience is demonstrated by its strong solvency and liquidity positions, with a solvency ratio of 180% and liquidity
coverage significantly above 100%. Cash flow for Discovery Life (including Invest) was strong at R771 million, with the cash conversion
ratio in excess of 35%.
Discovery Life
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	R million 	620 	561 	11%
Assets under administration 	R billion 	144.8 	130.8 	11%
Assets under management 	R billion 	99.0 	88.2 	12%
% linked assets in Discovery funds 	% 	80% 	81% 	(0.6)%
Net client cash flows 	R billion 	1.1 	2.9 	(62)%
New business API 	R million 	1 629 	1 505 	8%
Fee income 	R million 	1 375 	1 194 	15%
Discovery Invest’s normalised operating profit increased 11%, following growth in underlying assets. Assets under management ended
the period 12% higher, driven largely by positive market performance in the first half of the 2023 calendar year. Average assets under
administration were 10.7% higher than the prior year, lifting asset-based revenues. New business improved by 8%, driven by higher
sales of guaranteed endowments and linked investment business. Net flows were, however, impacted by higher maturities on
guaranteed endowment plans.
Discovery Invest
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	R million 	20 	8 	>100%
Personal lines 	R million 	2 	25 	-92%
Equity accounted profits (/losses) 	R million 	18 	(17) 	n/a
Operating margin Personal lines 	% 	0.1% 	0.9%
New business API Personal lines 	R million 	666 	616 	8%
Gross written premiums 	R million 	2 804 	2 579 	9%
Discovery Insure (DI)’s personal lines business recorded pleasing revenue growth and continued its efforts to improve the operating
margin, with various initiatives put in place to reduce claims costs and operating expenses. Claims due to loadshedding were
successfully brought under control through various actions and the increased severity of vehicle thefts was managed using a
combination of risk-based pricing, cover, and tracking device initiatives. However, the business faced unprecedented weather events
with floods in the Western Cape in September 2023 and severe hailstorms in Gauteng in November 2023, resulting in a catastrophic event.
Discovery Insure

-- 6 of 105 --

5
United Kingdom, including new initiatives
The UK Composite‘s normalised operating profit decreased by 2% to £34.7 million (increased 13% to R812 million). Earned premiums
increased by 11% year-on-year to £536.8 million (up 27% to R12.6 billion), and total lives insured increased by 5% to 1.83 million. New
business API increased 6% to £88 million (22% to R2 070 million). Solvency cover remains strong and was positively impacted by the risk margin
reforms passed in UK.
The UK Composite is well-positioned with the now completed closure of VitalityInvest and the run-down of VitalityCar progressing ahead of
plan. The business continues to focus on actions that position it for strong sustainable growth in the core health and life market, without
recourse to funding from the Group, with VitalityLife now fully self-funding.
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	GBP million 	22.5 	32.3 	(30%)
R million 	527 	658 	(20%)
Earned premiums 	GBP million 	338.6 	304.4 	11%
R million 	7 933 	6 204 	28%
New business API 	GBP million 	48.4 	43.7 	11%
R million 	1 135 	890 	28%
Lives covered 	Number 	989 492 	903 404 	10%
VitalityHealth (VH) experienced robust new business growth given increased demand for private medical insurance due to backlogs in
the National Health Service (NHS). However, there was a concomitant increase in claims experience due to a change in claim patterns
in respect of primary care demand, which impacted profit. Industry claims saw a sharp increase following an extended period of
reduced utilisation, caused by the COVID-19 pandemic. Pressure in the NHS resulted in challenges in accessing care and treatment as
NHS waiting times reached an all-time high, driving increased utilisation of private healthcare. VH claims authorisations per 1,000 lives
per month, which are strongly correlated to NHS waiting times, increased materially, largely due to higher primary care-related
authorisations. Increased utilisation was exacerbated by elevated medical and general inflation.
Management has taken various corrective actions, which include the implementation of pricing increases in line with the market.
Emerging earned premiums are expected to offset the claims increase going forward, however, these take time to come through since
increases are applied at policy anniversary. Alongside this, VH has continued to invest in its healthcare risk management capabilities
resulting in lower costs per authorisation.
Excluding claims, performance across key metrics was strong. Lives covered increased by 10% and earned premiums grew by 11%,
reflecting the strong new business and low lapse rates. Retention rates were strong, despite the cost-of-living crisis and higher renewal
premium increases. VH continues to prioritise prevention through the Vitality programme, while investing in expansive primary care
assets and digital servicing, to achieve cost efficiencies. The business is well-positioned to deliver sustainable growth going forward.
Vitality Health
Unit
December
2023
December
2022 	% Change
Normalised profit from operations 	GBP million 	16.6 	9.7 	71%
R million 	390 	198 	97%
Earned premium 	GBP million 	196.6 	178.1 	10%
R million 	4 607 	3 647 	26%
New business API 	GBP million 	39.9 	39.3 	2%
R million 	935 	801 	17%
Lives covered 	Number 	782 296 	735 202 	6%
VNB margin 	% 	(2.8%) 	1.4% 	n/a
VitalityLife’s (VL) normalised operating profit grew by 71%. Earnings were boosted by one-off cashflow variances and increased
investment income, in particular on the Prudential Assurance Company (PAC) book, given significantly higher UK interest rates.
New business grew modestly in a contracting UK market, with the business focusing on the quality of the portfolio through an improved
business mix and an increase in the proportion of index-linked policies. Higher long-term interest rates and expense inflation negatively
impacted new business margins. However, the business benefitted from GBP 13.8 million higher indexation on existing premiums given
elevated inflation rates. This value is presented in other comprehensive income (OCI) and will emerge as profit in the future.
Underlying business performance was robust despite a challenging macroeconomic backdrop, with positive lapse and claims
experience reflecting the continued engagement in Vitality – driving positive actuarial dynamics. Lives covered increased by 6%, while
earned premiums increased by 10%, highlighting the strong retention performance and high indexation increases.
Vitality Life

-- 7 of 105 --

6	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Results commentary continued
Vitality Global, including new initiatives
Vitality Global (VG) includes Vitality Network (VN), as well as Ping An Health Insurance (PAHI) within Vitality Health International (VHI).
VG increased operating profits by 55% to US$24.4 million (71% to R455 million).
Unit
December
2023
December
2022 	% Change
Revenue1 	US$ million 	50.3 	43.4 	16%
R million 	942 	754 	25%
Normalised profit from operations 	US$ million 	15.8 	11.5 	37%
R million 	296 	199 	49%
Integrated API by insurance partners 	US$ million 	807 	696 	16%
R billion 	15.1 	12.1 	25%
Number of lives: 	Million 	4.3 	3.4 	28%
1 Includes VN solutions revenue.
VN grew normalised operating profit 37% to US$15.8 million, following robust revenue and profit growth, with margin expansion. Strong
sales, membership, and revenue growth in Asia drove a 16% growth in total revenues, despite continued US dollar strength relative to
many Asian currencies, in particular relative to the yen. Revenues remain diversified across emerging and developed market currencies.
Total membership growth of 28%, driven largely by sales and growth in existing markets, demonstrates the expanding global relevance
of the Vitality Shared-value Insurance model. This reporting period also saw strong growth in India, through Tata AIA Vitality, growing
rapidly to over 290,000 members as at December 2023.
The business is appropriately scaled for further growth and the capital investment into the V1 Platform has now peaked. The profit
margin, now above 30%, is expected to continue to expand through continued revenue growth and a flat US dollar cost base, given the
cost bias to South African rand.
Vitality Network
Unit
December
2023
December
2022 	% Change
PAHI (25%), after Discovery’s costs 	R million 	344 	85 	305%
PAHI (25%), after Discovery’s costs 	US$ million 	18.4 	5.2 	254%
Other VHI 	US$ million 	(9.2) 	(0.5) 	1740%
Normalised operating profit-total 	US$ million 	9.2 	4.7 	96%
PAHI
New business PAHI own licence (100%) 	RMB million 	1 591 	1 298 	23%
New business PAHI Reinsurance 	RMB million 	173 	157 	11%
New business PAHI total (100%) 	RMB million 	1 764 	1 455 	21%
Written premium-own licence 	RMB million 	6 535 	5 603 	17%
Written premium-reinsurance 	RMB million 	2 479 	2 603 	-5%
Total written premium (100%) 	RMB million 	9 014 	8 206 	10%
Earned premiums – Total 	RMB million 	7 524 	6 623 	14%
Lives-own licence 	Million 	26.2 	19.6 	34%
Lives-reinsurance 	Million 	6.1 	8.6 	(29%)
Total lives 	Million 	32.3 	28.0 	15%
PAHI profit before income and gains (100%) 	RMB million 	357 	118 	203%
PAHI investment income and gains (100%) 	RMB million 	202 	139 	45%
PAHI pre-tax profit (100%) 	RMB million 	559 	257 	117%
VHI’s profit increased 96% to US$9.2 million in the period, driven by the Group’s share of PAHI’s after-tax operating profit, less
Discovery’s costs, increasing 254% to US$18.4 million. PAHI delivered an excellent performance in a complex operating environment in
China, with continued strong operating margins and consistently superior premium income growth compared to the industry. The
effective tax rate on net investment income benefitted significantly from higher dividend income over the period. PAHI has maintained
a robust balance sheet with a comprehensive solvency ratio of 306% driving increased investment income through a conservative
investment strategy.
New business on the PAHI insurance licence increased by 23%, propelled by a substantial rise in new business through non-Ping An
Life channels and a market shift towards higher-end products. Total written premiums increased by 10%, with premiums written on the
PAHI licence increasing by 17%, given the gradual run-down of Ping An Life’s business reinsured by PAHI, which was anticipated. Over
the calendar year 2023, growth was just under 10 percentage points ahead of the market growth. This has been driven by an uptick in
new business over the reporting period, as well as continued improvements to retention.
VHI is leveraging the deep data and unique assets of Discovery Group to take advantage of the rapidly evolving US market. The business
is doing this by investing in the technology and capabilities of Vitality USA and is showing early signs of success. Amplify Health has
made continued progress in the build of four solutions, with three key products already at the deployment stage with AIA markets. The
sales traction has increased, with a pipeline emerging in AIA markets as well as with third-party clients in the region. Quantium Health
continues to focus on seeking opportunities outside of its core market in Australia with some traction being shown in the UK and US.
Vitality Health International

-- 8 of 105 --

7
03 	Transitioning to the new IFRS 17 Insurance Contracts accounting standard
Earnings for the period are reported under the new IFRS 17 Insurance Contracts accounting standard for the first time and the earnings for
the prior period have been restated. At the Group’s June 2023 financial year results announcement, the Group highlighted that the transition
to IFRS 17 would result in a reduction in shareholder equity, with a resulting increase in the contractual service margin (CSM), which should
be seen as a store of value to be released as future profit. As such, the transition would not have any material impact on the Group’s
underlying economic value, solvency levels or cash flows, but would affect its incidence of profit recognition.
The restated normalised profit from operations under IFRS 17 for the prior period to 31 December 2022 was 16% lower than under the
previously disclosed IFRS 4 Insurance Contracts accounting standard. The new IFRS 17 reporting disclosures are detailed in this
announcement.
PROSPECTS AND DIVIDEND
Discovery’s growth strategy is based on the efficacy, repeatability and scalability of its Vitality Shared-value Insurance model through organic
growth and global partnerships. The performance during the period has enhanced the Group’s confidence in this strategy. In addition to the
robust growth expected from its core operations, Discovery has established strong platforms for growth after periods of investment, in
particular, Discovery Bank and Vitality Global. These are expected to deliver strong revenue growth and operational leverage, supporting
strong earnings growth and cash generation for the Group.
At the Group’s June 2023 financial year results announcement, Discovery described its dividend policy under IFRS 17. The annual ordinary
dividend is expected to be covered approximately five times by normalised headline earnings, with interim ordinary dividends expected to
be paid in the range of 30%-40% of the expected total annual ordinary dividend, with the remainder of the dividend to be paid as a final
dividend. The Group has declared its interim ordinary dividends for period at 65 cents per share.
NOTES TO ANALYSTS
Any forecast financial information contained in this announcement has not been reviewed or reported on by the Company’s external auditors.
Discovery has published supplemental unaudited information on the website. For this and other results information, visit
https://www.discovery.co.za/corporate/financial-results and go to Financial and annual reports.
On behalf of the Board
ME Tucker 	A Gore
Chairperson 	Group Chief Executive
Sandton
19 March 2024

-- 9 of 105 --

8	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Group statement of financial position
at 31 December 2023
R million 	Notes
Group
December
2023
Unaudited
Restated 1
Group
June 2023
Unaudited
Restated 1
Group
1 July 2022
Unaudited
Assets
Goodwill 	5 353 	5 406 	4 912
Intangible assets 	7 094 	7 064 	6 584
Property and equipment 	3 918 	3 910 	3 811
Assets arising from insurance contracts issued 	D.4.1. 	37 791 	32 914 	30 863
Assets arising from reinsurance contracts held 	D.4.1. 	791 	604 	873
Deferred tax asset 	5 359 	6 320 	5 688
Assets arising from contracts with customers 	2 473 	2 221 	1 709
Investment in equity-accounted investees 	7 867 	7 398 	6 338
Financial assets
– Loans and advances to customers at amortised cost 	5 219 	4 702 	3 944
– Investments at amortised cost 	10 257 	9 910 	7 161
– Investments at fair value through profit or loss 	155 172 	155 426 	141 494
– Derivative financial instruments at fair value through profit or loss 	157 	119 	276
Contract receivables and other receivables 	5 755 	5 684 	5 223
Non-current assets held for sale 	– 	– 	171
Current tax asset 	211 	41 	220
Cash and cash equivalents 	14 507 	16 260 	13 787
TOTAL ASSETS 	261 924 	257 979 	233 054
Equity
Capital and reserves
Ordinary share capital and share premium 	10 794 	10 351 	10 178
Perpetual preference share capital 	779 	779 	779
Other reserves 	3 860 	3 045 	2 243
Retained earnings 	36 769 	34 209 	27 617
Equity attributable to equity holders of the Company 	52 202 	48 384 	40 817
Non-controlling interest 	4 	4 	5
TOTAL EQUITY 	52 206 	48 388 	40 822
Liabilities
Liabilities arising from insurance contracts issued 	D.4.1. 	99 527 	95 695 	85 055
Liabilities arising from reinsurance contracts held 	D.4.1. 	5 684 	4 843 	5 207
Deferred tax liability 	6 687 	6 222 	6 313
Contract liabilities to customers 	591 	656 	944
Third-party interest in consolidated funds 	29 704 	28 346 	24 320
Financial liabilities
– Borrowings at amortised cost 	A.5. 	20 491 	20 586 	20 584
– Other financial payables at amortised cost 	6 834 	9 112 	8 492
– Deposits from customers 	16 667 	14 333 	10 881
– Investment contracts at fair value through profit or loss 	21 980 	28 903 	28 955
– Derivative financial instruments at fair value through profit or loss 	35 	20 	202
Other payables and provisions 	1 481 	710 	752
Current tax liability 	37 	165 	527
TOTAL LIABILITIES 	209 718 	209 591 	192 232
TOTAL EQUITY AND LIABILITIES 	261 924 	257 979 	233 054
1 The comparative information has been restated for the initial application of IFRS 17, changes in the presentation of specified line items and the correction
of prior period errors. Refer to section D, note D.1.1. – D.1.4. for more detail.

-- 10 of 105 --

9
Group income statement
for the six months ended 31 December 2023
R million 	Notes
Group
six months
ended
December
2023
Unaudited
Restated1
Group
six months
ended
December
2022
Unaudited
Restated 1
Group
year
ended
June
2023
Unaudited
Insurance revenue 	D.4.11. 	26 117 	22 532 	47 208
Insurance service expenses 	(22 953) 	(19 663) 	(41 634)
Net (expenses)/income from reinsurance contracts 	(609) 	13 	(188)
Insurance service result 	2 555 	2 882 	5 386
Net financial result from insurance finance income and expense 	D.4.12. 	(2 892) 	(4 233) 	(7 458)
– Net finance expense from insurance contracts 	(2 730) 	(4 085) 	(7 172)
– Net finance expense from reinsurance contracts 	(162) 	(148) 	(286)
Investment income using the effective interest rate method 	412 	248 	616
Net fair value gains on financial assets at fair value through profit or loss 	6 670 	8 587 	16 726
Fair value adjustment to liabilities under investment contracts 	(691) 	(1 092) 	(2 593)
Third party interest: fair value adjustment to liabilities under
investment contracts 	(1 149) 	(1 539) 	(2 978)
Other gains on financial instruments 	5 	– 	–
Net insurance and investment results 	4 910 	4 853 	9 699
Fee income from administration businesses 	A.4. 	6 903 	6 348 	13 224
Vitality income 	A.4. 	2 135 	1 943 	3 891
Net banking fee and commission income 	581 	449 	965
– Banking fee and commission income 	A.4. 	845 	583 	1 292
– Banking fee and commission expense 	(264) 	(134) 	(327)
Net bank interest and similar income 	366 	268 	574
– Bank interest and similar income using the effective interest rate 	869 	591 	1 318
– Bank interest and similar expense using the effective interest rate 	(503) 	(323) 	(744)
Other income 	779 	743 	1 544
Non-insurance revenue and income 	10 764 	9 751 	20 198
Net income 	15 674 	14 604 	29 897
Acquisition costs 	(456) 	(423) 	(880)
Expected credit losses 	(93) 	(43) 	(139)
Marketing and administration expenses 	(9 573) 	(8 674) 	(18 439)
Impairment of goodwill 	– 	– 	(9)
Operating profit before integral equity-accounted investments 	5 552 	5 464 	10 430
Loss on dilution and disposal of equity-accounted investments 	– 	– 	(5)
Share of net profits from equity-accounted investments 	278 	55 	525
Profit before finance costs and tax 	5 830 	5 519 	10 950
Finance costs 	(1 025) 	(924) 	(1 919)
Foreign exchange (losses)/gains 	(40) 	28 	151
Profit before tax 	4 765 	4 623 	9 182
Income tax expense 	(1 422) 	(1 385) 	(2 516)
Profit for the period/year 	3 343 	3 238 	6 666
Profit attributable to:
– Ordinary shareholders 	3 304 	3 207 	6 604
– Preference shareholders 	44 	31 	69
– Non-controlling interest 	(5) 	– 	(7)
3 343 	3 238 	6 666
Earnings per share for profit attributable to ordinary shareholders
of the Company during the period/year (cents):
– Basic 	492.9 	487.9 	986.5
– Diluted 	490.4 	480.9 	981.6
1 The comparative information has been restated for the initial application of IFRS 17 as well as for changes in the presentation of equity-accounted
investments to enhance the understandability of the Group income statement.

-- 11 of 105 --

10	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Group statement of other comprehensive income
for the six months ended 31 December 2023
R million 	Notes
Group
six months
ended
December
2023
Unaudited
Restated1
Group
six months
ended
December
2022
Unaudited
Restated 1
Group
year
ended
June
2023
Unaudited
Profit for the period/year 	3 343 	3 238 	6 666
Items that are or may be subsequently reclassified to profit or loss:
Currency translation differences 	(344) 	444 	3 172
– Unrealised (losses)/gains 	(356) 	444 	3 287
– Tax on unrealised losses/(gains) 	12 	– 	(115)
Cash flow hedges 	(70) 	32 	76
– Unrealised (losses)/gains 	(72) 	36 	76
– Gains/(losses) reclassified to profit or loss 	2 	(5) 	(1)
– Tax on reclassified gains 	– 	1 	1
Net finance income/(expense) from insurance contracts issued 	D.4.12. 	1 805 	(1 423) 	(3 712)
– Unrealised income/(expense) 	2 413 	(1 925) 	(5 072)
– Tax on unrealised (income)/expense 	(608) 	502 	1 360
Net finance (expense)/income from reinsurance contracts held 	D.4.12. 	(455) 	298 	433
– Unrealised (expense)/income 	(608) 	400 	589
– Tax on unrealised expense/(income) 	153 	(102) 	(156)
Share of other comprehensive income/(loss) from equity-accounted
investments 	18 	(36) 	433
– Change in fair value of debt instruments at fair value through other
comprehensive income 	(1) 	(12) 	(10)
– Currency translation differences 	19 	(24) 	443
Items that may not be reclassified to profit or loss:
Share of other comprehensive (loss)/income from equity-accounted
investments 	(2) 	2 	8
– Change in fair value of equity instruments at fair value through other
comprehensive income 	(2) 	2 	8
Other comprehensive income/(loss) for the period/year, net of tax 	952 	(683) 	410
Total comprehensive income for the period/year 	4 295 	2 555 	7 076
Attributable to:
– Ordinary shareholders 	4 251 	2 523 	7 014
– Preference shareholders 	44 	31 	69
– Non-controlling interest 	– 	1 	(7)
Total comprehensive income for the period/year 	4 295 	2 555 	7 076
1 The comparative information has been restated for the initial application of IFRS 17. Refer to section D, notes D.1.1. – D.1.4. for detail.

-- 12 of 105 --

11
Group statement of cash flows
for the six months ended 31 December 2023
R million
Group
six months
ended
December
2023
Unaudited
Restated1
Group
six months
ended
December
2022
Unaudited
Restated 1
Group
year
ended
June
2023
Unaudited
Cash flows from operating activities 	(1 009) 	1 163 	5 293
Cash (utilised)/generated by operations 	(1 042) 	5 876 	11 052
Purchase of investments held to back policyholder liabilities 	(31 756) 	(35 314) 	(62 773)
Proceeds from disposal of investments held to back policyholder liabilities 	30 931 	30 303 	55 908
Cash (utilised)/generated from operating activities 	(1 867) 	865 	4 187
Dividends received 	367 	186 	728
Interest received 	2 085 	2 086 	3 718
Interest paid 	(802) 	(932) 	(1 501)
Taxation paid 	(792) 	(1 042) 	(1 839)
Cash flows from investing activities 	556 	(740) 	(2 236)
Purchase of financial assets 	(14 243) 	(16 295) 	(30 966)
Proceeds from disposal of financial assets 	16 020 	16 567 	30 932
Purchase of property and equipment 	(246) 	(210) 	(551)
Proceeds from disposal of property and equipment 	– 	2 	2
Purchase of intangible assets 	(800) 	(751) 	(1 760)
Acquisition of business net of cash 	– 	– 	(3)
Additional investment in equity-accounted investments 	(176) 	(109) 	(182)
Proceeds from sale of non-current asset held for sale 	– 	– 	184
Dividends from equity-accounted investments 	1 	56 	108
Cash flows from financing activities 	(1 150) 	(651) 	(1 234)
Dividends paid to ordinary shareholders 	(739) 	– 	–
Dividends paid to preference shareholders 	(44) 	(31) 	(69)
Proceeds from borrowings 	500 	3 856 	7 442
Repayment of borrowings 	(867) 	(4 476) 	(8 607)
Net (decrease)/increase in cash and cash equivalents 	(1 603) 	(228) 	1 823
Cash and cash equivalents at beginning of the period/year 	16 227 	13 631 	13 631
Effects of exchange rate changes on cash and cash equivalents 	(117) 	94 	773
Cash and cash equivalents at end of the period/year 	14 507 	13 497 	16 227
Reconciliation to statement of financial position
Cash and cash equivalents 	14 507 	13 497 	16 260
Bank overdraft included in borrowings at amortised cost 	– 	– 	(33)
Cash and cash equivalents at end of the period/year 	14 507 	13 497 	16 227
1 The comparative information has been restated for the initial application of IFRS 17. Refer to section D, notes D.1.1. – D.1.4. for detail.

-- 13 of 105 --

12	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	13
Group statement of changes in equity
for the six months ended 31 December 2023
Attributable to equity holders of the Company 	Attributable to equity holders of the Company
R million
Share capital
and share
premium
Perpetual
preference
share capital
Share-based
payment
reserve
Investment
reserve 1
Insurance
finance
reserve
Foreign
currency
translation
reserve
Hedging
reserve
Retained
earnings 	Total
Non-
controlling
interest 	Total
Period ended 31 December 2023
At beginning of the period – July 2023 	10 351 	779 	1 190 	19 	(4 685) 	6 480 	41 	34 209 	48 384 	4 	48 388
Total comprehensive income for the period 	– 	44 	– 	(3) 	1 350 	(330) 	(70) 	3 304 	4 295 	– 	4 295
Profit for the period 	– 	44 	– 	– 	– 	– 	– 	3 304 	3 348 	(5) 	3 343
Other comprehensive income 	– 	– 	– 	(3) 	1 350 	(330) 	(70) 	– 	947 	5 	952
Transactions with owners 	443 	(44) 	(132) 	– 	– 	– 	– 	(744) 	(477) 	– 	(477)
Share issue 	432 	– 	– 	– 	– 	– 	– 	– 	432 	– 	432
Increase in treasury shares 	(432) 	– 	– 	– 	– 	– 	– 	– 	(432) 	– 	(432)
Delivery of treasury shares 	443 	– 	(438) 	– 	– 	– 	– 	(5) 	– 	– 	–
Employee share option schemes:
– Value of employee services, net of tax 	– 	– 	306 	– 	– 	– 	– 	– 	306 	– 	306
Dividends paid to preference shareholders 	– 	(44) 	– 	– 	– 	– 	– 	– 	(44) 	– 	(44 )
Dividends paid to ordinary shareholders 	– 	– 	– 	– 	– 	– 	– 	(739) 	(739) 	– 	(739)
At end of the period 	10 794 	779 	1 058 	16 	(3 335) 	6 150 	(29) 	36 769 	52 202 	4 	52 206
Period ended 31 December 2022
At beginning of the period – July 2022 	10 178 	779 	798 	35 	– 	2 823 	(35) 	38 972 	53 550 	5 	53 555
– New IFRS transitional adjustment2 	– 	– 	– 	(14) 	(1 406) 	– 	– 	(11 150) 	(12 570) 	– 	(12 570)
– Prior period error adjustments 	– 	– 	– 	– 	– 	42 	– 	(205) 	(163) 	– 	(163)
Restated balance at beginning of the period 	10 178 	779 	798 	21 	(1 406) 	2 865 	(35) 	27 617 	40 817 	5 	40 822
Total comprehensive income for the period 	– 	31 	– 	(10) 	(1 125) 	419 	32 	3 207 	2 554 	1 	2 555
Profit for the period 	– 	31 	– 	– 	– 	– 	– 	3 207 	3 238 	– 	3 238
Other comprehensive income 	– 	– 	– 	(10) 	(1 125) 	419 	32 	– 	(684) 	1 	(683)
Transactions with owners 	172 	(31) 	22 	– 	– 	– 	– 	(16) 	147 	– 	147
Share issue 	514 	– 	– 	– 	– 	– 	– 	– 	514 	– 	514
Increase in treasury shares 	(514) 	– 	– 	– 	– 	– 	– 	– 	(514) 	– 	(514)
Delivery of treasury shares 	172 	– 	(156) 	– 	– 	– 	– 	(16) 	– 	– 	–
Employee share option schemes:
– Value of employee services 	– 	– 	178 	– 	– 	– 	– 	– 	178 	– 	178
Dividends paid to preference shareholders 	– 	(31) 	– 	– 	– 	– 	– 	– 	(31) 	– 	(31)
At end of the period 	10 350 	779 	820 	11 	(2 531) 	3 284 	(3) 	30 808 	43 518 	6 	43 524
1 This relates to fair value adjustments on those equity instruments designated at fair value through other comprehensive income (FVOCI) and those debt
instruments measured at FVOCI, in terms of IFRS 9 Financial Instruments.
2 The comparative information has been restated for the initial application of IFRS 17.

-- 14 of 105 --

14	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Notes to the
summarised
financial
statements
A.1. 	Segment information
A.2. 	Normalised profit from operations
A.3. 	Earnings, headline earnings and normalised headline earnings
A.4. 	Revenue from non-insurance activities
A.5. 	Borrowings at amortised cost
A.6. 	Fair value hierarchy of financial instruments
A

-- 15 of 105 --

15
A.1. 	Segment information
Discovery’s operating segments are reported in a manner consistent with the internal reporting provided to the chief operating
decision-maker (CODM). The CODM has been identified as the Group Executive Committee who makes strategic decisions regarding
these businesses.
An operating segment is a component of an entity:
(a) That engages in business activities from which it may earn revenues and incur expenses, including revenues and expenses
relating to transactions with other components of the same entity.
(b) Whose operating results are regularly reviewed by the entity’s CODM to make decisions about resources to be allocated to the
segment and assess its performance; and
(c) For which discrete financial information is available.
An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may
be operating segments before earning revenues.
Discovery will report separately information about an operating segment that meets any of the following quantitative thresholds:
(a) Its reported revenue, including both sales to external customers and intersegment sales or transfers, is 10 percent or more of
the combined revenue, internal and external, of all operating segments.
(b) The absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount, of (i) the combined
reported profit of all operating segments that did not report a loss and (ii) the combined reported loss of all operating segments
that reported a loss; and
(c) Its assets are 10 percent or more of the combined assets of all operating segments.
Operating segments that do not meet any of the quantitative thresholds may be considered reportable, and separately disclosed,
if management believes that information about the segment would be useful to users of the financial statements.
Discovery may combine information about operating segments that do not meet the quantitative thresholds with information about
other operating segments that do not meet the quantitative thresholds to produce a reportable segment only if the operating
segments have similar economic characteristics.
The Group has identified its reportable segments based on a combination of products and services offered to customers and the
location of the markets served.
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS
DISCLOSURE
for the six months ended 31 December 2023

-- 16 of 105 --

16	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.1. 	Segment information continued
The following summary describes the operations of each of the Group’s reportable segments:
SA Health
 Administers and provides managed care
services to medical schemes in South Africa.
 Renders administration services to other
business segments within the Group.
 Together with Medical Services Organisation
International (MSO), a subsidiary company,
deliver health insurance, healthcare risk
management and third-party administration
services within rest of Africa markets.
SA Life
Offers a range of insurance and financial solutions
to the Group’s clients against the financial impact
of lifestyle-changing events in South Africa.
SA Invest
Offers, through a range of investment fund
choices, including Discovery managed unit trusts, a
comprehensive and flexible range of investment
choices. These products are sold through a
number of investment wrappers including
Discovery Life policies and are offered to
individuals in South Africa.
SA Insure
Offers a range of personal line insurance (motor,
building, household content and portable
possessions) to the Group’s SA clients against the
financial impact of loss or damage. The segment
also includes Discovery’s equity-accounted
interests including Cambridge Mobile Telematics
(CMT).
SA Bank
Offers retail banking solutions, including deposits
and loans and advances, to clients in the South
African market. The Bank is still in a start-up phase.
UK Health
Offers consumer-engaged private medical
insurance products to employer groups and
individuals in the UK. All contracts in this segment
are short-term insurance contracts.
UK Life
Offers a risk-only life assurance product. All
contracts in this segment are long-term assurance
contracts offered to both employer groups and
individuals in the UK.
All other
segments
Includes those segments that do not meet the quantitative thresholds set out in IFRS 8 Operating Segments and
cannot be aggregated with another reportable segment. It includes the following operating segments:
 SA Composite:
– SA Vitality, which offers health and lifestyle benefits with selected partners to the Group’s SA clients.
– SA Insure commercial: provides commercial short-term risk insurance products to the South African
market.
– Discovery Umbrella: offers pension and provident fund solutions that encourage employees to reach their
retirement goals with unique rewards, benefits and digital engagement.
– SA Distribution: provides sales and distribution services in respect of all SA products.
– Other new group initiatives, including Vitality Green, as well as unallocated central costs.
 UK Composite:
– Includes immaterial interests in equity-accounted interests, UK Invest which is currently in Other initiatives
and central costs.
 Vitality Global Composite:
– Vitality Health International, leverages Discovery Health and Vitality’s intellectual property to create
strategic partnerships through equity-accounted interests in health insurance and health technology and
solutions businesses, which includes the equity-accounted interests in Ping An Health Insurance and
Amplify Health.
– Vitality Network, which provides a Vitality platform to international insurance businesses.
– Central costs.

-- 17 of 105 --

17
A.1. 	Segment information continued
The Group Executive Committee assesses the performance of the reportable segments based on normalised profit/loss
from operations. Items which are excluded from the normalised profit/loss from operations are separately disclosed in the
segment information to reconcile to the segment results and Group income statement. The segment information is
presented on the same basis as reported to the CODM.
The segment total is then adjusted for accounting reclassifications and entries required to produce results compliant with
the IFRS Accounting Standards., i.e. IFRS reporting adjustments, these adjustments include the following:
(a) Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into
Discovery’s results for IFRS purposes. The IFRS reporting adjustments include the effects of consolidating the unit trusts
into Discovery’s results, effectively being the income and expenses relating to units held by third parties.
(b) The effects of eliminating intercompany transactions on consolidation and normalised operating profit adjustments;
and
(c) The effects of reclassifying items to align to the IFRS Group income statement.
Effective 1 July 2023, the following changes have been made to the Segment information and the comparative information
has been restated accordingly:
1. The Segment information has been updated, consistent with the changes to the Group income statement, to reflect the
new presentation requirements of IFRS 17.
2. SA Vitality is no longer presented as a separate reportable segment. Instead, SA Vitality is presented as part of ‘All other
segments’.
3. Africa Health results are included in the SA Health segment as management control of this operation had been moved
from Vitality Global to Discovery Health. This was previously disclosed in ‘All other segments’ as a new initiative and
comparative information has been restated accordingly.
4. Definitions of ’Investment income on assets backing policyholder liabilities‘ and ’Investment income earned on
shareholder investments and cash‘ have been refined in order to achieve consistent treatment across the regulated
insurance entities of the Group. Discovery includes in ’Investment income on assets backing policyholder liabilities‘ all
investment income from those assets backing client and policyholder liabilities, including those assets held for regulatory
capital requirements and related additional risk appetite margins. This refinement resulted in a reallocation of investment
income such that the component attributable to normalised profit from operations, increased by R67 million for the six
months ended 31 December 2022 (30 June 2023: R186 million) while investment income earned on shareholder
investments and cash decreased by the same amount. For the six months ended 31 December 2023, as a result of the
increases in interest rate and increasing insurance book, the consistently applied reallocation amounted to R177 million
of interest earned being included in normalised profit from operations rather than investment income earned on
shareholder investments and cash. These reallocations had no effect on total investment income nor total earnings.

-- 18 of 105 --

18	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	19
A.1. 	Segment information continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments
IFRS
total
31 December 2023
Income statement
Insurance revenue 	193 	8 595 	1 866 	2 792 	– 	7 960 	4 368 	343 	26 117 	– 	26 117
– Contracts measured under the General measurement model/Variable fee approach 	– 	6 859 	1 866 	– 	– 	– 	4 368 	– 	13 093 	– 	13 093
– Contracts measured under Premium allocation approach 	193 	1 736 	– 	2 792 	– 	7 960 	– 	343 	13 024 	– 	13 024
Insurance service expenses 	(139) 	(7 489) 	(1 174) 	(2 810) 	– 	(7 197) 	(3 768) 	(376) 	(22 953) 	– 	(22 953)
– Claims and benefits 	(77) 	(5 700) 	(202) 	(1 838) 	– 	(4 297) 	(2 281) 	(236) 	(14 631) 	– 	(14 631)
– Insurance service expense and other 	(62) 	(819) 	(525) 	(452) 	– 	(2 051) 	(209) 	(140) 	(4 258) 	– 	(4 258)
– Insurance acquisition cash flows 	– 	(970) 	(447) 	(520) 	– 	(849) 	(1 278) 	– 	(4 064) 	– 	(4 064)
Insurance service result (pre-reinsurance) 	54 	1 106 	692 	(18) 	– 	763 	600 	(33) 	3 164 	– 	3 164
Net (expense)/income from reinsurance contracts 	– 	(410) 	– 	19 	– 	(5) 	(214) 	1 	(609) 	– 	(609)
– Reinsurance expense 	– 	(1 800) 	– 	(249) 	– 	(5) 	(2 675) 	(135) 	(4 864) 	– 	(4 864)
– Insurance claims recovered from reinsurers 	– 	1 390 	– 	268 	– 	– 	2 461 	136 	4 255 	– 	4 255
Insurance service result 	54 	696 	692 	1 	– 	758 	386 	(32) 	2 555 	– 	2 555
Net financial result from insurance finance income and expense 	– 	1 318 	(3 939) 	– 	– 	– 	76 	– 	(2 545) 	(347) 	(2 892)
– Net finance income/(expense) from insurance contracts 	– 	1 414 	(3 939) 	– 	– 	– 	142 	– 	(2 383) 	(347) 	(2 730)
– Net finance expense from reinsurance contracts 	– 	(96) 	– 	– 	– 	– 	(66) 	– 	(162) 	– 	(162)
Investment income earned on assets backing policyholder liabilities 	– 	10 	26 	103 	– 	83 	41 	10 	273 	139 	412
Net fair value (losses)/gains on financial instruments at fair value through profit
or loss 	(4) 	520 	3 911 	4 	– 	56 	– 	424 	4 911 	1 759 	6 670
Fair value adjustments to liabilities under investment contracts 	– 	(1) 	(260) 	– 	– 	– 	– 	(430) 	(691) 	– 	(691)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(1 149) 	(1 149)
Intersegment funding 	– 	(121) 	121 	– 	– 	– 	– 	– 	– 	– 	–
Other gains on financial instruments 	– 	– 	– 	– 	5 	– 	– 	– 	5 	– 	5
Net insurance and investment results 	50 	2 422 	551 	108 	5 	897 	503 	(28) 	4 508 	402 	4 910
Fee income from administration businesses 	4 452 	– 	812 	4 	– 	25 	– 	1 610 	6 903 	– 	6 903
Vitality income 	– 	– 	– 	– 	– 	301 	131 	1 703 	2 135 	– 	2 135
Net banking fee and commission income 	– 	– 	– 	– 	567 	– 	– 	14 	581 	– 	581
– Banking fee and commission income 	– 	– 	– 	– 	845 	– 	– 	– 	845 	– 	845
– Banking fee and commission expense 	– 	– 	– 	– 	(278) 	– 	– 	14 	(264) 	– 	(264)
Net bank interest and similar income 	– 	– 	– 	– 	366 	– 	– 	– 	366 	– 	366
– Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	869 	– 	– 	– 	869 	– 	869
– Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(503) 	– 	– 	– 	(503) 	– 	(503)
Other income 	689 	1 	– 	11 	– 	12 	– 	66 	779 	– 	779
Non-insurance revenue and income 	5 141 	1 	812 	15 	933 	338 	131 	3 393 	10 764 	– 	10 764
Net income 	5 191 	2 423 	1 363 	123 	938 	1 235 	634 	3 365 	15 272 	402 	15 674
Acquisition costs 	– 	– 	(402) 	– 	– 	– 	– 	(54) 	(456) 	– 	(456)
Expected credit losses 	– 	– 	– 	– 	(93) 	– 	– 	– 	(93) 	– 	(93)
Marketing and administration expenses
– depreciation and amortisation 	(79) 	– 	(7) 	(35) 	(175) 	(228) 	(23) 	(409) 	(956) 	(84) 	(1 040)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(3) 	– 	(1) 	– 	(4) 	(8) 	– 	(8)
– other expenses 	(3 238) 	(156) 	(334) 	(84) 	(1 009) 	(480) 	(221) 	(2 917) 	(8 439) 	(86) 	(8 525)
Share of net profits from equity-accounted investments 	– 	– 	– 	19 	– 	1 	– 	282 	302 	(24) 	278
Normalised profit/(loss) from operations 	1 874 	2 267 	620 	20 	(339) 	527 	390 	263 	5 622 	208 	5 830
Investment income earned on shareholder investments and cash 	54 	13 	6 	– 	– 	– 	– 	66 	139 	(139) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	823 	823 	(823) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	29 	27 	– 	– 	– 	– 	– 	56 	(56) 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(24) 	– 	– 	– 	(28) 	(52) 	52 	–
Market rentals related to Head Office building adjusted for finance costs and
depreciation 	– 	– 	– 	– 	– 	– 	– 	(59) 	(59) 	59 	–
Restructuring costs 	– 	– 	– 	– 	– 	– 	– 	(20) 	(20) 	20 	–
Finance costs 	(11) 	(1) 	– 	– 	– 	(8) 	(112) 	(749) 	(881) 	(144) 	(1 025)
Intercompany finance costs 	(201) 	– 	– 	– 	– 	– 	(227) 	(395) 	(823) 	823 	–
Foreign exchange gains/(losses) 	1 	(4) 	(12) 	– 	– 	– 	– 	(25) 	(40) 	– 	(40)
Profit/(loss) before tax 	1 717 	2 304 	641 	(4) 	(339) 	519 	51 	(124) 	4 765 	– 	4 765
Income tax expense 	(470) 	(612) 	(228) 	(1) 	108 	(152) 	(26) 	(41) 	(1 422) 	– 	(1 422)
Profit/(loss) for the period 	1 247 	1 692 	413 	(5) 	(231) 	367 	25 	(165) 	3 343 	– 	3 343
Profit attributable to:
– Ordinary shareholders 	1 252 	1 692 	413 	(5) 	(231) 	367 	25 	(209) 	3 304 	– 	3 304
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	44 	44 	– 	44
– Non-controlling interest 	(5) 	– 	– 	– 	– 	– 	– 	– 	(5) 	– 	(5)
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued

-- 19 of 105 --

20	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	21
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.1. 	Segment information continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments
IFRS
total
31 December 2022
Income statement
Insurance revenue 	136 	8 221 	1 504 	2 536 	– 	6 425 	3 458 	252 	22 532 	– 	22 532
– Contracts measured under the General measurement model/Variable fee approach 	– 	6 591 	1 504 	– 	– 	– 	3 458 	– 	11 553 	– 	11 553
– Contracts measured under Premium allocation approach 	136 	1 630 	– 	2 536 	– 	6 425 	– 	252 	10 979 	– 	10 979
Insurance service expense 	(103) 	(7 255) 	(993) 	(2 461) 	– 	(5 415) 	(3 101) 	(335) 	(19 663) 	– 	(19 663)
– Claims and benefits 	(65) 	(5 585) 	(156) 	(1 629) 	– 	(3 200) 	(1 938) 	(210) 	(12 783) 	– 	(12 783)
– Insurance service expense and other 	(38) 	(799) 	(447) 	(421) 	– 	(1 573) 	(176) 	(125) 	(3 579) 	– 	(3 579)
– Insurance acquisition cash flows 	– 	(871) 	(390) 	(411) 	– 	(642) 	(987) 	– 	(3 301) 	– 	(3 301)
Insurance service result (pre-reinsurance) 	33 	966 	511 	75 	– 	1 010 	357 	(83) 	2 869 	– 	2 869
Net income/(expense) from reinsurance contracts 	– 	40 	– 	(22) 	– 	(4) 	(19) 	18 	13 	– 	13
– Reinsurance expense 	(1) 	(1 680) 	– 	(206) 	– 	(787) 	(1 670) 	(100) 	(4 444) 	– 	(4 444)
– Insurance claims recovered from reinsurers 	1 	1 720 	– 	184 	– 	783 	1 651 	118 	4 457 	– 	4 457
Insurance service result 	33 	1 006 	511 	53 	– 	1 006 	338 	(65) 	2 882 	– 	2 882
Net financial result from insurance finance income and expense 	– 	1 003 	(5 028) 	– 	– 	– 	(82) 	– 	(4 107) 	(126) 	(4 233)
– Net finance income/(expense) from insurance contracts 	– 	1 114 	(5 028) 	– 	– 	– 	(45) 	– 	(3 959) 	(126) 	(4 085)
– Net finance expense from reinsurance contracts 	– 	(111) 	– 	– 	– 	– 	(37) 	– 	(148) 	– 	(148)
Investment income earned on assets backing policyholder liabilities 	– 	3 	20 	62 	– 	29 	26 	6 	146 	102 	248
Net fair value (losses)/gains on financial instruments at fair value through profit
or loss 	(12) 	394 	5 244 	(6) 	– 	(10) 	– 	709 	6 319 	2 268 	8 587
Fair value adjustments to liabilities under investment contracts 	– 	(3) 	(383) 	– 	– 	– 	– 	(706) 	(1 092) 	– 	(1 092)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(1 539) 	(1 539)
Intersegment funding 	– 	(102) 	102 	– 	– 	– 	– 	– 	– 	– 	–
Net insurance and investment results 	21 	2 301 	466 	109 	– 	1 025 	282 	(56) 	4 148 	705 	4 853
Fee income from administration businesses 	4 121 	– 	746 	9 	– 	18 	– 	1 454 	6 348 	– 	6 348
Vitality income 	– 	– 	– 	– 	– 	185 	113 	1 645 	1 943 	– 	1 943
Net banking fee and commission income 	– 	– 	– 	– 	438 	– 	– 	11 	449 	– 	449
– Banking fee and commission income 	– 	– 	– 	– 	583 	– 	– 	– 	583 	– 	583
– Banking fee and commission expense 	– 	– 	– 	– 	(145) 	– 	– 	11 	(134) 	– 	(134)
Net bank interest and similar income 	– 	– 	– 	– 	268 	– 	– 	– 	268 	– 	268
– Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	591 	– 	– 	– 	591 	– 	591
– Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(323) 	– 	– 	– 	(323) 	– 	(323)
Other income 	667 	2 	– 	6 	– 	13 	– 	55 	743 	– 	743
Non-insurance revenue and income 	4 788 	2 	746 	15 	706 	216 	113 	3 165 	9 751 	– 	9 751
Net income 	4 809 	2 303 	1 212 	124 	706 	1 241 	395 	3 109 	13 899 	705 	14 604
Acquisition costs 	– 	– 	(374) 	– 	– 	– 	– 	(49) 	(423) 	– 	(423)
Expected credit losses 	– 	– 	– 	– 	(43) 	– 	– 	– 	(43) 	– 	(43)
Marketing and administration expenses
– depreciation and amortisation 	(70) 	– 	(5) 	(32) 	(157) 	(207) 	(28) 	(371) 	(870) 	(84) 	(954)
– derecognition of intangible assets and property and equipment 	– 	– 	– 	(4) 	– 	(60) 	(18) 	(5) 	(87) 	– 	(87)
– other expenses 	(2 991) 	(158) 	(272) 	(64) 	(904) 	(316) 	(151) 	(2 724) 	(7 580) 	(53) 	(7 633)
Share of net profits from equity-accounted investments 	– 	– 	– 	(16) 	– 	– 	– 	93 	77 	(22) 	55
Normalised profit/(loss) from operations 	1 748 	2 145 	561 	8 	(398) 	658 	198 	53 	4 973 	546 	5 519
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	391 	– 	391 	(391) 	–
Investment income earned on shareholder investments and cash 	34 	7 	13 	– 	– 	– 	– 	48 	102 	(102) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	530 	530 	(530) 	–
Net fair value (losses)/gains on financial assets at fair value through profit or loss 	– 	(2) 	34 	– 	– 	– 	– 	(2) 	30 	(30) 	–
Amortisation of intangibles from business combinations 	– 	– 	– 	(22) 	– 	– 	– 	(28) 	(50) 	50 	–
Market rentals related to Head Office building adjusted for finance costs
and depreciation 	– 	– 	– 	– 	– 	– 	– 	(73) 	(73) 	73 	–
Finance costs 	– 	– 	– 	– 	– 	(4) 	(77) 	(697) 	(778) 	(146) 	(924)
Intercompany finance costs 	(166) 	– 	– 	– 	– 	– 	(129) 	(235) 	(530) 	530 	–
Foreign exchange gains/(losses) 	1 	5 	6 	– 	– 	– 	(2) 	18 	28 	– 	28
Profit/(loss) before tax 	1 617 	2 155 	614 	(14) 	(398) 	654 	381 	(386) 	4 623 	– 	4 623
Income tax expense 	(441) 	(581) 	(214) 	(7) 	110 	(143) 	(57) 	(52) 	(1 385) 	– 	(1 385)
Profit/(loss) for the period 	1 176 	1 574 	400 	(21) 	(288) 	511 	324 	(438) 	3 238 	– 	3 238
Profit attributable to:
– Ordinary shareholders 	1 176 	1 574 	400 	(21) 	(288) 	511 	324 	(469) 	3 207 	– 	3 207
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	31 	31 	– 	31
– Non-controlling interest 	– 	– 	– 	– 	– 	– 	– 	– 	– 	– 	–

-- 20 of 105 --

22	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	23
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.1. 	Segment information continued
R million
SA
Health
SA
Life
SA
Invest
SA
Insure
SA
Bank
UK
Health
UK
Life
All other
segments
Segment
total
IFRS reporting
adjustments
IFRS
total
30 June 2023
Income statement
Insurance revenue 	303 	16 758 	3 231 	5 176 	– 	13 670 	7 535 	535 	47 208 	– 	47 208
– Contracts measured under the General measurement model/Variable fee approach 	– 	13 464 	3 231 	– 	– 	– 	7 535 	1 	24 231 	– 	24 231
– Contracts measured under Premium allocation approach 	303 	3 294 	– 	5 176 	– 	13 670 	– 	534 	22 977 	– 	22 977
Insurance service expense 	(234) 	(14 699) 	(2 050) 	(4 993) 	– 	(12 178) 	(6 819) 	(661) 	(41 634) 	– 	(41 634)
– Claims and benefits 	(152) 	(11 282) 	(331) 	(3 246) 	– 	(7 341) 	(3 891) 	(409) 	(26 652) 	– 	(26 652)
– Insurance service expense and other 	(82) 	(1 632) 	(957) 	(831) 	– 	(3 435) 	(827) 	(252) 	(8 016) 	– 	(8 016)
– Insurance acquisition cash flows 	– 	(1 785) 	(762) 	(916) 	– 	(1 402) 	(2 101) 	– 	(6 966) 	– 	(6 966)
Insurance service result (pre-reinsurance) 	69 	2 059 	1 181 	183 	– 	1 492 	716 	(126) 	5 574 	5 574
Net (expense)/income from reinsurance contracts 	– 	(225) 	– 	(70) 	– 	(9) 	92 	24 	188 	– 	188
– Reinsurance expense 	(1) 	(3 549) 	– 	(413) 	– 	(1 846) 	(3 464) 	(221) 	(9 494) 	– 	(9 494)
– Insurance claims recovered from reinsurers 	1 	3 324 	– 	343 	– 	1 837 	3 556 	245 	9 306 	– 	9 306
Insurance service result 	69 	1 834 	1 181 	113 	– 	1 483 	808 	(102) 	5 386 	– 	5 386
Net financial result from insurance finance income and expense 	– 	2 225 	(9 815) 	– 	– 	– 	(89) 	– 	(7 679) 	221 	(7 458)
– Net finance income/(expense) from insurance contracts 	– 	2 450 	(9 815) 	– 	– 	– 	(28) 	– 	(7 393) 	221 	(7 172)
– Net finance expense from reinsurance contracts 	– 	(225) 	– 	– 	– 	– 	(61) 	– 	(286) 	– 	(286)
Investment income earned on assets backing policyholder liabilities 	– 	28 	51 	145 	– 	90 	71 	15 	400 	216 	616
Net fair value (losses)/gains on financial instruments at fair value through profit or loss 	(6) 	760 	10 904 	– 	– 	– 	– 	1 282 	12 940 	3 786 	16 726
Fair value adjustments to liabilities under investment contracts 	– 	(3) 	(1 326) 	– 	– 	– 	– 	(1 264) 	(2 593) 	– 	(2 593)
Third party interest: fair value adjustments to liabilities under investment contracts 	– 	– 	– 	– 	– 	– 	– 	– 	– 	(2 978) 	(2 978)
Intersegment funding 	– 	(126) 	126 	– 	– 	– 	– 	– 	– 	– 	–
Net insurance and investment results 	63 	4 718 	1 121 	258 	– 	1 573 	790 	(69) 	8 454 	1 245 	9 699
Fee income from administration businesses 	8 575 	– 	1 566 	17 	– 	46 	– 	3 020 	13 224 	– 	13 224
Vitality income 	– 	– 	– 	– 	– 	462 	238 	3 191 	3 891 	– 	3 891
Net banking fee and commission income 	– 	– 	– 	– 	943 	– 	– 	22 	965 	– 	965
– Banking fee and commission income 	– 	– 	– 	– 	1 292 	– 	– 	– 	1 292 	– 	1 292
– Banking fee and commission expense 	– 	– 	– 	– 	(349) 	– 	– 	22 	(327) 	– 	(327)
Net bank interest and similar income 	– 	– 	– 	– 	574 	– 	– 	– 	574 	– 	574
– Bank interest and similar income using the effective interest rate 	– 	– 	– 	– 	1 318 	– 	– 	– 	1 318 	– 	1 318
– Bank interest and similar expense using the effective interest rate 	– 	– 	– 	– 	(744) 	– 	– 	– 	(744) 	– 	(744)
Other income 	1 381 	3 	– 	14 	– 	48 	– 	98 	1 544 	– 	1 544
Non-insurance revenue and income 	9 956 	3 	1 566 	31 	1 517 	556 	238 	6 331 	20 198 	– 	20 198
Net income 	10 019 	4 721 	2 687 	289 	1 517 	2 129 	1 028 	6 262 	28 652 	1 245 	29 897
Acquisition costs 	– 	– 	(780) 	– 	– 	– 	– 	(100) 	(880) 	– 	(880)
Expected credit losses 	– 	– 	– 	– 	(139) 	– 	– 	– 	(139) 	– 	(139)
Marketing and administration expenses
– depreciation and amortisation 	(144) 	– 	(12) 	(64) 	(314) 	(420) 	(49) 	(799) 	(1 802) 	(168) 	(1 970)
– derecognition of intangible assets and property and equipment 	(4) 	– 	– 	(3) 	– 	(241) 	(19) 	(57) 	(324) 	– 	(324)
– impairment of intangible assets and property and equipment 	– 	– 	– 	– 	– 	(45) 	– 	– 	(45) 	– 	(45)
– other expenses 	(6 173) 	(346) 	(622) 	(133) 	(1 831) 	(790) 	(373) 	(5 726) 	(15 994) 	(106) 	(16 100)
Share of net profits from equity-accounted investments 	– 	– 	– 	(16) 	– 	1 	2 	584 	571 	(46) 	525
Normalised profit/(loss) from operations 	3 698 	4 375 	1 273 	73 	(767) 	634 	589 	164 	10 039 	925 	10 964
Fair value losses on VitalityLife interest rate derivatives 	– 	– 	– 	– 	– 	– 	516 	– 	516 	(516) 	–
Investment income earned on shareholder investments and cash 	92 	– 	20 	– 	– 	– 	– 	104 	216 	(216) 	–
Intercompany investment income 	– 	– 	– 	– 	– 	– 	– 	1 184 	1 184 	(1 184) 	–
Net fair value gains/(losses) on financial assets at fair value through profit or loss 	– 	45 	95 	– 	– 	– 	– 	(2) 	138 	(138) 	–
Loss from dilution of equity accounted investments 	– 	– 	– 	(5) 	– 	– 	– 	– 	(5) 	– 	(5)
Impairment of goodwill 	– 	– 	– 	– 	– 	– 	– 	(9) 	(9) 	– 	(9)
Amortisation of intangibles from business combinations 	– 	– 	– 	(46) 	– 	– 	– 	(56) 	(102) 	102 	–
Market rentals related to Head Office building adjusted for finance costs and depreciation 	– 	– 	– 	– 	– 	– 	– 	(134) 	(134) 	134 	–
Finance costs 	(2) 	(1) 	– 	– 	– 	(8) 	– 	(1 617) 	(1 628) 	(291) 	(1 919)
Intercompany finance costs 	(348) 	– 	– 	– 	– 	– 	(316) 	(520) 	(1 184) 	1 184 	–
Foreign exchange (losses)/gains 	(4) 	33 	36 	– 	– 	1 	– 	85 	151 	– 	151
Profit/(loss) before tax 	3 436 	4 452 	1 424 	22 	(767) 	627 	789 	(801) 	9 182 	– 	9 182
Income tax expense 	(941) 	(1 192) 	(377) 	(24) 	226 	(141) 	(95) 	28 	(2 516) 	– 	(2 516)
Profit/(loss) for the year 	2 495 	3 260 	1 047 	(2) 	(541) 	486 	694 	(773) 	6 666 	– 	6 666
Profit attributable to:
– Ordinary shareholders 	2 502 	3 260 	1 047 	(2) 	(541) 	486 	694 	(842) 	6 604 	– 	6 604
– Preference shareholders 	– 	– 	– 	– 	– 	– 	– 	69 	69 	– 	69
– Non-controlling interest 	(7) 	– 	– 	– 	– 	– 	– 	– 	(7) 	– 	(7)

-- 21 of 105 --

24	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
A.2. 	Normalised profit from operations
The following table shows the main components of the normalised profit from operations for the six months ended 31 December 2023:
R million
Group
December
2023
Unaudited
Restated
Group
December
2022
Unaudited
%
Change
Restated
Group
June
2023
Unaudited
Discovery Health 	1 874 	1 748 	7 	3 698
Discovery Life 	2 267 	2 145 	6 	4 375
Discovery Invest 	620 	561 	11 	1 273
Discovery Insure – Personal lines 	20 	8 	>100 	73
Discovery Bank 	(339) 	(398) 	(15) 	(767)
Other initiatives and central costs* 	(87) 	(78) 	12 	(281)
– Discovery Vitality 	22 	21 	16
– Other initiatives and central costs 	(109) 	(99) 	(297)
Normalised profit from SA composite 	4 355 	3 986 	9 	8 371
VitalityHealth 	527 	658 	(20) 	634
VitalityLife 	390 	198 	97 	589
Closure costs of VitalityInvest in rundown* 	(57) 	(109) 	(48) 	(266)
Group other initiatives and central costs* 	(48) 	(26) 	85 	(79)
Normalised profit from UK composite 	812 	721 	13 	878
Vitality Health International – Ping An Health Insurance* 	344 	85 	>100 	609
Vitality Health International – Other* 	(173) 	(9) 	>100 	(195)
Vitality Network* 	296 	199 	49 	411
Group other initiatives and central costs* 	(12) 	(9) 	33 	(35)
Normalised profit from Vitality Global composite 	455 	266 	71 	790
Normalised profit from operations 	5 622 	4 973 	13 	10 039
* Presented in ‘All other segments’ on the Segment information disclosure note A.1.
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued

-- 22 of 105 --

A.3. 	Earnings, headline earnings and normalised headline earnings
Group
six months
ended
December
2023
Unaudited
Restated
Group
six months
ended
December
2022
Unaudited
Restated
Group
year ended
June 2023
Unaudited
Number of shares used in calculation
Weighted average number of shares in issue (’000) 	660 270 	657 288 	658 045
Diluted weighted number of shares (’000) 	663 670 	666 964 	661 328
Earnings per share (cents):
– basic 	492.9 	487.9 	986.5
– diluted 	490.4 	480.9 	981.6
Headline earnings per share (cents):
– basic 	493.8 	498.4 	1 035.3
– diluted 	491.2 	491.2 	1 030.2
Normalised headline earnings per share (cents):
– basic 	502.8 	457.0 	1 011.3
– diluted 	500.2 	450.3 	1 006.2
Weighted average number of shares
Group
six months
ended
December
2023
Unaudited
Group
ended
December
2022
Unaudited
Group
year ended
June 2023
Unaudited
Issued ordinary shares at 1 July 	658 424 	656 957 	656 957
Effect of treasury shares vested 	1 834 	310 	1 052
Effect of share options exercised and vesting of share awards 	12 	21 	36
Weighted average number of ordinary shares (basic) 	660 270 	657 288 	658 045
Effect of share options exercised and vesting of share awards 	3 400 	9 676 	3 283
Weighted average number of ordinary shares (diluted) 	663 670 	666 964 	661 328
Earnings reconciliation
R million
Group
six months
ended
December
2023
Unaudited
Restated
Group
six months
ended
December
2022
Unaudited
Restated
Group
year ended
June 2023
Unaudited
Profit attributable to ordinary shareholders adjusted for: 	3 304 	3 207 	6 604
– Profit attributable to non-forfeitable dividend share plan 	(50) 	– 	(113)
Profit attributable to ordinary shareholders of the Company (basic) 	3 254 	3 207 	6 491
25

-- 23 of 105 --

26	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.3. 	Earnings, headline earnings and normalised headline earnings continued
Headline earnings reconciliation
Headline earnings per share is disclosed per the Johannesburg Stock Exchange (JSE) Limited Listings Requirements and is calculated
in accordance with the circular titled: Headline Earnings, issued by the South African Institute of Chartered Accountants (SAICA),
as amended from time to time. Headline earnings per share is based on the net profit after tax attributable to ordinary
shareholders adjusted for items of a capital nature and the weighted average number of ordinary shares in issue.
Group
six months ended
31 December 2023
Unaudited
Restated
Group
six months ended
31 December 2022
Unaudited
Restated
Group
year
ended
30 June
2023
Unaudited
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net 	Net
Profit attributable to the ordinary shareholders 	3 254 	3 207 	6 491
Adjusted for:
– Loss on derecognition of intangible assets 	5 	(1) 	4 	82 	(17) 	65 	230
– Loss on derecognition of property and equipment 	3 	(1) 	2 	5 	(1) 	4 	27
– Loss on disposal of property and equipment 	– 	– 	– 	– 	– 	– 	7
– Impairment of goodwill 	– 	– 	– 	– 	– 	– 	9
– Impairment of property and equipment 	– 	– 	– 	– 	– 	– 	45
Adjustments attributable to equity-accounted
investments:
– Loss on dilution and disposal of equity-accounted
investments 	– 	– 	– 	– 	– 	– 	4
Headline earnings (basic and diluted) 	3 260 	3 276 	6 813
Normalised headline earnings reconciliation
Normalised headline earnings is calculated per Discovery’s policy as set out in the Accounting Policies in section C.2. Management
considers that Normalised headline earnings is an appropriate alternative performance measure to enhance the comparability and
understanding of the financial performance of the Group.
Group
six months ended
31 December 2023
Unaudited
Restated
Group
six months ended
31 December 2022
Unaudited
Restated
Group
year
ended
30 June
2023
Unaudited
R million 	Gross 	Tax 	Net 	Gross 	Tax 	Net 	Net
Headline earnings 	3 260 	3 276 	6 813
Adjusted for:
– Gain on fair value changes in respect of swaption
contract in VitalityLife 	– 	– 	– 	(391) 	80 	(311) 	(248)
– Amortisation of intangible assets arising from
business combinations 	28 	(7) 	21 	27 	(5) 	22 	44
– Restructuring cost 	20 	(5) 	15 	– 	– 	– 	–
Adjustments attributable to equity-accounted
investments:
– Amortisation of intangible assets arising from
business combinations 	24 	– 	24 	17 	– 	17 	46
Normalised headline earnings (basic and diluted) 	3 320 	3 004 	6 655

-- 24 of 105 --

27
A.4. 	Revenue from non-insurance activities
Discovery Group’s Revenue includes: Fee income from administration business, Vitality Income and Banking fee and commission
income.
The split of revenue per geographical region and reportable segment can be viewed in Note A.1. Segment information.
The split of revenue according to the timing of satisfaction of performance obligations, i.e. over time or a point-in-time, is as follows:
R million
Group
December
2023
Unaudited
Restated
Group
December
2022
Unaudited
Fee income from administration business 	6 903 	6 348
– Over time 	6 886 	6 330
– Point-in-time 	17 	18
Vitality Income 	2 135 	1 943
– Over time 	1 362 	1 317
– Point-in-time 	773 	626
Banking fee and commission income 	845 	583
– Over time 	471 	249
– Point-in-time 	374 	334
A.5. 	Borrowings at amortised cost
R million 	Reference
December
2023
Unaudited
June
2023
Audited
Borrowing from banks and listed debt 	16 226 	16 328
– UK borrowings 	A.5.1. 	3 621 	3 682
– South African borrowings 	A.5.2. 	12 605 	12 646
Bank overdraft in underlying liabilities of consolidated Unit Trusts 	– 	33
Lease liabilities 	4 265 	4 225
– 1 Discovery Place (1 DP) 	3 294 	3 326
– Other lease liabilities 	971 	899
Total borrowings at amortised cost 	20 491 	20 586
A.5.1 UK borrowings
Carrying value GBP/Rand million
Facility amount
GBP million 	Variable rate 	Capital repayment and maturity date
December 2023
Unaudited
June 2023
Audited
GBP 	R 	GBP 	R
25 	SONIA + 2.75% 1 	At maturity – 23 December 2025 	25 	587 	25 	597
75 	SONIA + 3.00%1 	At maturity – 21 December 2025 	75 	1 762 	75 	1 793
55 	SONIA + 2.85%1 	At maturity – 12 December 2025 	54 	1 272 	54 	1 292
Total UK borrowings at amortised cost 	154 	3 621 	154 	3 682
1 Interest payable quarterly in arrears.
Total finance costs in respect of the UK borrowings for the period ended 31 December 2023 was £6.5 million (R153 million)
(31 December 2022: £4.3 million (R88 million)).

-- 25 of 105 --

28	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued
A.5. 	Borrowings at amortised cost continued
A.5.2 South African borrowings
CREDIT RATING
In December 2023 Moody’s Investors Service (“Moody’s”) reaffirmed Discovery Limited’s global-scale long-term issuer rating of Ba3
and the national-scale long-term issuer rating at A1.za. The outlook remained unchanged as stable, aligned to the outlook of
the country.
A5.2.1 DISCOVERY LIMITED
Carrying value R million
Facility amount
R million 	Variable rate
Interest rate
per annum 	Capital repayment and maturity date
December
2023
Unaudited
June
2023
Audited
Listed DMTN1
500 	3-month Jibar + 205 bps 	4.25%2,3 	At maturity – 21 August 2023 	– 	505
200 	– 	10.46%4 	At maturity – 21 November 2024 	202 	202
800 	3-month Jibar + 191 bps 	8.40%2,3 	At maturity – 21 November 2024 	809 	808
1 200 	3-month Jibar + 191 bps 	7.30%2,3 	At maturity – 21 November 2024 	1 217 	1 218
700 	3-month Jibar + 180 bps 	8.49%2,3 	At maturity – 21 August 2026 	707 	707
300 	3-month Jibar + 180 bps 	7.60%2,3 	At maturity – 21 August 2026 	304 	304
792 	3-month Jibar + 173 bps 	7.98%3,5 	At maturity – 21 May 2027 	800 	799
226 	3-month Jibar + 180 bps 	7.98%3,5 	At maturity – 21 May 2029 	228 	228
Unlisted DMTN
2 500 	– 	9.62%3 	At maturity – 22 February 2025 	2 524 	2 522
1 650 	– 	9.55%3 	At maturity – 10 March 2026 	1 658 	1 658
Other
1 000 	3-month Jibar + 190 bps 	8.38%2 	At maturity – 2 March 2028 	996 	997
500 	3-month Jibar + 190 bps 	At maturity – 2 March 2028 	499 	–
Total Discovery Limited borrowings 	9 944 	9 948
1 DMTN refers to the R10 billion Discovery Domestic Medium Term Note (DMTN) program registered in 2017.
2 The interest rate has been fixed through interest rate swaps.
3 Interest is payable quarterly in arrears.
4 Interest is payable semi-annually in arrears.
5 The interest rate has been fixed through interest rate swaps and/or subject to interest rate caps.
A5.2.2 DISCOVERY CENTRAL SERVICES
Carrying value R million
Facility amount
R million 	Interest rate per annum 	Capital repayment and maturity date
December
2023
Unaudited
June
2023
Audited
1 400 	9.97% 1,2 	At maturity – 20 December 2028 	1 404 	1 408
650 	11.56%3 	At maturity – 29 October 2027 	412 	445
691 	3-month Jibar + 1.9% 	At maturity – 30 June 2027 	694 	694
1 500 	3-month Jibar + 1.45% 	At maturity – 8 June 2024 	151 	151
Total Discovery Central Services borrowings 	2 661 	2 698
1 Interest payable quarterly in arrears.
2 The interest rate on the facility has changed from a floating interest rate of 3-month Jibar +2.05% to a fixed interest rate of 9.97% due to
refinancing of the loan during the current financial period.
3 Instalments of interest and capital are monthly.
Total finance costs in respect of South African borrowings and related hedges for the six months ended 31 December 2023 was
R640 million (31 December 2022: R615 million).

-- 26 of 105 --

29
A.6. 	Fair value hierarchy of financial instruments
The Group’s financial instruments measured at fair value have been disclosed using a fair value hierarchy. The hierarchy has three
levels that reflect the significance of the inputs used in measuring fair value. These are as follows:
Level 1: includes financial instruments that are measured using unadjusted, quoted prices in an active market for identical financial
instruments. Quoted prices are readily and regularly available from an exchange, dealer, broker, industry group, pricing service or
regulatory agency and those prices represent actual and regularly occurring market transactions on an arm’s length basis.
Level 2: includes financial instruments that are valued using techniques based significantly on observable market data. Instruments
in this category are valued using:
(a) quoted prices for similar instruments or identical instruments in markets which are not considered to be active; or
(b) valuation techniques where all the inputs that have a significant effect on the valuation are directly or indirectly based on observable
market data.
Level 3: includes financial instruments that are valued using valuation techniques that incorporate information other than observable
market data and where at least one input (which could have a significant effect on the instruments’ valuation) cannot be based on
observable market data.
R million (unaudited)
December 2023
Level 1 	Level 2 	Level 3 	Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	61 141 	6 917 	– 	68 058
– Debt portfolios 	44 380 	1 367 	– 	45 747
– Money market portfolios 	– 	17 707 	– 	17 707
– Multi-asset portfolio 	– 	23 660 	– 	23 660
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	20 	– 	20
– not designated as hedging instruments 	– 	137 	– 	137
Total financial assets 	105 521 	49 808 	– 	155 329
Financial liabilities
Third-party interest in consolidated funds 	– 	29 704 	– 	29 704
Investment contracts at fair value through profit or loss 	– 	21 980 	– 	21 980
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	35 	– 	35
Total financial liabilities 	– 	51 719 	– 	51 719
There were no transfers between level 1 and 2 during the current financial period.

-- 27 of 105 --

30	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
A.6. 	Fair value hierarchy of financial instruments continued
June 2023
R million (unaudited) 	Level 1
Restated
Level 2 	Level 3
Restated
Total
Financial assets
Financial instruments mandatorily at fair value through
profit or loss:
– Equity portfolios 	50 204 	6 321 	– 	56 525
– Debt portfolios 	40 852 	1 721 	– 	42 573
– Money market portfolios 	– 	22 656 	– 	22 656
– Multi-asset portfolios 	– 	33 672 	– 	33 672
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	59 	– 	59
– not designated as hedging instruments 	– 	60 	– 	60
Total financial assets 	91 056 	64 489 	– 	155 545
Financial liabilities
Third-party interest in consolidated funds 	– 	28 346 	– 	28 346
Investment contracts at fair value through profit or loss 	– 	28 903 	– 	28 903
Derivative financial instruments at fair value:
– used as cash flow hedges 	– 	1 	– 	1
– not designated as hedging instruments 	– 	19 	– 	19
Total financial liabilities 	– 	57 269 	– 	57 269
Specific valuation techniques used to value financial instruments in level 2
If a quoted market price is not available on a recognised stock exchange or from a broker for non-exchange traded financial
instruments, the fair value of the instrument is estimated by the asset managers, using valuation techniques including the use of
recent arm’s length market transactions, reference to the current fair value of another instrument that is substantially the same,
discounted cash flow techniques, option pricing models or other valuation techniques that provide a reliable estimate of prices
obtained in actual market transactions.
A. 	NOTES TO THE SUMMARISED FINANCIAL STATEMENTS continued

-- 28 of 105 --

31
A.6. 	Fair value hierarchy of financial instruments continued
Valuation techniques used in determining the fair value of assets and liabilities:
Instruments 	Valuation technique
Main inputs and assumptions
for level 2 fair value hierarchy
items
Within equity
portfolios,
Equity-linked
notes
The calculation of the daily value of the equity-linked investments is
made by the provider of the note. Discovery has procedures in place
to ensure that these prices are correct. Aside from the daily
reasonableness checks versus similar funds and movement since
the prior day’s price, the fund values are calculated with reference
to a specific formula or index, disclosed to the policyholders, which
is recalculated by Discovery in order to check if the price provided
by the provider is correct.
– discount rate
– spot price of the underlying
Debt portfolios
and Money
market
instruments
Money market instruments are valued by discounting the future
cash flows using a risk-adjusted discount rate.
– discount rate, credit spread
Multi-assets 	The fair values of third-party financial liabilities arising on the
consolidation of mutual funds are determined using the quoted put
(exit) price provided by the fund manager and discounted for the
applicable notice period. The fair value of a financial liability with a
demand feature is not less than the amount payable on demand,
discounted from the first date on which the amount could be
required to be paid.
– discount rate
Third-party
interest in
consolidated funds
and Investment
contracts at fair
value through
profit or loss
Unit-linked policies: assets which are linked to the investment
contract liabilities are accounted for by the Group. The investment
contract obliges the Group to use these assets to settle these
liabilities. Therefore, the fair value of third-party interest in
consolidated funds and investment contract liabilities is determined
with reference to the fair value of the underlying assets (i.e. amount
payable on surrender of the policies).
Annuity: certain discounted cash flow models are used to determine
the fair value of the stream of future payments.
– discount rate
– spot price of the underlying
Derivatives 	Standard derivative contracts are valued using market accepted
models and quoted parameter inputs. More complex derivative
contracts are modelled using more sophisticated modelling
techniques applicable to the instrument. Techniques include:
 Discounted cash flow model
 Black-Scholes model
 Combination technique models
– discount rate
– spot price of the underlying
– correlation factors
– volatilities
– earnings yield
– valuation multiples

-- 29 of 105 --

32	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Other significant
items in these
results
B.1. 	Exchange rates to the South African Rand used in the
preparation of these results
B.2. 	Capital management, financial leverage ratio and covenants
B.3. 	Impact of and volatility in long-term interest rates in
the SA and UK markets
B.4. 	Change in hedge strategy – VitalityLife business
B.5. 	Consolidation of Discovery Unit Trusts
B.6. 	Material transactions with related parties
B.8. 	Changes in directorate
B.7. 	Major customers and other Discovery entities not part
of Discovery Group
B.9. 	Dividend declaration in respect of the six months ended
31 December 2023
B

-- 30 of 105 --

33
B.1. 	Exchange rates to the South African Rand used in the preparation of these results
Closing rates 	Average rates
Exchange rate
to SA rand
December
2023
June
2023
Change
%
June
2022
December
2023
December
2022
June
2023
US dollar 	18.54 	18.87 	(2) 	16.47 	18.71 	17.35 	17.79
Pound sterling 	23.57 	23.99 	(2) 	20.00 	23.43 	20.38 	21.43
Chinese Yuan 	2.61 	2.60 	– 	2.46 	2.58 	2.48 	2.55
B.2. 	Capital management, financial leverage ratio and covenants
The Group’s capital is defined as capital and reserves attributable to shareholders, as presented in the Group statement of financial
position. The Group’s objectives when managing capital are:
 To comply with the statutory capital requirements required by the regulators of the insurance markets in which the Group
operates;
 To maintain a capital buffer in excess of the statutory capital requirements in order to reduce the risk of breaching the statutory
requirements in the event of deviations from the main assumptions affecting the Group’s insurance businesses;
 To ensure that sufficient capital is available to fund the Group’s working capital and strategic capital requirements;
 To achieve an optimal and efficient capital funding profile; and
 To consider capital management needs both in the short term and over a five-year planning horizon.
Discovery has a Finance and Capital Committee that ensures alignment in strategic financial management between the centre and
subsidiaries within South Africa, UK and US. The committee is the governance body for all capital allocation activities across the
Group ultimately overseen by the Board.
A range of capital raising options are available to manage the capital structure of the Group, which includes the issue of new shares,
debt, reinsurance arrangements and other hybrid instruments.
Financial leverage ratio
As part of the capital management process, the Group monitors its capital structure utilising various measures, one of which is the
Financial Leverage Ratio (FLR). This ratio is calculated as total debt1 divided by total debt plus total equity. The Group’s strategy is to
maintain a prudent FLR of 28.0% per the Group Risk Appetite statement. However, the 28.0% measure is merely a risk appetite
indicator and does not necessarily indicate any form of a breach in terms of regulatory or covenant restrictions.
The table below summarises the FLR position as at the end of the reporting period. With the adoption of IFRS 17, a significant
amount has been reallocated to contractual service margin (CSM) and risk adjustment. In line with developing market practice this
CSM balance, representing the present value of margins to be released in future, is taken into account in the calculation of the FLR.
While some insurers recognise more, it appears that most ratings agencies the inclusion of at least 50% of the CSM into the equity
denominator.
R million
December
2023
Unaudited
June
2023
restated
Audited
1 July
2022
restated
Unaudited
– Borrowings at amortised cost1 	16 226 	16 361 	16 464
– Guaranteed deposit facilities 	– 	– 	300
Total debt and guarantees1 	16 226 	16 361 	16 764
Total equity 	52 206 	48 388 	40 822
Total Contractual Service Margin (CSM) 2 	27 838 	28 064 	25 938
Financial leverage ratio % (no CSM factored in) 2 	23.7% 	25.3% 	29.1%
Financial leverage ratio % (50% CSM factored in)2 	19.7% 	20.8% 	23.8%
1 Excluding all lease liabilities under IFRS 16 Leases of R4 265 million (30 June 2023: R4 225 million).
2 CSM net of reinsurance and net of tax.
The FLR at 31 December 2023 is within Discovery’s risk appetite.
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS

-- 31 of 105 --

34	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.2. 	Capital management, financial leverage ratio and covenants continued
Regulatory capital
For Group subsidiaries that operate in the insurance and financial services sectors, the relevant regulator specifies the minimum
amount and type of capital that must be held by each of the subsidiaries in addition to their insurance liabilities. The minimum
required capital must be maintained at all times throughout the period.
Discovery Life and Discovery Insure are regulated under the Insurance Act 18 of 2017 (Insurance Act), and the related Prudential
Standards, while VitalityHealth and VitalityLife are regulated under the European Solvency II regulatory regime.
The table below summarises the capital requirements on the statutory basis, across the Group subsidiaries, and the actual solvency
capital held in relation to these requirements as at the end of the reporting period.
December 2023 	June 2023
Statutory capital requirements 	Cover 	Statutory capital requirements 	Cover
Discovery Life 1 	R22 173 million 	1.8 times 	R20 814 million 	1.9 times
Discovery Insure 	R1 191 million 	1.5 times 	R1 113 million 	1.6 times
VitalityHealth 	£135.5 million 	1.4 times 	£130.8 million 	1.4 times
R3 194 million 	R3 139 million
VitalityLife 	£303.4 million 	2.3 times 	£272.1 million 	2.1 times
R7 150 million 	R6 528 million
Debt covenants
As per JSE Limited Listings and Debt Listings disclosure requirements, the following are the key debt covenant ratios and their
proximity to minimum requirements as per the contractual financial covenants.
Debt covenant 	Minimum requirement
December
2023
June
2023
Restated
Group debt1 to EBITDA Ratio2 	Less than 2.5 times 	1.4 times 	1.4 times
Group financial indebtedness to embedded value
– Group financial indebtedness is as per Group
debt in the calculation above
Less than 30% of Group
Embedded value
16.7% 	17.6%
Discovery Life Statutory Capital Requirement
(SCR)
SCR cover must be more than
1.1 times
1.8 times 	1.9 times
Group embedded value 	Greater than R30 billion 	R103 480 million 	R98 176 million
New business embedded value must not
be negative
Positive value of new business for
3 consecutive 6-month periods
December 2023:
R684 million
June 2023:
R500 million
December 2022:
R940 million
June 2023:
R500 million
December 2022:
R940 million
June 2022:
R1 234 million
1 Group debt is contractually defined and means the aggregate consolidated financial indebtedness of the Group and excludes items such as the
1 DP lease and includes guarantees issued to third parties.
2 EBITDA is contractually defined and specifically includes items such as dividends from associates, rental paid on 1DP and excludes items deemed
extraordinary and specified Financial Reinsurance (FinRe) arrangements.

-- 32 of 105 --

35
B.3. 	Impact of and volatility in long-term interest rates in the SA and UK markets
The long-term insurance businesses in South Africa (SA) and the United Kingdom (UK) are exposed to long-term nominal and real
interest rates, given the impact of rates on the long-term assumptions applicable to the valuation of insurance contracts. Under
IFRS 17, Discovery reflects the effects of financial risk, such as interest rates, as insurance finance income and expense (IFIE) in profit
or loss and other comprehensive income (OCI). (Refer to section D for further discussion on accounting for financial risk under
IFRS 17).
As communicated previously, the year ended 30 June 2023 was characterised by aggressive global monetary policy tightening by
central banks following sustained inflationary pressures, which resulted in rapidly increasing global bond yields.
Economic and political pressures in SA further contributed to increasing SA bond yields. For Discovery Life, increasing long-term
interest rates mainly manifest as a lower discounted value of future cash flows and, therefore, a lower valuation of those contracts.
The significant increase in interest rates during the three preceding financial years resulted in Discovery Life recognising an
accumulated IFIE expense in both profit or loss and OCI arising from changes in the valuation of insurance contracts. For the six
months ended 31 December 2023, long-term interest rates have remained relatively stable against the levels at 30 June 2023,
resulting in minor changes in the IFIE due to the valuation change. The IFIE expense within profit or loss for the six months includes
the effect of the IFIE previously recognised in OCI reclassifying to profit or loss.
In the UK, as noted at the time, the UK bond markets experienced significant volatility following political changes and rising inflation
levels resulting in interest rates increasing for the year ended 30 June 2023. For UK Life, within the PAC arrangement, the effect of
interest rates is largely hedged, resulting in limited IFIE impact due to changes in the valuation of insurance contracts. For VitalityLife,
increasing long-term interest rates manifest mainly as a lower discounted value of future cash flows and, therefore, a lower
valuation of those contracts. The effect of higher inflation rates within the UK market reflected positively on the inflation-linked
policies, resulting in a positive impact on valuation. For the six months ended 31 December 2023, long-term interest rates have
decreased significantly, resulting in a significant IFIE income recognised in OCI, with some value also being realised in profit or loss
due to the valuation change.
B.4. 	Change in hedge strategy – VitalityLife business
The introduction of IFRS 17 enabled VitalityLife to use the OCI election to remove the volatility of reported financial performance
arising from changes in economic assumptions and present a more reflective performance of the business over the long term. Given
this change, several of the VitalityLife swaps were exited shortly before the end of the year ended 30 June 2023. In addition, the
swaption purchased in June 2022 was sold in June 2023 as the business is now able to manage any remaining risk within its risk
appetite without incurring the ongoing costs of purchasing swaptions. The net fair value gain on this swaption for the comparative
six-month period ended 31 December 2022 of £15.3 million, net of tax, (R311 million) was excluded in the presentation of
normalised profit from operations measure and other normalised measures. VitalityLife continues to hold certain interest rate
swaps and total returns swaps (“TRS”) to manage the interest rate risk on the legacy PAC book of business. These instruments are
now contracted on the balance sheet of the PAC and, therefore, deemed integral to the underlying insurance contracts entered into
under IFRS17, and valuation movements are treated accordingly.

-- 33 of 105 --

36	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
B. 	OTHER SIGNIFICANT ITEMS IN THESE RESULTS continued
B.5. 	Consolidation of Discovery Unit Trusts
Unit trusts which the Group controls in terms of IFRS 10 Consolidated Financial Statements are consolidated into Discovery’s results
for accounting purposes, which results in the recognition of the underlying assets and liabilities of each of the funds.
As these policies are linked, the consolidation of the Discovery Unit Trusts has no impact on the net asset value for shareholders.
Assets and liabilities of these Discovery Unit Trusts however increased by R1 618 million, compared to the prior financial year ended
30 June 2023, with movements in the following line items on the Group’s statement of financial position:
R million
December
2023
Restated
June
2023 	Movements
Investments at fair value through profit or loss 	27 306 	25 439 	1 867
Contract receivables and other receivables 	669 	643 	26
Cash and cash equivalents 	2 071 	2 435 	(364)
Other assets 	89 	– 	89
Total change in assets 	30 135 	28 517 	1 618
Third-party interest in consolidated funds 	29 704 	28 346 	1 358
Borrowings at amortised costs (bank overdraft) 	– 	33 	(33)
Other payables and provisions 	431 	482 	(51)
Liabilities arising from insurance contracts issued1 	– 	(346) 	346
Other liabilities1 	– 	2 	(2)
Total change in liabilities 	30 135 	28 517 	1 618
1 The comparative balances have been restated for the reclassification of balances between Liabilities arising from insurance contracts issued and
Other liabilities.
There are significant trade volumes in the underlying funds of Discovery Unit Trusts. The cash flow impact of the movement in
policyholder investments for the period is included in the following line items on the Group’s statement of cash flows:
 Purchase of investments held to back policyholder liabilities includes cash outflows of R16 626 million.
 Proceeds from the disposal of investments held to back policyholder liabilities includes cash inflows of R15 707 million.
B.6. 	Material transactions with related parties
Discovery Long-term Incentive Plan Trust
At the Annual General Meeting (AGM) held on 28 November 2019, the shareholders approved the establishment of the Discovery
Long- term Incentive Plan Trust (Trust) with the purpose, inter alia, to subscribe, purchase and/or otherwise acquire and hold
Discovery ordinary shares from time to time for the benefit of the share-based payment plan for employees, in accordance with the
requirements of the Trust. During December 2023, 3 227 675 (31 December 2022: 4 182 946) new shares were issued by Discovery
Limited to the Trust at a value of R432 million (31 December 2022: R514 million). In addition, during the six months ended
31 December 2023, shares of 3 650 844 vested with participants. In terms of IFRS Accounting Standards, while held in the Trust,
these shares are treated as treasury shares and not treated as issued for accounting purposes.
B.7. 	Major customers and other Discovery entities not part of Discovery Group
Discovery Health Medical Scheme (DHMS)
Discovery Health administers DHMS and provides managed care services, for which it charges an administration fee and a managed
healthcare fee, respectively. These fees are determined on an annual basis and approved by the trustees of DHMS. The fees totalled
R3 857 million for the six months ended 31 December 2023 (31 December 2022: R3 546 million). Discovery offers the members of
DHMS access to the Vitality programme.

-- 34 of 105 --

37
B.8. 	Changes in directorate
Changes to the Board of Discovery Limited from 1 July 2023 to the date of this announcement are as follows:
 Ms L Chiume was appointed to the board as an independent non-executive director effective from 18 September 2023. She
is a member of the Discovery Limited Audit Committee and the Group and South African Risk and Compliance Committees.
She brings a wealth of financial services and investment experience.
 Ms KC Ramon was appointed to the board as an independent non-executive director effective from 18 September 2023
and as a member of the Discovery Limited Audit Committee and the Social and Ethics Committee. She brings diverse
leadership and board experience in multiple sectors. Effective 17 November 2023, she was appointed as a member of both
the Treating Customers Fairly and Remuneration Committees.
 Dr TV Maphai retired from the board as non-executive director effective 16 November 2023 at the conclusion of the AGM
to pursue other external opportunities. He served on various committees in a range of capacities over his tenure. He also
retired as a member of the Nominations Committee.
 Ms S Zilwa retired from the board as non-executive director effective 16 November 2023 at the conclusion of the AGM to pursue
other external opportunities. She served as a non-executive director of the Company since 2003 and on various Committees in
a range of capacities over the years. She also retired as a member and Chairperson of the Social and Ethics and a member of
the Risk and Compliance Committees.
 Mr T Mboweni has been appointed as a member of the Nominations Committee effective 17 November 2023.
 Ms FN Khanyile has been nominated as the chairperson of the Social and Ethics Committee effective 17 November 2023.
B.9. 	Dividend declaration in respect of the six months ended 31 December 2023
B Preference share cash dividend declaration
On Wednesday, 28 February 2024 the Board of Directors declared an interim gross cash dividend of 592.32877 cents (473.86302
cents net of dividend withholding tax) per B preference share for the period 1 July 2023 to 31 December 2023, payable from the
income reserves of the Company. A dividend withholding tax of 20% will be applicable to all shareholders who are not exempt.
The issued preference share capital at the declaration date is 8 million B preference shares.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Monday, 18 March 2024
Shares commence trading “ex” dividend 	Tuesday, 19 March 2024
Record date 	Friday, 22 March 2024
Payment date 	Monday, 25 March 2024
B preference share certificates may not be dematerialised or rematerialised between Tuesday 19 March 2024 and Friday 22 March 2024,
both days inclusive.
Ordinary share cash dividend declaration
On Tuesday, 19 March 2024, the Board of Directors declared an interim gross cash dividend of 65.00000 cents (52.00000 cents net
of dividend withholding tax) per ordinary share, out of the income reserves of Discovery Limited. A dividend withholding tax of 20%
will be applicable to all shareholders who are not exempt.
The number of ordinary shares in issue at the date of declaration is 676 374 092.
The salient dates for the dividend will be as follows:
Last day of trade to receive a dividend 	Tuesday, 16 April 2024
Shares commence trading “ex” dividend 	Wednesday, 17 April 2024
Record date 	Friday, 19 April 2024
Payment date 	Monday, 22 April 2024
Share certificates may not be dematerialised or rematerialised between Wednesday 17 April 2024 and Friday 19 April 2024, both
days inclusive.

-- 35 of 105 --

38	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Accounting
policies
C.1. 	New Accounting Standards and amendments to published
Accounting Standards not yet effective
C.2. 	Normalised headline earnings
C.3. 	Basis of preparation
C

-- 36 of 105 --

39
C. 	ACCOUNTING POLICIES
C.1. 	New Accounting Standards and amendments to published Accounting Standards not
yet effective
 For new Accounting Standards and interpretations that became effective for the financial year commencing 1 July 2023, refer to
Section D New Standards and interpretations and restatements. The section also includes the first-time adoption of IFRS 17.
 Discovery has not early adopted any IFRS Accounting Standards, amendments, or interpretations that have been issued but
have yet to be effective. Discovery does not expect any new IFRS® Accounting Standards, amendments, or interpretations that
have been issued but have yet to be effective to have a material impact on recognised amounts.
C.2. 	Normalised headline earnings
Discovery assesses its performance using normalised headline earnings, an alternative profit measure not under the IFRS
Accounting Standards, alongside its IFRS Accounting Standards profit measures. Management considers that Normalised
Headline Earnings Per Share (NHEPS) is an appropriate alternative performance measure to enhance the comparability and
understanding of the financial performance of the Group.
Measures not in terms of IFRS Accounting Standards are not uniformly defined or used by all entities and may not be
comparable with similarly labelled measures and disclosures provided by other entities.
Discovery calculates headline earnings in accordance with the latest SAICA circular ’Headline Earnings’. NHEPS is calculated by
starting with headline earnings and adjusted to exclude material items that are not considered to be part of Discovery’s normal
operations as follows:
 Once-off transactions – for example, restructuring costs, transaction costs related to interest rate derivatives and initial
deferred tax assets raised on previously unrecognised assessed losses.
 Unusual items – Discovery considers items to be unusual when they have limited predictive value, or it is reasonable that items
of a similar nature would not necessarily arise for several future reporting periods.
 Income or expenses not considered to be part of Discovery’s normal operations – for example, amortisation of intangibles from
business combinations and fair value gains or losses on foreign exchange contracts not designated as hedges.
Management is responsible for the calculation of NHEPS and determining the inclusions and exclusions in accordance with the
policy. The Discovery Limited Audit Committee reviews the normalised headline earnings for transparency and consistency.
C.3. 	Basis of preparation
Statement of compliance
Discovery Limited is a company incorporated in South Africa.
The unaudited condensed consolidated interim financial statements for the six months ended 31 December 2023 (interim results)
consolidate the results of Discovery and its subsidiaries (together the Group) and equity account for the Group’s interest in
associates and joint ventures.
The interim results comprise the condensed Group statement of financial position at 31 December 2023, condensed Group income
statement, condensed Group statement of comprehensive income, condensed Group statement of changes in equity, and
condensed Group statement of cash flows for the six months ended 31 December 2023, and selected explanatory notes.
The interim results have been prepared in accordance with the JSE Limited Listings and Debt Listings Requirements, IFRS Accounting
Standards and its interpretations adopted by the IASB including IAS 34 Interim Financial Reporting (IAS 34), the SAICA Financial
Reporting Guides as issued by the Accounting Practices Committee and Financial Pronouncements as issued by the Financial
Reporting Standards Council as well as the requirements of the South African Companies Act 71 of 2008. The accounting policies
adopted are consistent with the accounting policies applied in the prior Annual financial statements, except for the application of
the newly adopted Accounting Standard IFRS 17 Insurance Contracts.
Amendments to IFRS Accounting Standards effective from 1 July 2023 do not have a material effect on the Group’s interim results.
These interim results do not include all the notes typically included in the annual financial statements and must be read together
with the Group audited consolidated financial statements for the year ended 30 June 2023.
Independent Auditors’ review
The interim results for the six months ended 31 December 2023 and the 31 December 2022 comparative information have not been
reviewed or audited by the Group’s independent auditors Deloitte & Touche and KPMG Inc. The independent auditors have
reviewed the restated impacted financial statement captions following the adoption of IFRS 17 “Insurance Contracts” and the specific
financial statement captions impacted by other restatements and other presentation changes as at 30 June 2023 and 1 July 2022,
as detailed in notes D1.1, D1.2 and D1.3. Refer to the independent auditors’ Review Report on the restated IFRS 17 and Other
Presentation Changes and Restated Financial information pages 110 to 111.
Comparative information
Comparative information presented at and for the year ended 30 June 2023 within these financial statements has been extracted
from the Group’s audited consolidated financial statements for the year ended 30 June 2023, except as restated per notes D1.1,
D1.2, D1.3.

-- 37 of 105 --

40	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
New standards and
interpretations and
restatements
D.1.1. 	IFRS 17 Insurance Contracts (IFRS 17)
D.1.2. 	Restatement as a result of prior period errors
D.1.3. 	Changes in presentation of specified line items on the
statement of financial position
D.2. 	IFRS 17 Accounting policies
D.3. 	Critical estimates and judgements
D.4. 	Insurance and reinsurance contract notes
D

-- 38 of 105 --

41
D.1.1 IFRS 17 Insurance Contracts
Introduction
IFRS 17 became effective for the Discovery Group from 1 July 2023, with comparative restatement of the preceding year, namely the
financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as at 1 July 2022.
IFRS 17 is a new Accounting Standard for insurance contracts that provides guidelines on recognising, measuring, presenting, and
disclosing insurance contracts. It was introduced by the International Accounting Standards Board (IASB)® in May 2017. IFRS 17
replaces the previous Accounting Standard, IFRS 4, issued in 2005 as an interim Accounting Standard with limited prescribed
changes to pre-existing insurance accounting practices applied by insurers.
IFRS 17 represents a positive step towards enhancing transparency, comparability, and understanding of how insurers earn profits
from insurance contracts, namely insurance service result and financial results. The framework established by IFRS 17 outlines the
specific requirements that companies must adhere to when reporting information related to both the insurance contracts they issue
and the reinsurance contracts they hold. One of the noteworthy distinctions introduced by IFRS 17 pertains to the level of granularity
at which insurance contracts are recognised and measured. Discovery was well-prepared to embrace this enhanced granularity, as
it aligns with the Group’s actuarial approach.
IFRS 17 is not limited to insurance companies but also those companies that issue any contract that results in transfer of significant
insurance risk. For Discovery, the contracts within the scope of IFRS 17 are almost entirely aligned with those recognised in IFRS 4.
Whilst the underlying contractual terms and economic risks and rewards of each insurance contract remain unaltered, IFRS 17
impacts the accounting treatment of insurance contracts and most notably the timing of recognition of insurance related profits and
losses for accounting purposes. Importantly, it also separates the insurance related profit or losses between those arising from
insurance service results and those arising from financial results. IFRS 17 does not result in a change in the underlying business
value of contracts, including:
 No direct change to cash flows or underlying risk and reward of contracts. Future tax cash flow impacts are expected to be
immaterial.
 Immaterial impact on regulatory or economic solvency, capital position and capital management.
 The ability to pay dividends unaffected as cash flows and solvency remain unchanged.
 Immaterial impact on Embedded Value.
Transition to IFRS 17
Upon first-time adoption, IFRS 17 requires the Accounting Standard to be applied fully retrospectively as if it has always applied
unless impracticable. If impracticable to do so, the entity can elect to either apply a modified retrospective approach or use the fair
value approach. Discovery applied a fully retrospective restatement from inception for all material groups of insurance contracts,
other than the businesses accounted for using the VFA approach, which relates to the Discovery Invest portfolios as detailed in note
D.2.7. Discovery did not measure any of its portfolios using the fair value approach. Note D2.7. contains a summary of those less
material instances where a modified retrospective approach was applied.
The fully retrospective approach requires that Discovery identify, recognise, and measure groups of insurance contracts as if IFRS 17
had always applied. The restatement is much more pronounced for the long-term insurance business of Discovery Life in SA and
VitalityLife in the UK. In contrast, the impact of the retrospective restatement is limited for the short-term businesses except for
VitalityHealth where the impact is more significant due to the change in the treatment of insurance acquisition costs.
The changes resulting from the transition to IFRS 17 can be summarised as follows:
 Those changes that result in differences to the IFRS 17 margins relative to the IFRS 4 margins. These changes result in
concomitant temporary changes in equity. For example, to the extent that changes resulted in the strengthening of contractual
service margins that will release to profit in future periods, such changes are mirrored by a reduction in shareholders’ equity
upon transition.
 Other changes, such as remeasurement basis of the expected future cash flows or recognised assets and liabilities from short-
term insurance, e.g., deferred acquisition costs. These remeasurements result in a change in equity on transition without a
visible offset of insurance margins but similarly will indirectly result in higher or lower net profits in future periods (for a
reduction or increase in equity respectively).
In the case of Discovery, increases in insurance margins, most notably contractual service margin (CSM), have a far more material
impact. Such resulting increases of additional IFRS 17 margins on transition will be available as future profit.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued

-- 39 of 105 --

42	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.1.1 IFRS 17 Insurance Contracts continued
Transition to IFRS 17 continued
The most significant changes that result in an increase in IFRS 17 margins relative to margins under IFRS 4 can be summarised
as follows:
 The measurement under IFRS 17 includes only those cash inflows and outflows relating directly to the fulfilment of the group
of insurance contracts, termed directly attributable expenses. In addition to claims and benefits, these may include certain
directly attributable overhead expenses. However, non-directly attributable expenses such as general marketing and
sponsorships, allocated group executive and group function costs and research and development activities of new products,
are not included in the initial recognition value of the contract. Under IFRS 17, these non-directly attributable expenses are
immediately expensed and are therefore not considered when determining the expected fulfilment cash flows (EFCF) of the
insurance contracts being measured. The immediate expensing of such non-directly attributable expenses increases the
available margin on the portfolio compared to the IFRS 4 treatment where such expenses were brought into account when
determining the available margins. It should be noted that such expenses are brought into consideration when determining the
pricing of products and these increased IFRS 17 margins are therefore similarly available for recognition as profits in future or
to absorb adverse changes.
 Contracts are measured at a more granular level where portfolios are established and as a minimum with annual business
cohorts of no more than twelve months apart. Each of these cohorts is further categorised into separate groups based on
expected profitability being profitable, profitable at risk, and onerous groups. Losses are immediately expensed when they arise
on onerous contracts, effectively eliminating any cross-subsidisation or set-off applied within a portfolio. This immediate write-
off of shortfalls on contracts effectively increases the available margin on the remainder of the portfolio, which will be
recognised to profit in future.
 Other items, including, amongst others, the different treatment of certain basis changes and variances through the margin, the
different rates at which interest is accreted on the margins, and small differences in the run-off of the margins over time are
less material in the case of Discovery. Unlike IFRS 4, IFRS 17 separately recognises the finance related consequences of
insurance contracts from the underlying insurance activities. Finance income and expense related to insurance contracts and
the changes in the measurement of finance related items are recognised as insurance finance income and expense (IFIE) either
immediately in profit or loss or disaggregated and allocated using a systematic allocation to profit or loss with variances being
recognised through other comprehensive income (OCI).
 Discovery has elected to apply the OCI option to predominantly certain long-term insurance and reinsurance contracts. The
exclusion of certain elements of IFIE from the profit or loss is largely aligned to the existing treatment where Discovery excludes
the impact of economic assumptions, net of associated derivatives, from its normalised profit and normalised headline
earnings. The use of OCI removes the need for this normalisation after adoption of IFRS 17.
Other changes, resulting in a change in equity on transition without a visible offset of insurance margins:
 The remeasurement of best estimates of the future fulfilment cash flows and measurement and accounting treatment of
insurance acquisition cash flows, i.e., deferred acquisition costs, on the short-term business lines and
 Associated deferred tax and future tax impacts of the changes noted above.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued

-- 40 of 105 --

43
IFRS 17 acknowledges that different companies may manage their insurance contracts differently. As a result, IFRS 17 is principle
based and permits several accounting policy elections. The following is a summary of these material accounting elections and
specific elections made by Discovery:
Election 	Options 	Discovery elections
Transition approach 	Three transition approaches
 IFRS 17 requires full retrospective unless
impracticable.
 If full retrospective is impracticable, then
accounting election of modified
retrospective, or
 fair value approach.
 Given the availability of reliable and
accurate data and actuarial models,
Discovery is required to apply IFRS 17 fully
retrospectively to all material portfolios.
 For the remainder of portfolios, when full
retrospective adoption was impracticable,
then the modified retrospective approach
was applied.
 Discovery has not applied the fair value
approach to any portfolio.
Changes in time value of
money (IFIE presentation)
Two alternatives:
 Present all IFIE and IFIE changes in profit
or loss.
 Include IFIE in profit or loss using
systematic allocation. Remainder
recognised in OCI.
 The use of the OCI removes the volatility
from changes in IFIE (previously economic
assumptions) in the measurement of the
insurance contract. The amount recognised
in OCI is then reclassified to profit or loss
using a systematic allocation.
 Discovery has elected OCI on its long-term
life-insurance business lines in Discovery
Individual Life and VitalityLife and
associated reinsurance contracts. Discovery
has also elected OCI for its long-term
claims in GroupLife business. For the
remainder of business lines, the change in
measurement of the insurance contracts is
offset by a change in the measurement of
the assets backing those insurance
contracts.
Risk adjustment 	 No prescriptive approach is provided under
IFRS 17.
 Discovery uses the confidence level
approach.
 For its long-term businesses and group life
insurance, Discovery sets the confidence
level at 90%.
 For its short-term businesses, Discovery
sets the confidence level at 75%.
Acquisition cost
(for portfolios at (PAA))
Two alternatives:
 The default under IFRS 17 for contracts
with PAA is to defer the insurance
acquisitions cash flows and allocate the
expense to initial and renewal periods,
i.e., defer acquisition costs and amortise.
 Entity can elect to immediately expense
insurance acquisition cash flows.
 VitalityHealth applies the default
requirement of IFRS 17. This treatment
results in a largely similar treatment to the
FinRe arrangements VitalityHealth held
under IFRS 4.
 For other insurance portfolios measured
using the PAA, Discovery has elected to
immediately expense in profit or loss the
insurance acquisition cash flows as these
are not significant.
Reflect time value of
money (i.e., discount) in
measuring coverage units
Two alternatives, accounting policy election:
 Reflect time value of money in measuring
coverage units.
 Do not reflect time value of money in
measuring coverage units.
 Discovery elected to reflect time value of
money in the measurement of coverage
units. The discounting of coverage units
provides the most reasonable emergence
of profit, considering the projected level of
future margins on retained business for
Discovery.
D.1.1 IFRS 17 Insurance Contracts continued

-- 41 of 105 --

44	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.1.1 IFRS 17 Insurance Contracts continued
Tax changes
To transition to and implement IFRS 17, amendments in tax legislation in both South Africa (Section 28 and 29A of the South African
Income Tax Act) and the United Kingdom (The Insurance Contracts (Tax) Change in Accounting Standards Regulations 2022, 2022.
No. 1165). The amendments legislated phasing-in periods of the impact, which were 3 years for Discovery Insure, 6 years for
Discovery Life Limited, and 10 years for Vitality Life Limited. The main impact on the consolidated group at transition was the
recognition and remeasurement of the related deferred tax assets and liabilities on the respective reduction in equity on transition,
reflecting the change in the timing of income tax.
D.1.2 Restatement as a result of prior period errors
Item 1: Measurement of the pre-existing relationship of receivables and payables
During the six-month period ended 31 December 2023, Discovery identified that it had incorrectly adjusted specified debtors and
creditors that were reflective of pre-existing relationships in its business acquisition of Standard Life Healthcare in July 2010 and the
DiscoveryCard acquisition in March 2019. The incorrect treatment did not affect the goodwill at acquisition. It did, however, result
in an overstatement of debtors and understatement of creditors as well as an overstatement of profit in the periods to 30 June 2022.
Discovery corrected the error in the earliest period presented, 1 July 2022.
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or
current reported period Group income statement, basic or diluted earnings per share.
Item 2: Calculation of deferred tax asset
During the six months ended 31 December 2023, Discovery reviewed the interest expense deductions in its UK business lines with
the assistance of external specialists and identified restrictions that impacted income tax in a prior period. This resulted in the
overstatement of the deferred tax asset as at 30 June 2022. Discovery corrected the error in the earliest period presented, being
1 July 2022.
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or
current reported period Group income statement, basic or diluted earnings per share.
Item 3: Calculation of foreign currency translation reserve
During the six-month period ended 31 December 2023, Discovery identified that it had incorrectly calculated the foreign currency
translation reserve (FCTR), a component of equity, for specified assets and liabilities. In this transaction, balances arising from an
intergroup transaction for the year ended 30 June 2019 were incorrectly eliminated. This treatment resulted in certain foreign-
denominated intangible assets not being revalued. Discovery corrected the error in the earliest period presented, being 1 July 2022.
The restatement has had no change to operating, investing, and financing cash flows. The correction does not impact the prior or
current reported period income statement, basic or diluted earnings per share.

-- 42 of 105 --

45
D.1.2 Restatement as a result of prior period errors continued
The tables below summarise the restatement’s impact on the Group statement of financial position:
STATEMENT OF FINANCIAL POSITION
R million
Group
30 June 2022
(previously
reported)
Item 1
Correction
Increase
(decrease)
Item 2
Correction
Increase
(decrease)
Item 3
Correction
Increase
(decrease)
Group
1 July 2022
Restated
Intangible assets 	6 539 	– 	– 	45 	6 584
Deferred tax asset 	4 455 	– 	(105) 	– 	4 350
Insurance receivables, contract receivables
and other receivables 	13 113 	(42) 	– 	– 	13 071
Other reserves 1 	3 621 	– 	– 	42 	3 663
Retained earnings 	38 972 	(103) 	(105) 	3 	38 767
Other financial payables at amortised cost 	15 123 	61 	– 	– 	15 184
1 Other reserves reflect the impact on foreign currency translation reserve (FCTR).
STATEMENT OF FINANCIAL POSITION
R million
Group
30 June 2023
(previously
reported)
Item 1
Correction
Increase
(decrease)
Item 2
Correction
Increase
(decrease)
Item 3
Correction
Increase
(decrease)
Group
30 June 2023
Restated
Intangible assets 	6 982 	– 	– 	82 	7 064
Deferred tax asset 	4 404 	– 	(126) 	– 	4 278
Insurance receivables, contract receivables
and other receivables 	16 059 	(42) 	– 	– 	16 017
Other reserves 1 	8 622 	(7 ) 	(21) 	79 	8 673
Retained earnings 	44 218 	(103) 	(105) 	3 	44 013
Other financial payables at amortised cost 	14 780 	68 	– 	– 	14 848
1 Other reserves reflect the impact on foreign currency translation reserve (FCTR).
D.1.3 Changes in presentation of specified line items on the Group statement of financial position
Discovery has improved the presentation of specified transactions in the Group statement of financial position by adding new line
items. The changes have no impact on the total value of liabilities but enable the user to better understand the financial information.
The following changes were made:
 The new line item: Third-party interest in consolidated funds was added to separately reflect the interest of third parties in the
consolidated unit funds. These third-party interests were previously included as part of Investment contracts at fair value
through profit or loss.
 The new line item: Other payables and provisions, includes Employee benefits which was previously separately disclosed in the
Group statement of financial position, as well as the non-financial payables which was previously included as part of Other
payables. Other payables have been renamed to Other financial payables at amortised cost.
In addition, the order in which individual line items are presented in the Group statement of financial position has been amended
to better reflect their respective liquidity, as far as possible, from least liquid to the most liquid items. Assets from reinsurance
contracts held has moved from being above cash and cash equivalents to being above deferred tax asset. No values were
reclassified or restated between line items other than those noted above.

-- 43 of 105 --

46	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Below is the reconciliation of the restated Group statement of financial position as at 1 July 2022:
Group
R million
30 June 2022
As previously
reported
Audited
Reviewed
D.1.1
IFRS 17
remeasurement
and
reclassifications
D.1.2
Other
restatements
D.1.3
Other
presentation
changes
1 July 2022
Restated
Assets
Goodwill 	4 912 	– 	– 	– 	4 912
Intangible assets 	6 539 	– 	45 	– 	6 584
Property and equipment 	3 811 	– 	– 	– 	3 811
Assets arising from insurance contracts issued 	56 645 	(25 782) 	– 	– 	30 863
Assets arising from reinsurance contracts held 	511 	362 	– 	– 	873
Deferred tax asset 	4 455 	1 338 	(105) 	– 	5 688
Deferred acquisition costs 1 	640 	(623) 	– 	(17) 	–
Assets arising from contracts with customers 	1 692 	– 	– 	17 	1 709
Investment in equity-accounted investees 	6 008 	330 	– 	– 	6 338
Financial assets
– Loans and advances to customers at amortised cost 	3 944 	– 	– 	– 	3 944
– Investments at amortised cost 	7 161 	– 	– 	– 	7 161
– Investments at fair value through profit or loss 	141 494 	– 	– 	– 	141 494
– Derivative financial instruments at fair value through
profit or loss 	276 	– 	– 	– 	276
Contract receivables and other receivables2 	13 113 	(7 848) 	(42) 	– 	5 223
Non-current assets held for sale 	171 	– 	– 	– 	171
Current tax asset 	220 	– 	– 	– 	220
Cash and cash equivalents3 	19 775 	(5 988) 	– 	– 	13 787
TOTAL ASSETS 	271 367 	(38 211) 	(102) 	– 	233 054
Equity
Capital and reserves
Ordinary share capital and share premium 	10 178 	– 	– 	– 	10 178
Perpetual preference share capital 	779 	– 	– 	– 	779
Other reserves 4 	3 621 	(1 420) 	42 	– 	2 243
Retained earnings 	38 972 	(11 150) 	(205) 	– 	27 617
Equity attributable to equity holders of the Company 	53 550 	(12 570) 	(163) 	– 	40 817
Non-controlling interest 	5 	– 	– 	– 	5
TOTAL EQUITY 	53 555 	(12 570) 	(163) 	– 	40 822
Liabilities
Liabilities arising from insurance contracts issued 	108 067 	(23 012) 	– 	85 055
Liabilities arising from reinsurance contracts held 	13 192 	(7 985) 	– 	– 	5 207
Deferred tax liability 	9 335 	(3 022) 	– 	– 	6 313
Contract liabilities to customers 	944 	– 	– 	– 	944
Third-party interest in consolidated funds 	– 	– 	– 	24 320 	24 320
Financial liabilities
– Borrowings at amortised cost 	20 584 	– 	– 	– 	20 584
– Other financial payables at amortised cost 	15 123 	(6 280) 	61 	(412) 	8 492
– Deposits from customers 	10 881 	– 	– 	– 	10 881
– Investment contracts at fair value through profit or
loss 	38 637 	14 638 	– 	(24 320) 	28 955
– Derivative financial instruments at fair value through
profit or loss 	202 	– 	– 	– 	202
Other payables and provisions 	– 	20 	– 	732 	752
Employee benefits 	320 	– 	– 	(320) 	–
Current tax liability 	527 	– 	– 	– 	527
TOTAL LIABILITIES 	217 812 	(25 641) 	61 	– 	192 232
TOTAL EQUITY AND LIABILITIES 	271 367 	(38 211) 	(102) 	– 	233 054
1 The deferred acquisition costs will no longer be presented separately under IFRS 17 as all insurance cash flows, payables and receivables are
presented on a net basis, either as a liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the
insurance receivables as under IFRS 17 all insurance cash flows, payables and receivables are presented on a net basis, either as a liability or an asset
arising from insurance contract issued.
3 The treatment of the PAC arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is required to reflect the underlying
assets and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching insurance contract. Discovery
is treated as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015). One key difference is the
manner in which the cash and cash equivalents, which are held as the required capital backing for the policies, are reflected. Under IFRS 17, the cash
backing the capital requirement is presented and measured as a non-distinct investment component. This differs from IFRS 4, where the cash and cash
equivalents of the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In addition to the
resultant change in cash and cash equivalents on 1 July 2022 of R5 988 million (30 June 2023 R4 110 million), it also resulted in a change in cash utilized
and generated by operations of R1 953 million for the period ending 31 December 2022 (30 June 2023 R2 744 million).
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.1.4 Reconciliation of restated Group statement of financial position

-- 44 of 105 --

47
Below is the reconciliation of the restated Group statement of financial position as at 30 June 2023:
Group
R million
30 June
2023
As previously
reported
Audited
Reviewed
D.1.1
IFRS 17
remeasurement
and
reclassifications
D.1.2
Other
restatements
D.1.3
Other
presentation
changes
30 June
2023
Restated
Assets
Goodwill 	5 406 	– 	– 	– 	5 406
Intangible assets 	6 982 	– 	82 	– 	7 064
Property and equipment 	3 910 	– 	– 	– 	3 910
Assets arising from insurance contracts issued 	63 865 	(30 951) 	– 	– 	32 914
Assets arising from reinsurance contracts held 	709 	(105) 	– 	– 	604
Deferred tax asset 	4 404 	2 042 	(126) 	– 	6 320
Deferred acquisition costs1 	799 	(779) 	– 	(20) 	–
Assets arising from contracts with customers 	2 201 	– 	– 	20 	2 221
Investment in equity-accounted investments 	7 024 	374 	– 	– 	7 398
Financial assets
– Loans and advances to customers at amortised cost 	4 702 	– 	– 	– 	4 702
– Investments at amortised cost 	9 910 	– 	– 	– 	9 910
– Investments at fair value through profit or loss 	155 426 	– 	– 	– 	155 426
– Derivatives financial instruments at fair value
through profit or loss 	119 	– 	– 	– 	119
Contract receivables and other receivables2 	16 059 	(10 333) 	(42) 	– 	5 684
Non-current assets held for sale 	– 	– 	– 	– 	–
Current tax asset 	41 	– 	– 	– 	41
Cash and cash equivalents3 	20 370 	(4 110) 	– 	– 	16 260
TOTAL ASSETS 	301 927 	(43 862) 	(86) 	– 	257 979
Equity
Capital and Reserves
Ordinary share capital and share premium 	10 351 	– 	– 	– 	10 351
Perpetual preference share capital 	779 	– 	– 	– 	779
Other reserves4 	8 622 	(5 628) 	51 	– 	3 045
Retained earnings 	44 218 	(9 804) 	(205) 	– 	34 209
Equity attributable to equity holders of the Company 	63 970 	(15 432) 	(154) 	– 	48 384
Non-controlling interest 	4 	– 	– 	– 	4
TOTAL EQUITY 	63 974 	(15 432) 	(154) 	– 	48 388
Liabilities
Liabilities arising from insurance contracts issued 	114 807 	(19 112) 	– 	95 695
Liabilities arising from reinsurance contracts held 	14 669 	(9 826) 	– 	– 	4 843
Deferred tax liability 	9 559 	(3 337) 	– 	– 	6 222
Contract liabilities to customers 	656 	– 	– 	– 	656
Third-party interest in consolidated funds 	– 	– 	– 	28 346 	28 346
Financial liabilities
– Borrowings at amortised cost 	20 586 	– 	– 	– 	20 586
– Other financial payables at amortised cost 	14 780 	(5 375) 	68 	(361) 	9 112
– Deposits from customers 	14 333 	– 	– 	– 	14 333
– Investment contracts at fair value through profit or
loss 	48 044 	9 205 	– 	(28 346) 	28 903
– Derivate financial instruments at fair value through
profit or loss 	20 	– 	– 	– 	20
Other payables and provisions 	– 	15 	– 	695 	710
Employee Benefits 	334 	– 	– 	(334) 	–
Current tax liability 	165 	– 	– 	– 	165
TOTAL LIABILITIES 	237 953 	(28 430) 	68 	– 	209 591
TOTAL EQUITY AND LIABILITIES 	301 927 	(43 862) 	(86) 	– 	257 979
1 The deferred acquisition costs will no longer be presented separately under IFRS 17 as all insurance cash flows, payables and receivables are presented on a
net basis, either as a liability or an asset arising from insurance contract issued.
2 Previously named Insurance receivables, contract receivables and other receivables. The line item description has been updated to exclude the insurance
receivables as under IFRS 17 all insurance cash flows, payables and receivables presented on a net basis, either as a liability or an asset arising from
insurance contract issued.
3 The treatment of the PAC arrangement under IFRS 17 has resulted in a fundamental change in the way Discovery is required to reflect the underlying assets
and liabilities within the PAC arrangement. Under IFRS 17, the entire PAC arrangement is reflected as an overarching insurance contract. Discovery is treated
as the reinsurer for those VitalityLife policies underwritten on the PAC life insurance license (up to 31 December 2015). One key difference is the manner in
which the cash and cash equivalents, which are held as the required capital backing for the policies, are reflected. Under IFRS 17, the cash backing the
capital requirement is presented and measured as a non-distinct investment component. This differs from IFRS 4, where the cash and cash equivalents of
the capital backing the arrangement were treated as separable components and accordingly disclosed separately. In addition to the resultant change in
cash and cash equivalents on 1 July 2022 of R5 988 million (30 June 2023 R4 110 million), it also resulted in a change in cash utilized and generated by
operations of R1 953 million for the period ending 31 December 2022 (30 June 2023 R2 744 million).
4 Included in the Other reserves line item is the new IFRS 17 reserve for the cumulative IFIE recognised in OCI.
D.1.4 Reconciliation of restated Group statement of financial position continued

-- 45 of 105 --

48	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2 	IFRS 17 Accounting policies
Abbreviations 	Meaning
CSM 	Contractual Service Margin
DAC 	Deferred Acquisition Costs
DISCOVERY 	Discovery Group
DPF 	Direct Participation Features
DRO 	Discovery Retirement Optimiser
EFCF/FCF 	Expected Fulfilment Cash Flows/Fulfilment Cash Flows
FINANCIAL RISK 	The risk of a possible future change in one or more of a specified interest rate, financial
instrument price, commodity price, currency exchange rate, index of prices or rates, credit rating
or credit index or other variable, provided in the case of a non-financial variable that the variable
is not specific to a party to the contract.
GMM 	General Measurement Model
IACF 	Initial Acquisition Cash Flows
IFIE 	Insurance finance income and expense comprises the change in the carrying amount of the
group of insurance contracts arising from:
 the effect of the time value of money and changes in the time value of money, and
 the effect of financial risk and changes in financial risk.
IFRS 	IFRS Accounting Standards
IFRS 4 	IFRS 4 Insurance Contracts (effective pre 1 July 2023)
IFRS 17 	IFRS 17 Insurance Contracts (effective post 1 July 2023)
IFRS 17 margins 	IFRS 17 margins reference to the contractual service margin plus the risk adjustments
ISE 	Insurance Service Expenses
LIC 	Liability for Incurred Claims
LRC 	Liability for Remaining Coverage
OCI 	Other Comprehensive Income
PAA 	Premium Allocation Approach
PVFCF 	Present Value of Future Cash Flows
VFA 	Variable Fee Approach
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued

-- 46 of 105 --

49
D.2.1 Insurance contracts scope and grouping
D.2.1.1 DEFINITION AND CLASSIFICATION
Insurance contracts are contracts under which Discovery accepts significant insurance risk from a policyholder by agreeing to
compensate the policyholder should a specified uncertain future event adversely affect the policyholder. Insurance contracts are
contracts under which Discovery accepts all significant insurance risk from a policyholder by agreeing to compensate the
policyholder should a specified uncertain future event adversely affect the policyholder. Reinsurance contracts are contracts under
which the reinsurer accepts significant insurance risk from Discovery. Even in situations where the contract does not expose the
reinsurer to the possibility of a significant loss, the contract will still be deemed to be a reinsurance contract transferring significant
risk if it transfers substantially all of the insurance risk resulting from the reinsured portions of the underlying reinsurance contracts.
Discovery determines whether it has assumed significant insurance risk by comparing benefits payable after an insured event with
benefits payable if the insured event had not occurred. Insurance and reinsurance contracts can also expose Discovery to financial
risk, which is not taken into account in the determination of significant insurance risk.
D.2.1.2 SEPARATING COMPONENTS WITHIN INSURANCE CONTRACTS
IFRS 17 requires an analysis of whether the contract contains components that should be separated from the insurance contract
and accounted for under different IFRS Accounting Standards. IFRS 17 requires that cash flows relating to embedded derivatives,
cash flows relating to distinct investment components and promises to transfer distinct goods or distinct services, other than
insurance contract services, be accounted for separately.
Discovery presently has no contracts requiring further separation or a combination of insurance contracts.
D.2.1.3 UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS
Under IFRS 17, the unit of account is defined as a group of insurance contracts. The way insurance contracts are grouped affects
the timing of profit recognition for insurance services but does not affect the measurement of the estimated cash flows to fulfil the
insurance contracts. In terms of IFRS 17, the unit of account is determined by first establishing a portfolio of insurance contracts and
then creating separate cohorts within the portfolio based on the date of origination. Each such cohort is further grouped into three
groupings based on estimated profitability.
Insurance contracts that are subject to similar risks and managed together
E.g., whole-of-life insurance, guarantee endowments, household insurance
Only contracts issued within a given 12-month period (cohort) can be included in the same group.
Annual cohorts are further grouped into one of the following:
Portfolio
Cohort
Groups
Onerous at initial recognition
(Onerous)
At initial recognition, no
significant possibility of
becoming onerous
(Profitable)
Other
(Profitable at risk)
IFRS 17 Illustration of principles 1: Unit of account
At initial recognition, groups of insurance contracts issued are recognised from the earliest of the following:
 The beginning of the coverage period.
 The date when the policyholder’s first payment is due or received if there is no due date.
 When Discovery determines that a group of insurance contracts become onerous
D.2 	IFRS 17 Accounting policies continued

-- 47 of 105 --

50	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2.1 Insurance contracts scope and grouping continued
D.2.1.4 MEASUREMENT MODELS
IFRS 17 provides three possible measurement models.
1. The default model is the General Measurement Model (GMM). The GMM is typically used for measuring long-term insurance risk
and annuity contracts. The basic principles are set out below.
2. The GMM is supplemented by the Variable Fee Approach (VFA) for contracts where policyholders have purchased investment-
linked insurance contracts integrated with insurance coverage (meaning insurance contracts with direct participating features).
3. The Premium Allocation Approach (PAA) is a simplified approach of the GMM for short-duration contracts such as group risk,
personal lines and private medical insurance.
Direct participating contracts are contracts for which, at inception:
 The contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items.
 Discovery expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying
items; Discovery considers that a substantial share is a majority of returns, and
 Discovery expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change
in fair value of the underlying items. Discovery considers that a substantial proportion is a majority proportion of change on a
present value probability-weighted average of all scenarios.
Within Discovery the unit-linked products and Discovery Optimiser products offered by Discovery Life are examples of insurance
contracts with DPFs.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.2 	IFRS 17 Accounting policies continued

-- 48 of 105 --

51
D.2.2 Overview of the Discovery Group portfolios, measurement models and accounting policy
elections
The table below summarises the material insurance contracts Discovery issues and reinsurance contracts it holds. It sets out the
measurement model applied and key assumptions and elections.
Measurement
Model
Risk adjustment
confidence
level 1 	Elections on IFIE
PAA only – election for
treatment of initial
acquisition cash flows (IACF)
Insurance contract issued and business lines
Individual life insurance
contracts:
Discovery Life and VitalityLife GMM
90%
Elected to present
changes in IFIE in OCI
and profit or loss.
n/a
Insurance-linked investment
contracts:
General endowments in
Discovery Invest
Elected to present
changes in IFIE in OCI
and profit or loss.
Investment contracts:
Unit-linked and DRO in
Discovery Invest
VFA
Group life insurance
contracts:
Discovery Life
PAA
90% 	Elected to present
changes in IFIE in OCI
and profit or loss for
long-tail claims.
Elected not to reflect the
interest for cash flows
less than 12 months.
Elected to immediately
expense initial acquisition
cash flows (IACF)
Car, household and business
insurance:
Discovery Insure 75% Elected not to reflect
interest for cash flows
less than 12 months
Elected to immediately
expense initial acquisition
cash flows (IACF)
Health insurance:
VitalityHealth
Consistent with default IFRS
17 requirement, defer IACF
and amortise over the initial
and renewal periods
Reinsurance contracts held
Individual life:
Quota share reinsurance
for Discovery Individual Life
and VitalityLife 	GMM 	90% 	Elected to present
changes in IFIE in OCI
and profit or loss.
n/a
Individual life:
Excess of loss reinsurance
Group life insurance
contracts:
Catastrophe, group continuation
and mass lapse treaties
PAA
90%
Elected not to reflect
interest for cash flows
less than 12 months
Elected to immediately
expense initial acquisition
cash flows (IACF)	Car, household and
business insurance:
Quota share reinsurance and
excess of loss insurance
75%
Health insurance:
Quota share reinsurance
1 Risk adjustment was determined using the confidence level technique unless otherwise stated.
D.2 	IFRS 17 Accounting policies continued

-- 49 of 105 --

52	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2.3 Contracts measured under the GMM and VFA
Under IFRS 17, any company that issues insurance contracts must report those contracts on the Group statement of financial
position as the total of
 The expected fulfilment cash flows (EFCF): the current estimates of amounts that the company expects to collect from premiums
net of and payout for claims, benefits, and expenses, including an adjustment for the timing and risk of those amounts, and
 The CSM: the expected profit for providing insurance coverage recognised in profit or loss over the period of insurance
coverage.
Under IFRS 17, Insurance Contracts are measured
as the sum of:
the expected fulfilment cash flows (EFCF), representing
the present value of current estimates of amounts that
the insurer expects to collect from premiums net of and
pay out for claims, benefits and expenses, including an
adjustment for the risk of those cash flows.
Those cash flows for future services are known as “liability
for remaining coverage” (LRC) and those cash flows
for services already incurred constitutes
liability for incurred claims (LIC)
the contractual service margin (CSM), represents the
remaining inherent value of the cohort and is similar to
unearned profit for providing future insurance coverage.
On initial recognition, for profitable contracts, the CSM is
the equal and opposite amount of the net cash inflow,
resulting in no income or expense arising on initial
recognition.
+
EFCF –
Inflow
EFCF –
Outflow
EFCF –
Risk adj
CSM	EFCF –
discounting
= 	+Insurance
contracts
Present value of expected
fulfilment cash flows
Unearned
profit
IFRS 17 Illustration of principles 2: General Measurement Model (GMM)
D.2.3.1 EXPECTED FULFILMENT CASH FLOWS (EFCF)
The measurement of a group of insurance contracts includes all future cash flows expected to arise within the contract boundary
of each contract in the group. Cash flows are within the contract boundary if they arise from substantive rights and obligations that
exist during the reporting period in which Discovery can compel the policyholder to pay premiums or has a substantive obligation
to provide services (including insurance coverage and any investment services).
EFCF include payments to (or on behalf of) policyholders, insurance acquisition cash flows and other costs incurred in fulfilling
contracts. Other costs incurred to fulfil a group of contracts include direct costs and an allocation of fixed and variable overheads
directly attributable to fulfilling the group of insurance contracts.
The estimates of these future cash flows are based on probability-weighted expected future cash flows. Discovery estimates which
cash flows are expected and the probability that they will occur as at the measurement date. When estimating, Discovery uses
information about past events, current conditions and forecasts of future conditions.
Insurance acquisition cash flows arise from activities of selling, underwriting and commencing a group of contracts that are directly
attributable to the portfolio of contracts to which the group belongs.
D.2 	IFRS 17 Accounting policies continued
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued

-- 50 of 105 --

53
D.2.3 Contracts measured under the GMM and VFA continued
D.2.3.2 REFLECTING THE TIME VALUE OF MONEY AND DISCOUNT RATES
Discounting adjusts the estimates of expected cash flows to reflect the time value of money and the financial risks associated with
those cash flows, to the extent that the financial risks are not already included in the cash flow estimates.
The following table shows which discount rate to apply throughout measuring a group of insurance contracts and the general
objective of determining that discount rate.
Element of measurement model
Fulfilment cash flows 	Current discount rates
CSM interest accretion for contracts without direct
participation features (i.e., portfolios under GMM).
Discount rates are determined on initial recognition of the
group, i.e., locked-in at inception.
Adjustments to the CSM for changes in the fulfilment cash
flows for contracts without direct participation features (DPF)
(i.e., portfolios under GMM).
Discount rates are determined on initial recognition of the
group, i.e., locked-in at inception.
Adjustments to the CSM for changes in the fulfilment cash
flows for DPF contracts that do not vary based on the returns
on underlying items (i.e., portfolios under VFA), excluding
the change in the effect of the time value of money and
financial risks.
Current discount rates.
The bottom-up approach is used to derive the discount rate for the cash flows. Under this approach, the discount rate is determined
as the risk-free yield, adjusted for differences in liquidity characteristics of the insurance contracts sold. For portfolios of contracts
where the insurance contract liability is materially matched with assets, a top-down approach is used to derive the discount rate for
the cash flows.
For Discovery, the risk-free yield curve will be ‘current’ and reflect the risk-free yield curve derived on the last day of the reporting
period. The nominal risk-free yield curve is used to discount nominal cash flows, while real cash flows are discounted using the real
risk-free yield curve.
D.2.3.3 RISK ADJUSTMENT
The risk adjustment for non-financial risk for a group of insurance contracts, determined separately from the other estimates, is the
compensation required for bearing uncertainty about the amount and timing of the cash flows that arise from non-financial risk as
Discovery fulfils insurance contracts. It measures the compensation that the entity would require to make it indifferent between:
 Fulfilling a liability that has a range of possible outcomes arising from non-financial risk and
 Fulfilling a liability that will generate fixed cash flows with the same expected present value as the insurance contract.
A lower risk adjustment would be observed for those insurance contracts with shorter durations, high frequency and low severity
type products and narrow probability of distribution. A higher risk adjustment would be observed for insurance contracts that are
longer in duration, have a low frequency and high severity and have a wide probability of distribution.
IFRS 17 does not prescribe methods for determining the risk adjustment for non-financial risk. Therefore, management’s judgement
is necessary to determine an appropriate risk adjustment technique.
When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an
equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk
adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future
claims. For the specified percentages applied, refer to section D.2.2.
D.2 	IFRS 17 Accounting policies continued

-- 51 of 105 --

54	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2.3 Contracts measured under the GMM and VFA continued
D.2.3.4 CONTRACTUAL SERVICE MARGIN (CSM)
The CSM represents the future unearned profit. On initial recognition of a group of insurance contracts, if the total of the fulfilment
cash flows, including insurance acquisition cash flows:
 Is a net inflow, then the group is profitable. In this case, the CSM is measured as the equal and opposite amount of the net
inflow, which results in no income or expenses arising on initial recognition.
 Is a net outflow, then the group is onerous. In this case, the net outflow is recognised immediately as a loss in profit or loss.
A loss component is created to depict the amount of the net cash outflow, which determines the amounts that are subsequently
presented in profit or loss as reversals of losses on onerous contracts and are excluded from insurance revenue.
D.2.3.5 SUBSEQUENT MEASUREMENT
The carrying amount of a group of insurance contracts at each reporting date is the sum of the liability for remaining coverage (LRC)
and the liability for incurred claims (LIC).
 The LRC comprises the fulfilment cash flows related to services that will be provided under the contracts in future periods and
any remaining CSM at that date.
 The LIC includes the fulfilment cash flows for incurred claims and expenses that have not yet been paid, including claims that
have been incurred but not yet reported.
IFRS 17 requires a company to update the EFCF at each reporting date, using current estimates of the amount, timing, and
uncertainty of cash flows and discount rates. Discovery:
 accounts for changes to estimates of future cash flows from one reporting date to another, either as an amount in profit or loss
or as an adjustment to the expected profit for providing insurance coverage, depending on the type of change and the reason
for it; and
 chooses where to present IFIE either:
– All in profit or loss, or
– Include IFIE in profit or loss using systematic allocation. The remainder of IFIE is recognised in OCI.
The treatment can be summarised as follows:
Fulfilment
cash
inflows
OCI
P/L
CSM
CSM allocation
Financial risk assumptions (e.g., interest rates & inflation index)
Past and current service
Future service
Reclassify
Either
Or
IFRS 17 Illustration of principles 3: Subsequent measurement
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.2 	IFRS 17 Accounting policies continued

-- 52 of 105 --

55
D.2.3 	Contracts measured under the GMM and VFA continued
D.2.3.5 SUBSEQUENT MEASUREMENT continued
D.2.3.5.1 Changes in EFCF
Changes in expected fulfilment cash flows from the estimates at the previous reporting date or inceptions of the contracts are
recognised as follows:
Nature of change 	Treatment
Changes relating to current or past services 	Recognised in the insurance service results in profit or
loss.
Changes relating to future services 	Adjusted against the CSM (or recognised in the insurance
service results in profit or loss if the group is onerous).
Effects of the time value of money, financial risk and changes
therein on estimated future cash flows
Recognised as insurance finance income or expenses.
Changes in the obligation to pay policyholders an amount equal to
the fair value of the underlying items for a group of direct
participating contracts (VFA)
Recognised in the insurance service results in profit or
loss.
Accounting policy election: Presentation of IFIE
Discovery has elected to disaggregate IFIE for the period in OCI and present in profit or loss IFIE using a systematic allocation
on its long-term life insurance business lines in Discovery Life, VitalityLife and associated reinsurance contracts and long-tail
claims in its GroupLife business. For the remainder of business lines, the IFIE and changes therein relating to insurance
contracts are presented in profit or loss, offset by the changes in the value of assets backing the insurance contracts.
Changes in CSM
As noted in D.2.3.4, the CSM represents the future unearned profit. The movement in the CSM during a financial reporting period
can be summarised as follows:
CSM at the end
of previous
reporting
period
1. New business
written during
the period
2. Interest
accretion
at locked-in
rate
3. Changes in
fullfillment
cash flows
for future
services (Non IFIE)
4. Effect of
currency
exchange
differences
on CSM
5. VFA only –
change in the
amount
of the entity’s
share in FV of
underlying items
6. Amounts in
CSM recognised
in profit or loss
for any
insurance service
for period
(coverage units)
CSM at the end
of the current
reporting period
Movement of the CSM in sequence of which changes are made
IFRS 17 Illustration of principles 4: Subsequent changes in CSM
D.2 	IFRS 17 Accounting policies continued

-- 53 of 105 --

56	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2.3 	Contracts measured under the GMM and VFA continued
D.2.3.5 SUBSEQUENT MEASUREMENT continued
D.2.3.5.1 Changes in EFCF continued
The carrying amount of the CSM at each reporting date is the carrying amount at the start of the financial year, adjusted for:
1. 	The CSM of any new contracts added to the group in the year.
2. 	I nterest accreted on the carrying amount of the CSM during the year. As noted in D.2.3.2, discount rates are determined on
initial recognition of the group, meaning locked-in at inception. As noted in D.2.3.2., the CSM for group of insurance contracts
in VFA is not locked-in.
3. 	Changes in fulfilment cash flows that relate to future services, except to the extent that:
a. Any increases in the fulfilment cash outflows exceed the carrying amount of the CSM, in which case the excess is recognised
immediately in profit or loss.
b. Any decreases in the fulfilment cash outflows are allocated to the loss component, reversing losses previously recognised
in profit or loss.
4. 	Reflects changes in exchange rates for those contracts denominated in different currency than the functional currency of the
insurer that issued the policy
5. 	For contracts measured using the VFA, the change in the amount of the insurer’s share of the fair value of the underlying item.
6. 	The amount recognised as insurance revenue because of the services provided in the year, meaning release of CSM using
coverage units. In determining the coverage units, Discovery has elected to reflect the time value of money in the coverage
units using a real rate of return for insurance contracts measured using the GMM. For insurance contracts measured using the
VFA, Discovery has elected to reflect the time value of money in the coverage units using a nominal rate of return.
D.2.4 Contracts measured under the PAA
As permitted in IFRS 17, Discovery has elected to apply the premium allocation approach (PAA) to measure a group of insurance
contracts issued or reinsurance contracts held if, at the inception of the group:
 The coverage period of each contract in the group of insurance contracts is one year or less, or
 Discovery reasonably expects that the PAA would produce a measurement of the LRC for a group of insurance contracts that
would not differ materially from the measurement achieved by applying the GMM.
The PAA simplifies the general measurement model. At initial recognition, the insurance contract is measured as:
 The premiums, if any, received at initial recognition.
 Minus any insurance acquisition cash flows (applicable only if the group has elected to defer the insurance acquisition cash
flows), and
 Plus/minus non-acquisition assets or liabilities previously recognised for cash flows related to the group of insurance contracts.
Where insurance acquisition cash flows are directly attributable to a group of contracts, Discovery allocates costs to that group and
the groups that will include renewals of those contracts. Discovery expects to recover part of the related insurance acquisition cash
flows through renewals of these contracts. The allocation to renewals is based on how Discovery expects to recover those cash
flows.
At each reporting date, Discovery revises the amounts allocated to groups to reflect any changes in assumptions that determine
the inputs to the allocation method used. Amounts allocated to a group are not revised once all contracts have been added to the
group.
At each reporting date, if facts and circumstances indicate that an asset for insurance acquisition cash flows may be impaired,
Discovery:
 Recognises an impairment loss in profit or loss so that the carrying amount of the asset does not exceed the expected net cash
inflow for the related group, and
 If the asset relates to future renewals, Discovery recognises an impairment loss in profit or loss to the extent that it expects
those insurance acquisition cash flows to exceed the net cash inflow for the expected renewals, and this excess has not already
been recognised as an impairment loss.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.2 	IFRS 17 Accounting policies continued

-- 54 of 105 --

57
D.2.4 Contracts measured under the PAA continued
Discovery reverses any impairment losses in profit or loss and increases the asset’s carrying amount to the extent that the
impairment conditions have improved.
IFRS 17 permits an accounting policy election on a group-by-group basis:
 Not to adjust the components of the insurance contracts and onerous contracts for the time value of money (i.e., no
discounting).
 An entity may elect to immediately expense insurance acquisition cash flows when incurred.
Accounting policy elections
For those contracts that apply the PAA, Discovery has elected not to reflect the time value of money in the measurement
of the LRC and the LIC when:
 LRC: On initial recognition of the contract, the time between the insurance service and the related premium is less than
a year.
 LIC: The cash flows are expected to be paid or received in less than one year from the date the claim is incurred. In
some instances, claims might be disputed. If the claim is expected to be disputed and settlement deferred beyond 12
months, the exception would not apply.
Discovery has elected to immediately expense insurance acquisition cash flows for the following material portfolios:
 Group Life
 Discovery Insure – Discovery Insure has the following portfolios: Personal lines for motor and household, Business
insurance, Medical gap, trauma cover and travel insurance.
 AfricaHealth portfolios.
D.2.4.1 RISK ADJUSTMENT
Refer to section D.2.3.3 for the detailed accounting policy on risk adjustment. For the specified percentages applied, refer to
section D.2.2.
D.2.5 Reinsurance contracts
Groups of reinsurance contracts are established such that each treaty is allocated to the applicable group of reinsurance contracts,
which differs from the group in which the underlying insurance contract is included. Discovery concludes that the reinsurance
contract’s legal form as a single contract reflects the substance of Discovery’s contractual rights and obligations.
A group of reinsurance contracts is recognised, as required under IFRS 17, on the following dates.
 Reinsurance contracts initiated by Discovery that provide proportionate coverage: The date on which any underlying insurance
contract is initially recognised. This applies to Discovery’s quota share reinsurance contracts.
 Other reinsurance contracts initiated by Discovery: The beginning of the coverage period of the group of reinsurance contracts.
Where Discovery recognises an onerous group of underlying insurance contracts on an earlier date and the related reinsurance
contract was entered into before that earlier date, in that case, the group of reinsurance contracts is recognised on that earlier
date. This applies to Discovery’s excess of loss and stop-loss reinsurance contracts.
 Reinsurance contracts acquired: The date of acquisition.
Discovery applies the same accounting policies to measure a group of reinsurance contracts, adapted where necessary to reflect
features that differ from those of the underlying insurance contracts. When a loss-recovery component is created for a group of
reinsurance contracts measured under the PAA, Discovery will adjust the asset’s carrying amount for remaining coverage instead of
adjusting the CSM.
D.2 	IFRS 17 Accounting policies continued

-- 55 of 105 --

58	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.2.6 Derecognition and modifications
Discovery derecognises a contract when it is extinguished, meaning when the specified obligations in the contract expire or are
discharged the contract is cancelled.
Discovery also derecognises a contract if its terms are modified in a way that would have changed the accounting for the contract
significantly had the new terms always existed, in which case a new contract based on the modified terms is recognised. If a contract
modification does not result in derecognition, Discovery treats the changes in cash flows caused by the modification as changes in
estimates of fulfilment cash flows.
On derecognition of a contract from within a group of contracts not measured under the PAA:
 The fulfilment cash flows allocated to the group are adjusted to eliminate those that relate to the rights and obligations
derecognised.
 The CSM of the group is adjusted for the change in the fulfilment cash flows, except where such changes are allocated to a loss
component.
 The number of coverage units for the expected remaining services is adjusted to reflect the coverage units derecognised from
the group.
If a contract is derecognised because it is transferred to a third party, then the CSM is also adjusted for the premium charged by the
third party unless the group is onerous.
D.2.7. Exceptions where the modified retrospective approach was applied
DISCOVERY INDIVIDUAL LIFE PORTFOLIO
Discovery has applied the modified retrospective approach within the Discovery Individual Life portfolio by aggregating contracts
issued more than one year apart prior to 2003 into a single group of insurance contracts in respect of insurance contracts issued
before June 2003. The application of the full retrospective approach on transition for these groups were determined to be
impracticable as Discovery Life does not have the model used nor data of sufficient quality to either retrospectively model business
sold before the June 2002 financial year or to identify new business policies sold in the June 2002 financial year. It should be noted
that these portfolios or cohorts of business are immaterial in the context as Discovery Life only commenced business in 2000.
DISCOVERY INVEST PORTFOLIOS - THE UNIT-LINKED AND DRO PORTFOLIO AND THE GENERAL
ENDOWMENTS PORTFOLIO
Discovery has applied the modified retrospective approach within the Discovery Invest portfolios by aggregating contracts issued
more than one year apart into a single group of insurance contracts issued before June 2016 for the DRO portfolio and groups of
insurance contracts issued before June 2012 for the general endowments and unit-linked portfolio. The application of the fully
retrospective approach on transition for these portfolios was determined to be impracticable for Discovery Invest as it did not collect
the data of policies sold with sufficient granularity in the periods prior to June 2012. Discovery Invest only commenced trading in 2007.
VITALITYHEALTH PRIVATE MEDICAL INSURANCE CONTRACTS
Discovery applied the modified approach to identify, recognise, and measure assets arising from insurance acquisition cash flows
for the VitalityHealth PMI portfolio as of 1 July 2022. It is impracticable to apply the full retrospective approach as eight years ago
(of the ten years that DAC is being applied for), the data was not collected with sufficient granularity for the purposes of setting up
a deferred acquisition cost reserve, and its omission has an immaterial impact on the equity.
D.3. 	Critical estimates and judgements
D.3.1 Insurance contracts scope and grouping
DEFINITION AND CLASSIFICATION
IFRS 17 does not specify what significant insurance risk is. Discovery’s policy defines significant insurance risk as follows: The
possibility that the present value of losses arising on the insurance contract exceeds 10% of the present value of income and
receipts collected when applying a worst-case scenario upon the inception of the insurance contract.
UNIT OF ACCOUNT, AGGREGATION AND RECOGNITION OF INSURANCE AND REINSURANCE CONTRACTS
Discovery uses judgement to determine at what level of granularity Discovery has reasonable and supportable information that is
sufficient to conclude that all contracts within a set are sufficiently homogeneous and will be allocated to the same group without
performing an individual contract assessment.
Discovery performs stress testing on portfolios measured using GMM and VFA. The stresses may differ between portfolios but will
correspond to the most significant non-financial stresses currently running as part of the risk appetite work. If any policy that was
originally determined to be profitable becomes onerous under any of the three additional stresses calculated, that policy is classified
as profitable-at-risk.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.2 	IFRS 17 Accounting policies continued

-- 56 of 105 --

59
D.3.2 Contracts measured under the GMM and VFA
D.3.2.1 FULFILMENT CASH FLOWS
In line with the requirements of IFRS 17, Discovery applies judgement to determine which cash flows within the boundary of
insurance contracts relate directly to the fulfilment of the contracts, including the extent to which fixed and variable overheads are
directly attributable to fulfilling insurance contracts.
IFRS 17 does not specify a methodology for attributing directly attributable fixed overhead expenses to the respective groups of
insurance contracts and to individual policies. It requires that the methods used be systematic and rational. Discovery has applied
judgement in developing its methodology and has consistently applied this methodology period-to-period, except as noted below.
Given the diversified product range in UK Life, from 1 July 2022, UK Life has further refined its methodology used for allocating the
directly attributable fixed overhead expenses related to new business activities (i.e. directly attributable but fixed initial expenses).
As the change in methodology is a change in estimate, this change has been applied prospectively and therefore differs from the
estimate used in performing the fully retrospective approach used with the initial transition to IFRS 17 given practicality and
availability of historical information. The new methodology better reflects the drivers of fixed initial expenses given the core strategy
and mix of business written by UK Life as well as the related effort to underwrite and administer the various products. This change
in estimate has been implemented for both the current period under review and retrospectively for the restated comparative for
the 2023 financial year and six month period.
Discovery primarily uses deterministic projections to estimate the present value of future cash flows, and for some groups, it uses
stochastic modelling techniques. The following assumptions were used when estimating future cash flows:
 Mortality and morbidity rates.
 Surrender and lapse rates.
 Economic assumptions or investment returns.
 Vitality status assumptions.
 Expense assumptions.
 Policy alterations and automatic premium increases
D.3.2.2 RISK ADJUSTMENT
When applying a confidence level technique, the first step in the process is to calculate the best estimate reserve, where there is an
equal chance that the actual amount needed to pay future claims will be higher or lower than the calculated best estimate. The risk
adjustment is then calculated such that there is a specified percentage probability that the reserves will be sufficient to cover future
claims. For Discovery, the determination of specified percentage is set out in D.2.2.
D.3.3 Contracts measured under the PAA
D.3.3.1 INSURANCE ACQUISITION CASH FLOWS
Discovery uses judgement in determining the initial and renewal periods for which the insurance acquisition cash flows are
attributed to groups. For VitalityHealth, the initial and subsequent renewal period is set at ten years.
For contracts measured under the PAA, the explicit risk adjustment for non-financial risk is estimated to measure the LIC. The risk
adjustment will be determined by applying a confidence level technique. For Discovery, the determination of specified percentage
is set out in D.2.2.
D.3. 	Critical estimates and judgements continued

-- 57 of 105 --

60	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.4. 	Insurance and reinsurance contracts related disclosures
The following disclosures enable the user to assess the effect of insurance contracts issued and reinsurance contracts held on
Discovery’s financial position, financial performance and cash flows. In addition to the disclosures on significant judgements and
estimates above, the following disclosures provide a quantitative summary of the amount recognised in the financial statements.
IFRS 17 requires that in determining the level at which to aggregated group of insurance contracts to provide useful information to
the user, Discovery considers:
 The type of contract which would consider the nature of the product and the measurement model.
 The geographical areas may expose the entity to different sets of risks, even for similar products.
 Reportable segments.
Having applied the guidance, Discovery has aggregated its portfolios for the disclosures as set out below.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
SA Life and Invest (Risk) | GMM
(Life: Individual Life, Dollar LifePlan,
Health Protection Plans, Standalone Global Educator;
Invest: Guaranteed endowments)
SA Life and Invest (Participating) | VFA
(Unit-linked invest products,
Discovery Retirement Optimiser)
SA Life and Invest: Group Life and other | PAA
(Group Risk, Funeral and other including Discovery Card
Protector, Standalone Cancer Protector and LifeDrive)
SA Insure and other | PAA
(Personal and Commercial lines, GAP and Trauma Cover,
Travel Cover and AfricaHealth)
UK Life (Risk) | GMM
(Own Licence and PAC book)
UK Health | PAA
(Private Medical Insurance)
SA Composite 	UK Composite

-- 58 of 105 --

61
D.4. 	Insurance and reinsurance contracts related disclosures continued
The following index is a summary of all the quantitative disclosures set out in the notes:
Note 	Description
Analysis of Statement of financial position
D.4.1 Summary of insurance contracts issued and
reinsurance contracts held
The note summarises the total value of insurance and
reinsurance contracts held across the disclosed portfolios
showing separately those insurance and reinsurance contracts
in a net liability or net asset position.
D.4.2 Insurance acquisition assets 	The note provides a movement in the Insurance acquisition
assets, reflecting the movement in the capitalised initial
acquisition cash flows of the VitalityHealth portfolio.
Reconciliation of insurance contracts
Analysis by remaining coverage and incurred claims
GMM
 D.4.3.1 SA Life and Invest (Risk)
 D.4.3.2 UK Life (Risk)
VFA
 D.4.5.1 SA Life and Invest (Participating)
PAA
 D.4.7.1 SA Life and Invest: Group Life and other
 D.4.7.2 SA Insure and other
 D.4.7.3 UK Health
Reconciliation of reinsurance contracts
Analysis by remaining coverage and incurred claims
GMM
 D.4.8.1 SA Life and Invest (Risk)
 D.4.8.2 UK Life (Risk)
The notes provide a detailed reconciliation of disclosed
portfolios showing the build-up of:
 The liability for remaining coverage (LRC) reflects
Discovery's obligation for the unexpired portion of the
coverage period. For contracts measured using the
simplified approach, LRC includes the unearned premium.
 The liability of incurred claims (LIC) reflects Discovery’s
obligation to cover the insured events that have occurred.
Reconciliation of insurance contracts
Analysis by measurement component
GMM
 D.4.4.1 SA Life and Invest (Risk)
 D.4.4.2 UK Life (Risk)
VFA
 D.4.6.1 SA Life and Invest (Participating)
Reconciliation of reinsurance contracts
Analysis by measurement component
GMM
 D.4.9.1 SA Life and Invest (Risk)
 D.4.9.2 UK Life (Risk)
PAA
 D.4.10.1 SA Life and Invest: Group Life and other
 D.4.10.2 SA Insure and other
 D.4.10.3 UK Health
The notes provide a detailed reconciliation of disclosed
portfolios showing the build-up of the measurement
components, namely:
 Estimates of the present value of expected fulfilment
cash flows.
 The Risk adjustment.
 The Contractual service margin reflects unearned profit.
The CSM is further separated to reflect how the CSM was
calculated at transition, being modified retrospectively or
fully retrospectively.

-- 59 of 105 --

62	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
Note 	Description
Analysis of Income statement
D.4.11 Insurance revenue 	The note provides a breakdown of the makeup of insurance
revenue for each disclosed portfolio business unit.
For those contracts not measured using the PAA approach,
the amount reflects the change in the LRC, namely
 CSM recognised during the period for the service
provided.
 The change in the Risk adjustment for non-financial risk.
 Expected claims and insurance services expenses.
 Experience adjustments.
 Recovery of insurance acquisition cash flows.
D.4.12 Net investment result 	The note provides a holistic combined view of the following:
 The investment returns on financial assets held.
 The insurance and reinsurance finance income and
expenses, including the amounts recognised in profit or
loss and other comprehensive income (OCI).
Additional information
Effect of contracts initially recognised in the
year:
 D.4.13 Effects of insurance contracts initially
recognised in the year
 D.4.14 Effect of reinsurance contracts initially
recognised in the year.
The notes provide a breakdown of the contracts initially
recognised during the period for each disclosed portfolio
business unit.
 For insurance contracts, differentiate between profitable
contracts recognised with CSM and onerous contracts.
 Reinsurance contracts reflect contracts originated with
and without the loss-recovery component.
D.4.15 Contractual service margin 	The note provides, for each disclosed portfolio business unit,
the expected recognition of CSM, with interest accretion over
the lifetime of the group of insurance contracts.
The note also sets out the release of accumulated IFIE OCI
balances into profit or loss.
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 60 of 105 --

63
D.4.1 Summary of insurance contracts issued and reinsurance contracts held
Group
R million
(Assets)/Liabilities 	Navigation
SA Life
and
Invest
Risk
(GMM)
SA Life
and
Invest
Participating
(VFA)
UK Life
Risk
(GMM)
SA Life
Group
Risk
(PAA)
SA
Insure
(PAA)
UK
Health
(PAA) 	Total
Six months ended
31 December 2023
Insurance contracts 	A=D+E 	3 337 	69 286 	(13 151) 	5 670 	981 	(4 387) 	61 736
Reinsurance contracts 	B=F 	740 	– 	4 944 	(605) 	(172) 	(14) 	4 893
Total 	C=A+B 	4 077 	69 286 	(8 207) 	5 065 	809 	(4 401) 	66 629
Insurance contracts issued
Insurance contract assets
– Insurance contract balances 	(19 901) 	– 	(13 151) 	– 	– 	– 	(33 052)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(4 739) 	(4 739)
D 	(19 901) 	– 	(13 151) 	– 	– 	(4 739) 	(37 791)
Insurance contract liabilities
– Insurance contract balances 	23 238 	69 286 	– 	5 670 	981 	352 	99 527
Total 	E 	23 238 	69 286 	– 	5 670 	981 	352 	99 527
Reinsurance contracts held
Reinsurance contract assets 	– 	– 	– 	(605) 	(172) 	(14) 	(791)
Reinsurance contract liabilities 	740 	– 	4 944 	– 	– 	– 	5 684
Total 	F 	740 	– 	4 944 	(605) 	(172) 	(14) 	4 893
Year ended 30 June 2023
Insurance contracts 	4 365 	66 308 	(10 314) 	5 109 	822 	(3 509) 	62 781
Reinsurance contracts 	567 	– 	4 276 	(529) 	(71) 	(4) 	4 239
Total 	4 932 	66 308 	(6 038) 	4 580 	751 	(3 513) 	67 020
Insurance contracts issued
Insurance contract assets
– Insurance contract balances 	(18 056) 	– 	(10 314) 	– 	– 	– 	(28 370)
– Assets for insurance
acquisition cash flows 	– 	– 	– 	– 	– 	(4 544) 	(4 544)
(18 056) 	– 	(10 314) 	– 	– 	(4 544) 	(32 914)
Insurance contract liabilities
– Insurance contract balances 	22 421 	66 308 	– 	5 109 	822 	1 035 	95 695
22 421 	66 308 	– 	5 109 	822 	1 035 	95 695
Reinsurance contracts held
– Reinsurance contract assets 	– 	– 	– 	(529) 	(71) 	(4) 	(604)
– Reinsurance contract
liabilities 	567 	– 	4 276 	– 	– 	– 	4 843
Total 	567 	– 	4 276 	(529) 	(71) 	(4) 	4 239
Cross reference to related notes
of insurance contracts issued
– Analysis by remaining
coverage and incurred claims 	D.4.3.1. 	D.4.5.1. 	D.4.3.2. 	D.4.7.1. 	D.4.7.2. 	D.4.7.3.
– Analysis by measurement
components 	D.4.4.1. 	D.4.6.1. 	D.4.4.2.
– Insurance acquisition assets 	D.4.2.
Cross reference to related notes
of reinsurance contracts issued
– Analysis by remaining
coverage and incurred claims 	D.4.8.1. 	D.4.8.2. 	D.4.10.1. 	D.4.10.2. 	D.4.10.3.
– Analysis by measurement
components 	D.4.9.1. 	D.4.9.2.
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 61 of 105 --

64	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued
D.4.2 Insurance acquisition assets
Group
R million
UK Health
(PAA)
Year ended 30 June 2023
Balance at the beginning of the year 	3 358
Amounts Incurred during the year 	1 355
Amounts derecognised and included in the measurement of insurance contracts 	(893)
Effect of movements in exchange rates 	724
Balance at the end of the year 	4 544
Six months ended 31 December 2023
Amounts Incurred during the period 	795
Amounts derecognised and included in the measurement of insurance contracts 	(521)
Effect of movements in exchange rates 	(79)
Balance at the end of the period 	4 739
Balance as at 1 July 2022
Presented in insurance contract assets 	3 358
Balance as at 30 June 2023
Presented in insurance contract assets 	4 544
Balance as at 31 December 2023
Presented in insurance contract assets 	4 739

-- 62 of 105 --

65
The following table sets out when the Group expects to derecognise assets for insurance acquisition cash flows after the
reporting date.
Group
R million
UK Health
(PAA)
31 December 2023
Year 1 	914
Year 1 – 2 	763
Year 3 – 5 	1 319
Year 6 – 10 	1 208
>10 years 	–
30 June 2023
Year 1 	878
Year 1 – 2 	734
Year 3 – 5 	1 790
Year 6 – 10 	1 142
>10 years 	–
D.4. 	Insurance and reinsurance contracts related disclosures continued
D.4.2 Insurance acquisition assets continued

-- 63 of 105 --

66	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	67
D.4.3 Reconciliation of insurance contracts – GMM
D.4.3.1 SA LIFE AND INVEST (RISK)
Analysis by remaining coverage and incurred claims
December 2023 	June 2023
Group
R million
(Assets)/Liabilities
Liabilities for
remaining coverage
Liabilities for
incurred
claims 	Total
Liabilities for
remaining coverage
Liabilities for
incurred
claims	Navigation
Excluding
loss
component
Loss
component
Excluding
loss
component
Loss
component 	Total
Opening assets arising from insurance
contracts issued 	(26 510) 	1 833 	6 621 	(18 056) 	(27 422) 	1 424 	6 339 	(19 659)
Opening liabilities arising from insurance
contracts issued 	22 236 	185 	– 	22 421 	21 091 	133 	– 	21 224
Net balance at beginning of the period/year 	(4 274) 	2 018 	6 621 	4 365 	(6 331) 	1 557 	6 339 	1 565
Adjust: transfer of product from SA Life and
Invest (Participating) to SA Life and Invest
(Risk) 	(22) 	128 	– 	106
Opening assets arising from insurance
contracts issued (rebased) 	(27 444) 	1 552 	6 339 	(19 553)
Opening liabilities arising from insurance
contracts issued (rebased) 	21 091 	133 	– 	21 224
Net balance at beginning of the period/year
(rebased) 	A 	(4 274) 	2 018 	6 621 	4 365 	(6 353) 	1 685 	6 339 	1 671
Changes in the income statement and OCI
Insurance revenue transitional split
Contracts under the modified retrospective
approach 	(172) 	– 	– 	(172) 	(334) 	– 	– 	(334)
Contracts under the full retrospective approach
on transition 	(6 467) 	– 	– 	(6 467) 	(12 790) 	– 	– 	(12 790)
Subsequent to transition: All other contracts 	(6 964) 	– 	– 	(6 964) 	(13 503) 	– 	– 	(13 503)
B 	(7 136) 	– 	– 	(7 136) 	(13 837) 	– 	– 	(13 837)
Insurance service expenses
Incurred claims and other insurance service
expenses 	– 	– 	5 084 	5 084 	– 	– 	10 348 	10 348
Amortised assets for insurance acquisition
cash flows 	970 	– 	– 	970 	1 713 	– 	– 	1 713
Losses and reversal of losses on onerous
contracts 	– 	99 	– 	99 	– 	304 	– 	304
C 	970 	99 	5 084 	6 153 	1 713 	304 	10 348 	12 365
Investment components 	D 	(2 964) 	– 	2 964 	– 	(3 817) 	– 	3 817 	–
Insurance service result 	E=B+C+D 	(9 130) 	99 	8 048 	(983) 	(15 941) 	304 	14 165 	(1 472)
Net finance (income)/expense from
insurance contracts 	F 	(931) 	48 	226 	(657) 	3 046 	29 	191 	3 266
Net changes to income statement and OCI 	G=E+F 	(10 061) 	147 	8 274 	(1 640) 	(12 895) 	333 	14 356 	1 794
Cash Flows
Premiums received 	9 913 	– 	– 	9 913 	17 477 	– 	– 	17 477
Insurance acquisition cash flows 	(1 436) 	– 	– 	(1 436) 	(2 503) 	– 	– 	(2 503)
Claims and other directly attributable expenses
paid 	– 	– 	(7 865) 	(7 865) 	– 	– 	(14 074) 	(14 074)
Total cash flows 	H 	8 477 	– 	(7 865) 	612 	14 972 	– 	(14 074) 	898
Net balance at the end of the period/year 	J=A+G+H 	(5 858) 	2 165 	7 030 	3 337 	(4 274) 	2 018 	6 621 	4 365
Closing assets arising from insurance contracts
issued 	(28 918) 	1 987 	7 030 	(19 901) 	(26 510) 	1 833 	6 621 	(18 056)
Closing liabilities arising from insurance
contracts issued 	23 060 	178 	– 	23 238 	22 236 	185 	– 	22 421
Net balance at the end of the period/year 	(5 858) 	2 165 	7 030 	3 337 	(4 274) 	2 018 	6 621 	4 365
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 64 of 105 --

68	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	69
D.4.3 Reconciliation of insurance contracts – GMM continued
D.4.3.2 UK LIFE (RISK)
Analysis by remaining coverage and incurred claims
December 2023 	June 2023
Group
R million
(Assets)/Liabilities 	Navigation
Liabilities for
Remaining Coverage
Liabilities for
incurred
claims 	Total
Liabilities for
Remaining Coverage
Liabilities for
incurred
Claims
Excluding
loss
Component
Loss
component
Excluding
Loss
Component
Loss
component 	Total
Opening assets arising from insurance
contracts issued 	(17 021) 	5 076 	1 631 	(10 314) 	(13 527) 	4 239 	1 157 	(8 131)
Net balance at beginning of
the period/year 	A 	(17 021) 	5 076 	1 631 	(10 314) 	(13 527) 	4 239 	1 157 	(8 131)
Changes in the income statement and OCI
Insurance revenue transitional split
Contracts under the full retrospective
approach on transition 	(4 368) 	– 	– 	(4 368) 	(7 535) 	– 	– 	(7 535)
B 	(4 368) 	– 	– 	(4 368) 	(7 535) 	– 	– 	(7 535)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	– 	2 560 	2 560 	– 	– 	4 414 	4 414
Amortised assets for insurance acquisition
cash flows 	1 278 	– 	– 	1 278 	2 101 	– 	– 	2 101
Losses and reversal of losses on onerous
contracts 	– 	(70) 	– 	(70) 	– 	304 	– 	304
C 	1 278 	(70) 	2 560 	3 768 	2 101 	304 	4 414 	6 819
Insurance service result 	D=B+C 	(3 090) 	(70) 	2 560 	(600) 	(5 434) 	304 	4 414 	(716)
Net finance (income)/expense from
insurance contracts 	E 	(2 255) 	(17) 	– 	(2 272) 	706 	(211) 	– 	495
Net changes to income statement
and OCI 	F=D+E 	(5 345) 	(87) 	2 560 	(2 872) 	(4 728) 	93 	4 414 	(221)
Cash Flows
Premiums received 	4 606 	– 	– 	4 606 	7 771 	– 	– 	7 771
Insurance acquisition cash flows 	(2 355) 	– 	– 	(2 355) 	(4 074) 	– 	– 	(4 074)
Claims and other directly attributable
expenses paid 	– 	– 	(2 382) 	(2 382) 	– 	– 	(4 168) 	(4 168)
Total cash flows 	G 	2 251 	– 	(2 382) 	(131) 	3 697 	– 	(4 168) 	(471)
Effect of movements in exchange rates 	H 	284 	(90) 	(28) 	166 	(2 463) 	744 	228 	(1 491)
Net balance at the end of
the period/year 	I= A+F+G+H 	(19 831) 	4 899 	1 781 	(13 151) 	(17 021) 	5 076 	1 631 	(10 314)
Closing assets arising from insurance
contracts issued 	(19 831) 	4 899 	1 781 	(13 151) 	(17 021) 	5 076 	1 631 	(10 314)
Net balance at the end of
the period/year 	(19 831) 	4 899 	1 781 	(13 151) 	(17 021) 	5 076 	1 631 	(10 314)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 65 of 105 --

70	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	71
D.4.4 Reconciliation of insurance contracts – GMM
D.4.4.1 SA LIFE AND INVEST (RISK)
Analysis by measurement component
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Estimates
of PVFCF
RA for
non-
financial risk
CSM
Total
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
Other
contracts
Other
contracts
Opening assets arising from insurance
contracts issued 	(52 454) 	6 960 	27 438 	(18 056) 	(55 257) 	7 765 	27 833 	(19 659)
Opening liabilities arising from insurance
contracts issued 	21 521 	86 	814 	22 421 	20 578 	72 	574 	21 224
Net balance at beginning of the period/year 	(30 933) 	7 046 	28 252 	4 365 	(34 679) 	7 837 	28 407 	1 565
Adjust: transfer of product from SA Life and
Invest (Participating) to SA Life and Invest (Risk) 	1 731 	(183) 	(1 442) 	106
Opening assets arising from insurance contracts
issued (rebased) 	(53 526) 	7 582 	26 391 	(19 553)
Opening liabilities arising from insurance contracts
issued (rebased) 	20 578 	72 	574 	21 224
Net balance at beginning of the period/year
(rebased) 	A 	(30 933) 	7 046 	28 252 	4 365 	(32 948) 	7 654 	26 965 	1 671
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(954) 	(954) 	– 	– 	(1 835) 	(1 835)
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	(272) 	– 	(272) 	– 	(599) 	– 	(599)
Experience adjustments 	48 	– 	– 	48 	513 	– 	– 	513
Changes that relate to future services 	– 	–
Contracts initially recognised in the period 	(1 259) 	236 	1 064 	41 	(2 203) 	450 	1 836 	83
Changes in estimates that adjust CSM 	371 	225 	(596) 	– 	1 548 	(193) 	(1 355) 	–
Changes in estimates that result in onerous
contract losses or reversal of losses 	124 	10 	– 	134 	350 	(16) 	– 	334
Servicing expenses and commission for
onerous contracts 	20 	– 	– 	20 	32 	– 	– 	32
Changes that relate to past services
Adjustment to liability for incurred claims 	– 	– 	– 	– 	– 	2 	– 	2
Insurance service result 	B 	(696) 	199 	(486) 	(983) 	240 	(356) 	(1 354) 	(1 470)
Net finance (income)/expense from
insurance contracts 	C 	(2 136) 	390 	1 089 	(657) 	877 	(252) 	2 641 	3 266
Net changes to income statement and OCI 	D=B+C 	(2 832) 	589 	603 	(1 640) 	1 117 	(608) 	1 287 	1 796
Cash flows 	E 	612 	– 	– 	612 	898 	– 	– 	898
Net balance at the end of the period/year 	G=A+D+E 	(33 153) 	7 635 	28 855 	3 337 	(30 933) 	7 046 	28 252 	4 365
Closing assets arising from insurance
contracts issued 	(55 267) 	7 530 	27 836 	(19 901) 	(52 454) 	6 960 	27 438 	(18 056)
Closing liabilities arising from insurance
contracts issued 	22 114 	105 	1 019 	23 238 	21 521 	86 	814 	22 421
Net balance at the end of the period/year 	(33 153) 	7 635 	28 855 	3 337 	(30 933) 	7 046 	28 252 	4 365
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 66 of 105 --

72	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	73
D.4.4 Reconciliation of insurance contracts – GMM model continued
D.4.4.2 UK LIFE (RISK)
Analysis by measurement component
December 2023 	June 2023
Group
R million
(Assets)/Liabilities 	Navigation
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
Estimates of
PVFCF
RA for non-
financial risk
CSM
Total
Other
contracts
Other
contracts
Opening assets arising from insurance
contracts issued 	(26 042) 	2 016 	13 712 	(10 314) 	(21 126) 	1 741 	11 432 	(7 953)
Net balance at beginning of the period/year 	A 	(26 042) 	2 016 	13 712 	(10 314) 	(21 126) 	1 741 	11 432 	(7 953)
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(633) 	(633) 	– 	– 	(1 074) 	(1 074)
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	(112) 	– 	(112) 	– 	(308) 	– 	(308)
Experience adjustments 	51 	– 	– 	51 	115 	– 	– 	115
Changes that relate to future services
Contracts initially recognised in the period 	(477) 	163 	427 	113 	(1 227) 	330 	1 167 	270
Changes in estimates that adjust CSM 	48 	12 	(60) 	– 	189 	46 	(235) 	–
Changes in estimates that result in onerous
contract losses or reversal of losses 	(35) 	16 	– 	(19) 	265 	15 	– 	280
Insurance service result 	B 	(413) 	79 	(266) 	(600) 	(658) 	83 	(142) 	(717)
Net finance (income)/expense from insurance
contracts 	C 	(2 530) 	164 	94 	(2 272) 	500 	(147) 	142 	495
Net changes to income statement and OCI 	D=B+C 	(2 943) 	243 	(172) 	(2 872) 	(158) 	(64) 	– 	(222)
Cash flows 	E 	(6) 	– 	– 	(6) 	(22) 	– 	– 	(22)
Effect of movements in exchange rates 	F 	319 	(34) 	(244) 	41 	(4 736) 	339 	2 280 	(2 117)
Net closing balance at the end of
the period/year 	G=A+D+E+F 	(28 672) 	2 225 	13 296 	(13 151) 	(26 042) 	2 016 	13 712 	(10 314)
Closing assets arising from insurance
contracts issued 	(28 672) 	2 225 	13 296 	(13 151) 	(26 042) 	2 016 	13 712 	(10 314)
Net closing balance at the end of the period/
year 	(28 672) 	2 225 	13 296 	(13 151) 	(26 042) 	2 016 	13 712 	(10 314)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 67 of 105 --

74	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	75
D.4.5 Reconciliation of insurance contracts – VFA
D.4.5.1 SA LIFE AND INVEST (PARTICIPATING)
Analysis by remaining and incurred claims
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Liabilities for
remaining coverage
Liabilities
for
incurred
Claims 	Total
Liabilities for
remaining coverage 	Liabilities
for
incurred
claims 	Total
Excluding
loss
component
Loss
component
Excluding
loss
component
Loss
component
Opening liabilities arising from insurance
contracts issued 	66 236 	72 	– 	66 308 	56 983 	136 	– 	57 119
Net opening balance at beginning of
the period/year 	66 236 	72 	– 	66 308 	56 983 	136 	– 	57 119
Adjust: transfer of product from SA Life and
Invest (Participating) to SA Life and Invest (Risk) 	2 	(64) 	– 	(62)
Opening liabilities arising from insurance contracts
issued (rebased) 	56 985 	72 	– 	57 057
Net balance at beginning of the period/year
(rebased) 	A 	66 236 	72 	– 	66 308 	56 985 	72 	– 	57 057
Changes in the statement of profit or loss
and OCI
Insurance revenue transitional split
Contracts under the modified retrospective
approach 	(1 417) 	– 	– 	(1 417) 	(2 809) 	– 	– 	(2 809)
Other contracts 	(172) 	– 	– 	(172) 	(53) 	– 	– 	(53)
B 	(1 589) 	– 	– 	(1 589) 	(2 862) 	– 	– 	(2 862)
Insurance service expenses
Incurred claims and other insurance service
expenses 	– 	– 	559 	559 	– 	– 	1 020 	1 020
Experience adjustments adjusting CSM 	(10) 	– 	– 	(10) 	(77) 	– 	– 	(77)
Amortised assets for insurance acquisition cash
flows 	370 	– 	– 	370 	694 	– 	– 	694
Losses and reversal of losses on onerous contracts 	– 	8 	– 	8 	– 	– 	– 	–
C 	360 	8 	559 	927 	617 	– 	1 020 	1 637
Investment components 	D 	(5 593) 	– 	5 593 	– 	(9 191) 	– 	9 191 	–
Insurance service result 	E=B+C+D 	(6 822) 	8 	6 152 	(662) 	(11 436) 	– 	10 211 	(1 225)
Net finance (income)/expense from
insurance contracts 	F 	3 025 	– 	– 	3 025 	8 283 	– 	– 	8 283
Net changes to income statement and OCI 	G=E+F 	(3 797) 	8 	6 152 	2 363 	(3 153) 	– 	10 211 	7 058
Cash Flows
Premiums received 	7 104 	– 	– 	7 104 	13 089 	– 	– 	13 089
Insurance acquisition cash flows 	(337) 	– 	– 	(337) 	(685) 	– 	– 	(685)
Claims and other directly attributable expenses paid 	– 	– 	(6 152) 	(6 152) 	– 	– 	(10 211) 	(10 211)
Total cash flows 	H 	6 767 	– 	(6 152) 	615 	12 404 	– 	(10 211) 	2 193
Net balance at the end of the period/year 	J=A+G+H 	69 206 	80 	– 	69 286 	66 236 	72 	– 	66 308
Closing liabilities arising from insurance
contracts issued 	69 206 	80 	– 	69 286 	66 236 	72 	– 	66 308
Net balance at the end of the period/year 	69 206 	80 	– 	69 286 	66 236 	72 	– 	66 308
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 68 of 105 --

76	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	77
D.4.6 Reconciliation of insurance contracts – VFA
D.4.6.1 SA LIFE AND INVEST (PARTICIPATING)
Analysis by measurement component
Navigation
December 2023 	June 2023
Group
R million
(Assets)/Liabilities
CSM 	CSM
Estimates
of
PVFCF
RA for
non-financial
risk
Transition:
Modified
retrospective
Other
contracts 	Total
Estimates
of
PVFCF
RA for
non-financial
risk
Transition:
Modified
Retrospective
Other
contracts 	Total
Opening liabilities arising from
insurance contracts issued 	59 328 	912 	5 430 	638 	66 308 	52 546 	663 	3 910 	– 	57 119
Net balance at beginning of
the period/year 	59 328 	912 	5 430 	638 	66 308 	52 546 	663 	3 910 	– 	57 119
Adjust: transfer of product from SA
Life and Invest (Participating) to SA
Life and Invest (Risk) 	(1 729) 	166 	1 501 	– 	(62)
Opening liabilities arising from
insurance contracts issued (rebased) 	50 817 	829 	5 411 	– 	57 057
Net balance at beginning of
the period/year 	A 	59 328 	912 	5 430 	638 	66 308 	50 817 	829 	5 411 	– 	57 057
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	(507) 	(60) 	(567) 	– 	– 	(1 072) 	(29) 	(1 101)
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	(97) 	– 	– 	(97) 	– 	(149) 	– 	– 	(149)
Experience adjustments 	43 	– 	(25) 	(29) 	(11) 	7 	– 	2 	(9) 	–
Changes that relate to future services
Contracts initially recognised in the
period 	(334) 	35 	– 	314 	15 	(831) 	70 	– 	782 	21
Changes in estimates that adjust CSM 	326 	(118) 	(145) 	(63) 	– 	(531) 	116 	362 	53 	–
Changes in estimates that result in
onerous contract losses or reversal of
losses 	1 	(2) 	– 	– 	(1) 	1 	3 	– 	– 	4
Insurance service result 	B 	36 	(182) 	(677) 	162 	(661) 	(1 354) 	40 	(708) 	797 	(1 225)
Net finance (income)/expense from
insurance contracts 	C 	2 537 	41 	493 	(47) 	3 024 	7 672 	43 	727 	(159) 	8 283
Net changes to income statement
and OCI 	D=B+C 	2 573 	(141) 	(184) 	115 	2 363 	6 318 	83 	19 	638 	7 058
Cash flows 	E 	615 	– 	– 	– 	615 	2 193 	– 	– 	– 	2 193
Net balance at the end of
the period/year 	G=A+D+E 	62 516 	771 	5 246 	753 	69 286 	59 328 	912 	5 430 	638 	66 308
Closing liabilities arising from insurance
contracts issued 	62 516 	771 	5 246 	753 	69 286 	59 328 	912 	5 430 	638 	66 308
Net balance at the end of
the period/year 	62 516 	771 	5 246 	753 	69 286 	59 328 	912 	5 430 	638 	66 308
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 69 of 105 --

78	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	79
D.4.7 Reconciliation of insurance contracts – PAA
D.4.7.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER
Analysis by remaining coverage, incurred claims and measurement component
Navigation
December 2023 	June 2023
Group
R million
(Assets)/Liabilities
Liabilities for
remaining
coverage
(LRC)
Liabilities for Incurred
Claims (LIC)
Liabilities for
remaining
coverage
Liabilities for Incurred Claims
Estimates of
PV of future
cash flows
RA for
non-financial
risk 	Total
Estimates of
PV of future
cash flows
RA for
non-financial
risk 	Total
Opening liabilities arising from insurance
contracts issued 	(162) 	5 167 	104 	5 109 	(127) 	4 840 	91 	4 804
Net balance at the beginning of the period/year 	A 	(162) 	5 167 	104 	5 109 	(127) 	4 840 	91 	4 804
Insurance revenue 	B 	(1 741) 	– 	– 	(1 741) 	(3 307) 	– 	– 	(3 307)
Insurance service expenses 	C
Incurred claims and other insurance
service expenses 	– 	1 498 	9 	1 507 	– 	2 600 	12 	2 612
Amortisation of insurance acquisition cash flows 	77 	– 	– 	77 	141 	– 	– 	141
77 	1 498 	9 	1 584 	141 	2 600 	12 	2 753
Insurance service result 	D=B+C 	(1 664) 	1 498 	9 	(157) 	(3 166) 	2 600 	12 	(554)
Net finance (income)/expense from
insurance contracts 	E 	– 	219 	5 	224 	– 	200 	1 	201
Net changes to statement of profit or loss
and OCI 	F=D+E 	(1 664) 	1 717 	14 	67 	(3 166) 	2 800 	13 	(353)
Cash flows
Premiums received 	1 748 	– 	– 	1 748 	3 272 	– 	– 	3 272
Insurance acquisition cash flows 	(77) 	– 	– 	(77) 	(141) 	– 	– 	(141)
Claims and other directly attributable
expenses paid 	– 	(1 177) 	– 	(1 177) 	– 	(2 473) 	– 	(2 473)
Total cash flows 	G 	1 671 	(1 177) 	– 	494 	3 131 	(2 473) 	– 	658
Net balance at the end of the period/year 	H=A+F+G 	(155) 	5 707 	118 	5 670 	(162) 	5 167 	104 	5 109
Closing liabilities arising from insurance
contracts issued 	(155) 	5 707 	118 	5 670 	(162) 	5 167 	104 	5 109
Net balance at the end of the period/year 	(155) 	5 707 	118 	5 670 	(162) 	5 167 	104 	5 109
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 70 of 105 --

80	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	81
D.4.7 Reconciliation of insurance contracts – PAA continued
D.4.7.2 SA INSURE AND OTHER
Analysis by remaining coverage, incurred claims and measurement component
Navigation
December 2023 	June 2023
Liabilities for
remaining
coverage
(LRC)
Liabilities for Incurred
Claims (LIC)
Liabilities for
remaining
coverage
Liabilities for Incurred
Claims (LIC)
Group
R million
(Assets)/Liabilities
Estimates
of PVFCF
RA for
non-financial
risk 	Total
Estimates of
PV of future
cash flows
RA for
non-financial
risk 	Total
Opening liabilities arising from insurance
contracts held 	52 	758 	12 	822 	77 	749 	13 	839
Net balance at beginning of the period/year 	A 	52 	758 	12 	822 	77 	749 	13 	839
Insurance revenue 	B 	(3 323) 	– 	– 	(3 323) 	(6 000) 	– 	– 	(6 000)
Insurance service expenses 	C
Incurred claims and other insurance
service expenses 	– 	3 224 	– 	3 224 	– 	5 744 	– 	5 744
Gross claims and insurance service expenses 	– 	3 394 	– 	3 394 	– 	6 123 	– 	6 123
Salvages 	– 	(170) 	– 	(170) 	– 	(379) 	– 	(379)
Adjustment to liability for incurred claims 	– 	96 	5 	101 	– 	141 	(1) 	140
– 	3 320 	5 	3 325 	– 	5 885 	(1) 	5 884
Insurance service result 	D=B+C 	(3 323) 	3 320 	5 	2 	(6 000) 	5 885 	(1) 	(116)
Net finance (income)/expense from
insurance contracts 	E 	– 	– 	– 	– 	– 	– 	– 	–
Net changes to statement of profit or loss
and OCI 	F=D+E 	(3 323) 	3 320 	5 	2 	(6 000) 	5 885 	(1) 	(116)
Cash flows
Premiums received 	3 334 	– 	– 	3 334 	5 975 	– 	– 	5 975
Claims and other directly attributable
expenses paid 	– 	(3 177) 	– 	(3 177) 	– 	(5 877) 	– 	(5 877)
Gross claims and insurance service expenses paid 	– 	(3 373) 	– 	(3 373) 	– 	(6 262) 	– 	(6 262)
Salvages 	– 	196 	– 	196 	– 	385 	– 	385
Total cash flows 	G 	3 334 	(3 177) 	– 	157 	5 975 	(5 877) 	– 	98
Effect of movements in exchange rates 	H 	– 	– 	– 	– 	– 	1 	– 	1
Net balance at the end of the period/year 	I=A+F+G+H 	63 	901 	17 	981 	52 	758 	12 	822
Closing liabilities arising from insurance
contracts issued 	63 	901 	17 	981 	52 	758 	12 	822
Net balance at the end of the period/year 	63 	901 	17 	981 	52 	758 	12 	822
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 71 of 105 --

82	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	83
D.4.7 Reconciliation of insurance contracts – PAA continued
D.4.7.3 UK HEALTH
Analysis by remaining coverage, incurred claims and measurement component
Navigation
December 2023 	June 2023
Liabilities for
remaining
coverage
(LRC)
Liabilities for incurred
claims (LIC)
Total
Liabilities for
remaining
coverage
(LRC)
Liabilities for incurred claims
Total
Group
R million
(Assets)/Liabilities
Estimates of
PV of future
cash flows
RA for
non-financial
risk
Estimates of
PV of future
cash flows
RA for
non-financial
risk
Opening liabilities arising from insurance
contracts issued 	(372) 	1 350 	57 	1 035 	105 	989 	37 	1 131
Net balance at the beginning of
the period/year 	A 	(372) 	1 350 	57 	1 035 	105 	989 	37 	1 131
Insurance revenue 	B 	(7 960) 	– 	– 	(7 960) 	(13 670) 	– 	– 	(13 670)
Insurance service expenses
Incurred claims and other insurance
service expenses 	– 	6 367 	(20) 	6 347 	– 	10 765 	11 	10 776
Amortisation of insurance acquisition cash flows 	850 	– 	– 	850 	1 403 	– 	– 	1 403
Losses and reversal of losses on onerous
contracts 	– 	– 	– 	– 	(1) 	– 	– 	(1)
C 	850 	6 367 	(20) 	7 197 	1 402 	10 765 	11 	12 178
Insurance service result 	D=B+C 	(7 110) 	6 367 	(20) 	(763) 	(12 268) 	10 765 	11 	(1 492)
Net finance (income)/expense from
insurance contracts 	E 	– 	– 	– 	– 	– 	– 	– 	–
Net changes to income statement and OCI 	F=D+E 	(7 110) 	6 367 	(20) 	(763) 	(12 268) 	10 765 	11 	(1 492)
Cash flows
Premiums received 	7 741 	– 	– 	7 741 	13 324 	– 	– 	13 324
Insurance acquisition cash flows 	(324) 	– 	– 	(324) 	(607) 	– 	– 	(607)
Claims and other directly attributable
expenses paid 	– 	(6 793) 	– 	(6 793) 	– 	(10 619) 	– 	(10 619)
Total cash flows 	G 	7 417 	(6 793) 	– 	624 	12 717 	(10 619) 	– 	2 098
Allocation from assets for insurance
acquisition cash flows to group of
insurance contracts 	H 	(521) 	– 	– 	(521) 	(893) 	– 	– 	(893)
Effect of movements in exchange rates 	I 	5 	(27) 	(1) 	(23) 	(33) 	215 	9 	191
Net balance at the end of the period/year 	J=A+F+G+H+I 	(581) 	897 	36 	352 	(372) 	1 350 	57 	1 035
Closing liabilities arising from insurance
contracts issued 	(581) 	897 	36 	352 	(372) 	1 350 	57 	1 035
Net balance at the end of the period/year 	(581) 	897 	36 	352 	(372) 	1 350 	57 	1 035
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 72 of 105 --

84	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	85
D.4.8 Reconciliation of reinsurance contracts – GMM
D.4.8.1 SA LIFE AND INVEST (RISK)
Analysis by remaining coverage and incurred claims
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Assets for remaining
coverage
Assets for
incurred
claims 	Total
Assets for remaining
coverage
Assets for
incurred
claims 	Total
Excluding
loss
recovery
component
Loss
recovery
component
Excluding
loss
recovery
component
Loss
recovery
component
Opening liabilities arising from insurance
contracts issued 	3 027 	(202) 	(2 258) 	567 	3 423 	(148) 	(2 151) 	1 124
Net balance at beginning of the period/year 	A 	3 027 	(202) 	(2 258) 	567 	3 423 	(148) 	(2 151) 	1 124
Changes in the income statement and OCI
Allocation of reinsurance premiums paid 	1 660 	– 	– 	1 660 	3 268 	– 	– 	3 268
Recoveries of incurred claims and other insurance
service expenses 	– 	– 	(1 273) 	(1 273) 	– 	– 	(3 131) 	(3 131)
Recoveries and reversals of recoveries of losses
on onerous underlying contracts 	– 	(13) 	– 	(13) 	– 	(55) 	– 	(55)
Adjustments to assets for incurred claims 	– 	– 	– 	– 	– 	– 	– 	–
1 660 	(13) 	(1 273) 	374 	3 268 	(55) 	(3 131) 	82
Net expenses from reinsurance contracts 	B 	1 660 	(13) 	(1 273) 	374 	3 268 	(55) 	(3 131) 	82
Net finance (income)/expense from
reinsurance contracts 	C 	230 	2 	(55) 	177 	(154) 	1 	(17) 	(170)
Net changes to income statement and OCI 	D=B+C 	1 890 	(11) 	(1 328) 	551 	3 114 	(54) 	(3 148) 	(88)
Cash Flows
Premiums paid 	(1 996) 	– 	– 	(1 996) 	(3 510) 	– 	– 	(3 510)
Claims recovered 	– 	– 	1 618 	1 618 	– 	– 	3 041 	3 041
Total cash flows 	F 	(1 996) 	– 	1 618 	(378) 	(3 510) 	– 	3 041 	(469)
Net balance at the end of the period/year 	H=A+D+F 	2 921 	(213) 	(1 968) 	740 	3 027 	(202) 	(2 258) 	567
Closing liabilities arising from reinsurance
contracts held 	2 921 	(213) 	(1 968) 	740 	3 027 	(202) 	(2 258) 	567
Net balance at the end of the period/year 	2 921 	(213) 	(1 968) 	740 	3 027 	(202) 	(2 258) 	567
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 73 of 105 --

86	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	87
D.4.8 Reconciliation of reinsurance contracts – GMM continued
D.4.8.2 UK LIFE (RISK)
Analysis by remaining coverage and incurred claims
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Assets for remaining
coverage
Assets for
incurred
claims 	Total
Assets for remaining
coverage
Assets for
incurred
claims 	Total
Excluding
loss
recovery
component
Loss
recovery
component
Excluding
loss
recovery
component
Loss
recovery
component
Opening liabilities arising from reinsurance
contracts held 	7 679 	(2 374) 	(1 029) 	4 276 	6 668 	(1 810) 	(683) 	4 175
Net balance at beginning of the period/year 	A 	7 679 	(2 374) 	(1 029) 	4 276 	6 668 	(1 810) 	(683) 	4 175
Changes in the income statement and OCI
Allocation of reinsurance premiums paid 	2 675 	– 	– 	2 675 	3 464 	– 	– 	3 464
Recoveries of incurred claims and other
insurance service expenses 	– 	– 	(2 502) 	(2 502) 	– 	– 	(3 272) 	(3 272)
Recoveries and reversals of recoveries of losses
on onerous underlying contracts 	– 	41 	– 	41 	– 	(284) 	– 	(284)
2 675 	41 	(2 502) 	214 	3 464 	(284) 	(3 272) 	(92)
Net expenses from reinsurance contracts 	B 	2 675 	41 	(2 502) 	214 	3 464 	(284) 	(3 272) 	(92)
Net finance (income)/expense from
reinsurance contracts 	C 	596 	22 	– 	618 	(162) 	60 	– 	(102)
Net changes to income statement and OCI 	D=B+C 	3 271 	63 	(2 502) 	832 	3 302 	(224) 	(3 272) 	(194)
Cash Flows
Premiums paid 	(2 365) 	– 	– 	(2 365) 	(3 430) 	– 	– 	(3 430)
Claims recovered 	– 	– 	2 273 	2 273 	– 	– 	3 069 	3 069
Total cash flows 	F 	(2 365) 	– 	2 273 	(92) 	(3 430) 	– 	3 069 	(361)
Effect of movements in exchange rates 	G 	(131) 	42 	17 	(72) 	1 139 	(340) 	(143) 	656
Net balance at the end of the period/year 	H=A+D+F+G 	8 454 	(2 269) 	(1 241) 	4 944 	7 679 	(2 374) 	(1 029) 	4 276
Closing liabilities arising from reinsurance
contracts held 	8 454 	(2 269) 	(1 241) 	4 944 	7 679 	(2 374) 	(1 029) 	4 276
Net balance at the end of the period/year 	8 454 	(2 269) 	(1 241) 	4 944 	7 679 	(2 374) 	(1 029) 	4 276
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 74 of 105 --

88	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	89
D.4.9 Reconciliation of reinsurance contracts – GMM
D.4.9.1 SA LIFE AND INVEST (RISK)
Analysis by measurement component
Navigation
December 2023 	June 2023
CSM 	CSM
Group
R million
(Assets)/Liabilities
Estimates
of PVFCF
RA for
non-financial
risk
Transition:
Modified
retrospective
Other
contracts 	Total
Estimates
of PVFCF
RA for
non-financial
risk
Transition:
Modified
retrospective
Other
contracts 	Total
Opening liabilities arising from
reinsurance contracts held 	6 094 	(698) 	(80) 	(4 749) 	567 	6 315 	(704) 	(75) 	(4 412) 	1 124
Net balance at beginning of
the period/year 	A 	6 094 	(698) 	(80) 	(4 749) 	567 	6 315 	(704) 	(75) 	(4 412) 	1 124
Changes in the income statement
and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	2 	161 	163 	– 	– 	4 	307 	311
Change in Risk Adjustment for
non-financial risk that relates to
expired risk 	– 	33 	– 	– 	33 	– 	63 	– 	– 	63
Experience adjustments 	195 	– 	– 	– 	195 	(221) 	– 	– 	– 	(221)
Changes that relate to future services
Contracts initially recognised in
the period 	106 	(11) 	– 	(100) 	(5) 	221 	(25) 	– 	(209) 	(13)
Changes in estimates that adjust CSM 	30 	18 	– 	(20) 	28 	41 	(7) 	– 	(31) 	3
Changes in estimates that relate to
losses and reversal of losses on
underlying contracts 	(24) 	(17) 	– 	– 	(41) 	(62) 	2 	– 	– 	(60)
Changes that relate to past services
Adjustment to assets for incurred
claims 	– 	1 	– 	– 	1 	– 	(1) 	– 	– 	(1)
Net Expenses from reinsurance
contracts held 	B 	307 	24 	2 	41 	374 	(21) 	32 	4 	67 	82
Net finance (income)/expense from
reinsurance contracts 	C 	409 	(33) 	(4) 	(195) 	177 	269 	(26) 	(9) 	(404) 	(170)
Net changes to income statement
and OCI 	D=B+C 	716 	(9) 	(2) 	(154) 	551 	248 	6 	(5) 	(337) 	(88)
Cash flows 	E 	(378) 	– 	– 	– 	(378) 	(469) 	– 	– 	– 	(469)
Net balance at the end of
the period/year 	G=A+D+E 	6 432 	(707) 	(82) 	(4 903) 	740 	6 094 	(698) 	(80) 	(4 749) 	567
Closing liabilities arising from reinsurance
contracts held 	6 432 	(707) 	(82) 	(4 903) 	740 	6 094 	(698) 	(80) 	(4 749) 	567
Net balance at the end of
the period/year 	6 432 	(707) 	(82) 	(4 903) 	740 	6 094 	(698) 	(80) 	(4 749) 	567
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 75 of 105 --

90	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	91
D.4.9 Reconciliation of reinsurance contracts – GMM continued
D.4.9.2 UK LIFE (RISK)
Analysis by measurement component
Navigation
December 2023 	June 2023
CSM 	CSM
Group
R million
(Assets)/Liabilities
Estimates
of PVFCF
RA for
non-financial
risk
Other
contracts 	Total
Estimates
of PVFCF
RA for
non-financial
risk
Other
contracts 	Total
Opening liabilities arising from reinsurance
contracts held 	9 703 	(430) 	(4 997) 	4 276 	8 515 	(438) 	(3 993) 	4 084
Net balance at beginning of the period/year 	A 	9 703 	(430) 	(4 997) 	4 276 	8 515 	(438) 	(3 993) 	4 084
Changes in the income statement and OCI
Changes that relate to current services
CSM recognised for services provided 	– 	– 	242 	242 	– 	– 	399 	399
Change in Risk Adjustment for non-financial risk
that relates to expired risk 	– 	13 	– 	13 	– 	18 	– 	18
Experience adjustments 	(21) 	– 	– 	(21) 	(87) 	– 	– 	(87)
Changes that relate to future services
Contracts initially recognised in the period 	481 	(26) 	(528) 	(73) 	650 	(56) 	(777) 	(183)
Changes in estimates that adjust CSM 	9 	3 	(12) 	– 	(298) 	77 	246 	25
Changes in estimates that relate to losses and
reversal of losses on underlying contracts 	55 	(2) 	– 	53 	(244) 	(20) 	– 	(264)
Net Expenses from reinsurance contracts held 	B 	524 	(12) 	(298) 	214 	21 	19 	(132) 	(92)
Net finance (income)/expense from
reinsurance contracts 	C 	703 	(42) 	(43) 	618 	(115) 	67 	(54) 	(102)
Net changes to income statement and OCI 	D=B+C 	1 227 	(54) 	(341) 	832 	(94) 	86 	(186) 	(194)
Cash flows 	E 	(92) 	– 	– 	(92) 	(362) 	– 	– 	(362)
Effect of movements in exchange rates 	F 	(166) 	7 	87 	(72) 	1 644 	(78) 	(818) 	748
Net balance at the end of the period/year 	G=A+D+E+F 	10 672 	(477) 	(5 251) 	4 944 	9 703 	(430) 	(4 997) 	4 276
Closing liabilities arising from reinsurance
contracts held 	10 672 	(477) 	(5 251) 	4 944 	9 703 	(430) 	(4 997) 	4 276
Net balance at the end of the period/year 	10 672 	(477) 	(5 251) 	4 944 	9 703 	(430) 	(4 997) 	4 276
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 76 of 105 --

92	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	93
D.4.10 Reconciliation of reinsurance contracts – PAA
D.4.10.1 SA LIFE AND INVEST: GROUP LIFE AND OTHER
Analysis by remaining coverage, incurred claims and measurement component
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Asset for
remaining
coverage
Asset for incurred claims
Total
Asset for
remaining
coverage
Asset for incurred claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from reinsurance
contracts held 	398 	(910) 	(17) 	(529) 	378 	(1 054) 	(15) 	(691)
Net balance at beginning of the period/year 	A 	398 	(910) 	(17) 	(529) 	378 	(1 054) 	(15) 	(691)
Changes in the statement of profit or loss
and OCI
Net expenses from reinsurance contracts held
Reinsurance premiums expense 	141 	– 	– 	141 	282 	– 	– 	282
Claims recovered from reinsurer 	– 	(102) 	(2) 	(104) 	– 	(138) 	(2) 	(140)
Net finance (income)/expense from
reinsurance contracts 	– 	(28) 	(1) 	(29) 	– 	(31) 	– 	(31)
Net changes to statement of profit or loss
and OCI 	B 	141 	(130) 	(3) 	8 	282 	(169) 	(2) 	111
Cash Flows
Premiums paid net of commissions and other
attributable expenses 	(399) 	– 	– 	(399) 	(262) 	– 	– 	(262)
Reinsurance recoveries 	– 	315 	– 	315 	– 	313 	– 	313
Total cash flows 	C 	(399) 	315 	– 	(84) 	(262) 	313 	– 	51
Net balance at end of the period/year 	D=A+B+C 	140 	(725) 	(20) 	(605) 	398 	(910) 	(17) 	(529)
Closing assets arising from reinsurance
contracts held 	140 	(725) 	(20) 	(605) 	398 	(910) 	(17) 	(529)
Net balance at end of the period/year 	140 	(725) 	(20) 	(605) 	398 	(910) 	(17) 	(529)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 77 of 105 --

94	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	95
D.4.10 Reconciliation of reinsurance contracts – PAA continued
D.4.10.2 SA INSURE AND OTHER
Analysis by remaining coverage and incurred claims
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Asset for
remaining
coverage
Asset for incurred claims
Total
Asset for
remaining
coverage
Asset for incurred claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from reinsurance
contracts held 	776 	(845) 	(2) 	(71) 	260 	(440) 	(2) 	(182)
Net balance at beginning of the period/year 	A 	776 	(845) 	(2) 	(71) 	260 	(440) 	(2) 	(182)
Changes in the income statement and OCI
Net expenses from reinsurance contracts held
Reinsurance premiums expense 	383 	– 	– 	383 	635 	– 	– 	635
Claims recovered from reinsurer 	– 	(403) 	(1) 	(404) 	– 	(590) 	– 	(590)
Net changes to statement of profit or loss
and OCI 	B 	383 	(403) 	(1) 	(21) 	635 	(590) 	– 	45
Cash flows
Premiums paid net of commissions and other
attributable expenses 	(800) 	– 	– 	(800) 	(119) 	– 	– 	(119)
Reinsurance recoveries 	– 	720 	– 	720 	– 	185 	– 	185
Total cash flows 	C 	(800) 	720 	– 	(80) 	(119) 	185 	– 	66
Net balance at end of the period/year 	D=A+B+C 	359 	(528) 	(3) 	(172) 	776 	(845) 	(2) 	(71)
Closing assets arising from reinsurance
contracts held 	359 	(528) 	(3) 	(172) 	776 	(845) 	(2) 	(71)
Net balance at the end of the period/year 	359 	(528) 	(3) 	(172) 	776 	(845) 	(2) 	(71)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 78 of 105 --

96	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	97
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4.10 Reconciliation of reinsurance contracts – PAA continued
D.4.10.3 UK HEALTH
Analysis by remaining coverage and incurred claims
Group
R million
(Assets)/Liabilities 	Navigation
December 2023 	June 2023
Asset for
remaining
coverage
Asset for Incurred Claims
Total
Asset for
remaining
coverage
Asset for Incurred Claims
Total
Estimates
of PVFCF
RA for
non-financial
risk
Estimates
of PVFCF
RA for
non-financial
risk
Opening assets arising from reinsurance
contracts held 	8 	(9) 	(3) 	(4) 	6 	(5) 	(2) 	(1)
Net balance at beginning of the period/year 	A 	8 	(9) 	(3) 	(4) 	6 	(5) 	(2) 	(1)
Changes in the income statement and OCI
Net expenses from reinsurance contracts held
Reinsurance premiums expense 	5 	– 	– 	5 	1 847 	– 	– 	1 847
Claims recovered from reinsurer 	– 	– 	– 	– 	– 	(1 837) 	(1) 	(1 838)
Net changes income statement and OCI 	B 	5 	– 	– 	5 	1 847 	(1 837) 	(1) 	9
Cash flows
Premiums paid net of commissions and other
attributable expenses 	(17) 	– 	– 	(17) 	(1 845) 	– 	– 	(1 845)
Reinsurance recoveries 	– 	1 	1 	2 	– 	1 833 	– 	1 833
Total cash flows 	C 	(17) 	1 	1 	(15) 	(1 845) 	1 833 	– 	(12)
Net balance at the end of the period/year 	D=A+B+C 	(4) 	(8) 	(2) 	(14) 	8 	(9) 	(3) 	(4)
Closing assets arising from reinsurance
contracts held 	(4) 	(8) 	(2) 	(14) 	8 	(9) 	(3) 	(4)
Net balance at the end of the period/year 	(4) 	(8) 	(2) 	(14) 	8 	(9) 	(3) 	(4)
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 79 of 105 --

98	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	99
D.4.11 Insurance revenue
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Group Risk
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA) 	Total
Six months ended 31 December 2023
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	6 166 	1 219 	– 	– 	3 091 	– 	10 476
– CSM recognised for services provided 	953 	568 	– 	– 	633 	– 	2 154
– Change in risk adjustment for non-financial risk for risk expired 	269 	96 	– 	– 	109 	– 	474
– Expected incurred claims and other insurance service expenses 	5 022 	543 	– 	– 	2 470 	– 	8 035
– Experience adjustments 	(78) 	12 	– 	– 	(121) 	– 	(187)
Recovery of insurance acquisition cash flows 	970 	370 	– 	– 	1 277 	– 	2 617
Contracts not measured under the PAA 	7 136 	1 589 	– 	– 	4 368 	– 	13 093
Contracts measured under the PAA 	– 	– 	1 741 	3 323 	– 	7 960 	13 024
Total insurance revenue 	7 136 	1 589 	1 741 	3 323 	4 368 	7 960 	26 117
Six months ended 31 December 2022
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	5 898 	1 012 	– 	– 	2 471 	– 	9 381
– CSM recognised for services provided 	901 	527 	– 	– 	587 	– 	2 015
– Change in risk adjustment for non-financial risk for risk expired 	278 	61 	– 	– 	139 	– 	478
– Expected incurred claims and other insurance service expenses 	4 739 	422 	– 	– 	2 063 	– 	7 224
– Experience adjustments 	(20) 	2 	– 	– 	(318) 	– 	(336)
Recovery of insurance acquisition cash flows 	834 	351 	– 	– 	987 	– 	2 172
Contracts not measured under the PAA 	6 732 	1 363 	– 	– 	3 458 	– 	11 553
Contracts measured under the PAA 	– 	– 	1 637 	2 917 	– 	6 425 	10 979
Total insurance revenue 	6 732 	1 363 	1 637 	2 917 	3 458 	6 425 	22 532
Year ended 30 June 2023
Contracts not measured under the PAA
Amounts relating to changes in liabilities for remaining coverage 	12 122 	2 168 	– 	(1) 	5 434 	– 	19 723
– CSM recognised for services provided 	1 835 	1 101 	– 	– 	1 074 	– 	4 010
– Change in risk adjustment for non-financial risk for risk expired 	595 	148 	– 	– 	299 	– 	1 042
– Expected incurred claims and other insurance service expenses 	9 653 	927 	– 	(1) 	4 339 	– 	14 918
– Experience adjustments 	39 	(8) 	– 	– 	(278) 	– 	(247)
Recovery of insurance acquisition cash flows 	1 713 	694 	– 	– 	2 101 	– 	4 508
Contracts not measured under the PAA 	13 835 	2 862 	– 	(1) 	7 535 	– 	24 231
Contracts measured under the PAA 	– 	– 	3 307 	6 000 	– 	13 670 	22 977
Total insurance revenue 	13 835 	2 862 	3 307 	5 999 	7 535 	13 670 	47 208
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 80 of 105 --

100	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	101
D.4.12 Net investment result
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million
Income/(expense) 	Navigation
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Group Risk
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA) 	Other 	Total
Six month period ended 31 December 2023
Investment return
Interest revenue from financial assets not measured at FVTPL 	10 	– 	– 	122 	41 	83 	156 	412
Net gains on FVTPL investments 	2 210 	2 703 	– 	4 	– 	56 	1 697 	6 670
Total investment return 	2 220 	2 703 	– 	126 	41 	139 	1 853 	7 082
Finance income/(expense) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(3 014) 	– 	– 	– 	– 	– 	(3 014)
Interest accreted on CSM 	(1 134) 	(446) 	– 	– 	(94) 	– 	– 	(1 674)
Interest accreted on FCF and other finance (income)/expense 1 	817 	436 	(186) 	– 	2 366 	– 	– 	3 433
Effect of changes in interest rates and other financial assumptions 	516 	– 	(40) 	– 	– 	– 	– 	476
Effect of changing FCF at current rates when adjusting the CSM at rates on initial
recognition 	488 	– 	– 	– 	– 	– 	– 	488
Effect of movements in exchange rates 	(28) 	– 	2 	– 	– 	– 	– 	(26)
Net finance expense from insurance contracts 	A 	659 	(3 024) 	(224) 	– 	2 272 	– 	– 	(317)
Finance income/(expense) from reinsurance contracts
Interest accreted 	199 	– 	26 	– 	43 	– 	– 	268
Other 	(379) 	– 	3 	– 	(661) 	– 	– 	(1 037)
Net finance Income from reinsurance contracts 	B 	(180) 	– 	29 	– 	(618) 	– 	– 	(769)
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(691) 	(691)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(1 149) 	(1 149)
– 	– 	– 	– 	– 	– 	(1 840) 	(1 840)
Represented by:
Amounts recognised in statement of profit or loss 	250 	(3 024) 	(193) 	– 	76 	– 	– 	(2 892)
Amounts recognised in OCI 	229 	– 	(2) 	– 	1 578 	– 	– 	1 805
C=A+B 	479 	(3 024) 	(195) 	– 	1 654 	– 	– 	(1 086)
Insurance finance income and expenses
Net finance expenses from insurance contracts
Amounts recognised in statement of profit or loss 	377 	(3 024) 	(225) 	– 	142 	– 	– 	(2 730)
Amounts recognised in OCI 	282 	– 	1 	– 	2 130 	– 	– 	2 413
A 	659 	(3 024) 	(224) 	– 	2 272 	– 	– 	(317)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(127) 	– 	32 	– 	(66) 	– 	– 	(162)
Amounts recognised in OCI 	(53) 	– 	(3) 	– 	(552) 	– 	– 	(608)
B 	(180) 	– 	29 	– 	(618) 	– 	– 	(769)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 81 of 105 --

102	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	103
D.4.12 Net investment result continued
The following table analyses the Group’s net investment result in profit or loss and OCI.
Group
R million
Income/(expense)
SA Life and
Invest Risk
(GMM)
SA Life and
Invest
Participating
(VFA)
SA Life and
Group Risk
(PAA)
SA Insure
and other
immaterial
(PAA)
UK Life Risk
(GMM)
UK Health
(PAA) 	Other 	Total
Year ended 30 June 2023
Investment return
Interest revenue from financial assets not measured at FVTPL 	28 	– 	– 	181 	71 	90 	246 	616
Net gains on FVTPL investments 	4 576 	8 473 	– 	– 	516 	1 	3 161 	16 727
Total investment return 	4 604 	8 473 	– 	181 	587 	91 	3 407 	17 343
Finance income/(expense) from insurance contracts
Changes in fair value of underlying items of direct participation contracts 	– 	(8 252) 	– 	– 	– 	– 	– 	(8 252)
Interest accreted on CSM 	(2 280) 	(599) 	– 	– 	(142) 	– 	– 	(3 021)
Interest accreted on FCF and other finance (income)/expense 2 	1 571 	568 	(267) 	– 	(353) 	– 	– 	1 519
Effect of changes in interest rates and other financial assumptions 	(3 098) 	– 	84 	– 	– 	– 	– 	(3 014)
Effect of changing FCF at current rates when adjusting the CSM at rates on initial recognition 	446 	– 	– 	– 	– 	– 	– 	446
Effect of movements in exchange rates 	97 	– 	(18) 	– 	– 	– 	– 	79
Net finance expense from insurance contracts 	(3 264) 	(8 283) 	(201) 	– 	(495) 	– 	– 	(12 243)
Finance income/(expense) from reinsurance contracts
Interest accreted 	413 	– 	42 	– 	54 	– 	– 	509
Other 	(242) 	– 	(12) 	– 	48 	– 	– 	(206)
Net finance Income from reinsurance contracts 	171 	– 	30 	– 	102 	– 	– 	303
Movement in investment contract liabilities 	– 	– 	– 	– 	– 	– 	(2 593) 	(2 593)
Movement in third party interests in consolidated funds 	– 	– 	– 	– 	– 	– 	(2 978) 	(2 978)
– 	– 	– 	– 	– 	– 	(5 571) 	(5 571)
Represented by:
Amounts recognised in statement of profit or loss 	1 267 	(8 283) 	(354) 	– 	(88) 	– 	– 	(7 458)
Amounts recognised in OCI 	(4 362) 	– 	183 	– 	(304) 	– 	– 	(4 483)
(3 095) 	(8 283) 	(171) 	– 	(392) 	– 	– 	(11 941)
Insurance finance income and expenses
Net finance expenses from insurance contracts
Amounts recognised in statement of profit or loss 	1 553 	(8 283) 	(415) 	– 	(27) 	– 	– 	(7 172)
Amounts recognised in OCI 	(4 819) 	– 	214 	– 	(467) 	– 	– 	(5 072)
(3 266) 	(8 283) 	(201) 	– 	(494) 	– 	– 	(12 244)
Net finance income from reinsurance contracts
Amounts recognised in statement of profit or loss 	(286) 	– 	61 	– 	(61) 	– 	– 	(286)
Amounts recognised in OCI 	457 	– 	(31) 	– 	163 	– 	– 	589
171 	– 	30 	– 	102 	– 	– 	303
1 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/ expense includes for Individual life finance income
of R2 059 million, and guaranteed endowments finance expense of R1 242 million.
2 For SA Life and Invest GMM Risk, the interest accreted on FCF and other finance (income)/ expense includes for Individual life finance income
of R2 284 million, and guaranteed endowments finance expense of R1 293 million
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 82 of 105 --

104	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	105
D.4.13 Effect of insurance contracts initially recognised in the year
Profitable contracts issued 	Onerous contracts issued
Group
R million
(Assets)/Liabilities
SA Life
and Invest
Risk
(GMM)
SA Life
and Invest
Participating
(VFA)
UK Life Risk
(GMM) 	Total
SA Life
and Invest
Risk
(GMM)
SA Life
and Invest
Participating
(VFA)
UK Life Risk
(GMM) 	Total
Six months ended 31 December 2023
Insurance acquisition cash flows 	(179) 	(217) 	– 	(396) 	27 	(47) 	– 	(20)
Claims and other insurance service expenses payable 	(4 325) 	(2 949) 	(1 816) 	(9 090) 	(326) 	(836) 	(835) 	(1 997)
Estimates of present value of cash outflows 	(4 504) 	(3 166) 	(1 816) 	(9 486) 	(299) 	(883) 	(835) 	(2 017)
Estimates of present value of cash inflows 	5 790 	3 513 	2 372 	11 675 	272 	870 	756 	1 898
Risk adjustment for non-financial risk 	(222) 	(33) 	(129) 	(384) 	(14) 	(2) 	(34) 	(50)
CSM 	(1 064) 	(314) 	(427) 	(1 805) 	– 	– 	– 	–
Losses recognised on initial recognition 	– 	– 	– 	– 	(41) 	(15) 	(113) 	(169)
Year ended 30 June 2023
Insurance acquisition cash flows 	(325) 	(437) 	– 	(762) 	(9) 	(66) 	– 	(75)
Claims and other insurance service expenses payable 	(6 900) 	(6 733) 	(3 930) 	(17 563) 	(777) 	(1 232) 	(1 728) 	(3 737)
Estimates of present value of cash outflows 	(7 225) 	(7 170) 	(3 930) 	(18 325) 	(786) 	(1 298) 	(1 728) 	(3 812)
Estimates of present value of cash inflows 	9 474 	8 019 	5 370 	22 863 	740 	1 280 	1 515 	3 535
Risk adjustment for non-financial risk 	(413) 	(67) 	(273) 	(753) 	(37) 	(3) 	(57) 	(97)
CSM 	(1 836) 	(782) 	(1 167) 	(3 785) 	– 	– 	– 	–
Losses recognised on initial recognition 	– 	– 	– 	– 	(83) 	(21) 	(270) 	(374)
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 83 of 105 --

106	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D.4. 	Insurance and reinsurance contracts related disclosures continued
D.4.14 Effects of reinsurance contracts initially recognised in the year
REINSURANCE CONTRACTS
Group of contracts with a net
cost on initial recognition 1
Group
R million
(Asset)/Liability
SA Life and
Invest Risk
(GMM)
UK Life Risk
(GMM) 	Total
Six months ended 31 December 2023
Estimates of present value of cash outflows 	(584) 	1 595 	1 011
Estimates of present value of cash inflows 	478 	(2 076) 	(1 598)
Risk adjustment for non-financial Risk 	11 	26 	37
Income recognised on initial recognition (for offset) 	(5) 	(73) 	(78)
Contractual service margin (CSM) 	(100) 	(528) 	(628)
Year ended 30 June 2023
Estimates of present value of cash outflows 	(1 241) 	3 480 	2 239
Estimates of present value of cash inflows 	1 020 	(4 130) 	(3 110)
Risk adjustment for non-financial Risk 	25 	56 	81
Income recognised on initial recognition (for offset) 	(13) 	(183) 	(196)
Contractual service margin (CSM) 	(209) 	(777) 	(986)
1 Group of contracts with a net cost on initial recognition refers to those reinsurance contracts with a CSM on initial recognition, that will reflect as
a future cost relative to the insurance contract CSM that will release as future revenue.
2 Group of contracts with a net gain on initial recognition refers to those reinsurance contracts where at inception the full profit from the
reinsurance contracts was recognised, which offset losses on onerous contracts at inception.
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued

-- 84 of 105 --

107
D 4.15 Contractual service margin
The following table sets out when the group expects to recognise the remaining CSM in profit or loss after the reporting date for
contracts not measured under the PAA:
D 4.15.1 INSURANCE CONTRACTS ISSUED
Group
R million
Years of expected release of the CSM
<1 year 1 – 2 years 3 – 5 years 6 – 10 years 	>10 years 	Total
Six months ended 31
SA Life and Invest Risk (GMM)
Balance at beginning of the period 	28 855 	29 046 	29 574 	32 447 	42 367 	28 855
Accretion of interest 	2 499 	2 688 	9 334 	20 707 	406 215 	441 443
Recognised in income statement 	(2 308) 	(2 160) 	(6 461) 	(10 787) 	(448 582) 	(470 298)
Balance at end of the period 	29 046 	29 574 	32 447 	42 367 	– 	–
SA Life and Invest Risk (VFA)
Balance at beginning of the period 	5 999 	5 810 	5 567 	5 326 	6 109 	5 999
Accretion of interest 	1 063 	1 050 	3 645 	8 358 	21 126 	35 242
Recognised in income statement 	(1 252) 	(1 293) 	(3 886) 	(7 575) 	(27 235) 	(41 241)
Balance at end of the period 	5 810 	5 567 	5 326 	6 109 	– 	–
UK Life Risk (GMM)
Balance at beginning of the period 	13 296 	12 299 	11 403 	9 137 	6 168 	13 296
Accretion of interest 	216 	200 	517 	661 	1 044 	2 638
Recognised in income statement 	(1 213) 	(1 096) 	(2 783) 	(3 630) 	(7 212) 	(15 934)
Balance at end of the period 	12 299 	11 403 	9 137 	6 168 	– 	–
Total balance at beginning of the period 	48 150
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of the period 	28 252 	28 582 	29 104 	31 775 	41 229 	28 252
Accretion of interest 	2 437 	2 626 	9 073 	19 945 	391 041 	425 122
Recognised in income statement 	(2 107) 	(2 104) 	(6 402) 	(10 491) 	(432 270) 	(453 374)
Balance at end of the period 	28 582 	29 104 	31 775 	41 229 	– 	–
SA Life and Invest Participating (VFA)
Balance at beginning of the period 	6 068 	5 881 	5 686 	5 596 	6 460 	6 068
Accretion of interest 	1 077 	1 120 	3 926 	8 699 	23 514 	38 336
Recognised in income statement 	(1 264) 	(1 315) 	(4 016) 	(7 835) 	(29 974) 	(44 404)
Balance at end of the period 	5 881 	5 686 	5 596 	6 460 	– 	–
UK Life Risk (GMM)
Balance at beginning of the year 	13 712 	12 650 	11 702 	9 333 	6 271 	13 712
Accretion of interest 	205 	191 	496 	636 	954 	2 482
Recognised in income statement 	(1 267) 	(1 139) 	(2 865) 	(3 698) 	(7 225) 	(16 194)
Balance at end of the year 	12 650 	11 702 	9 333 	6 271 	– 	–
Total balance at beginning of the period 	48 032
D.4. 	Insurance and reinsurance contracts related disclosures continued

-- 85 of 105 --

108	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
D. 	NEW STANDARDS AND INTERPRETATIONS AND RESTATEMENTS continued
D.4. 	Insurance and reinsurance contracts related disclosures continued
D 4.15 Contractual service margin continued
D 4.15.2 REINSURANCE CONTRACTS HELD
Group
R million
Years of expected release of the CSM
<1 year 1 – 2 years 3 – 5 years 6 – 10 years 	>10 years 	Total
Six months ended 31 December 2023
SA Life and Invest Risk (GMM)
Balance at beginning of the period 	4 985 	5 068 	5 167 	5 670 	6 802 	4 985
Accretion of interest 	439 	461 	1 535 	3 146 	48 864 	54 445
Recognised in income statement 	(356) 	(362) 	(1 032) 	(2 014) 	(55 666) 	(59 430)
Balance at end of the period 	5 068 	5 167 	5 670 	6 802 	– 	–
UK Life Risk (GMM)
Balance at beginning of the period 	5 251 	4 879 	4 543 	3 689 	2 565 	5 251
Accretion of interest 	111 	102 	252 	318 	552 	1 335
Recognised in income statement 	(483) 	(438) 	(1 106) 	(1 442) 	(3 117) 	(6 586)
Balance at end of the period 	4 879 	4 543 	3 689 	2 565 	– 	–
Total balance at beginning of the period 	10 236
Year ended 30 June 2023
SA Life and Invest Risk (GMM)
Balance at beginning of the year 	4 829 	4 907 	5 002 	5 467 	6 506 	4 829
Accretion of interest 	423 	445 	1 478 	3 009 	45 918 	51 273
Recognised in income statement 	(345) 	(350) 	(1 013) 	(1 970) 	(52 424) 	(56 102)
Balance at end of the year 	4 907 	5 002 	5 467 	6 506 	– 	–
UK Life Risk (GMM)
Balance at beginning of the year 	4 997 	4 622 	4 284 	3 438 	2 345 	4 997
Accretion of interest 	87 	80 	198 	251 	389 	1 005
Recognised in income statement 	(462) 	(418) 	(1 044) 	(1 344) 	(2 734) 	(6 002)
Balance at end of the year 	4 622 	4 284 	3 438 	2 345 	– 	–
Total balance at beginning of the period 	9 826

-- 86 of 105 --

109
Review opinion
External review and comparative information
E

-- 87 of 105 --

110	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Independent auditors’ report
To the shareholders of Discovery Limited
Report on the restated IFRS 17 and Other Presentation Changes and Restated Financial information
We have reviewed the restated impacted financial statement captions following the adoption of IFRS 17 “Insurance Contracts” as set out
below as at 30 June 2023 and 1 July 2022 included in the Discovery Limited’s Interim Results for the six months ended 31 December 2023
(“Interim Financial Information”):
 Assets arising from insurance contracts issued;
 Assets arising from reinsurance contracts held;
 Deferred tax asset;
 Deferred acquisition costs;
 Investment in equity-accounted investments;
 Contract receivables and other receivables;
 Cash and cash equivalents;
 Other reserves;
 Retained earnings;
 Equity attributable to equity holders of the company;
 Liabilities arising from insurance contracts issued;
 Liabilities arising from reinsurance contracts held;
 Deferred tax liability;
 Other financial payables at amortised cost;
 Investment contracts at fair value through profit or loss; and
 Other payables and provisions,
and the financial statement captions impacted by Other restatements and Other presentation changes as set out below as at 30 June 2023
and 1 July 2022 in the Interim Financial Information:
 Intangible assets;
 Deferred tax asset;
 Contract receivables and other receivables;
 Other reserves;
 Retained earnings;
 Equity attributable to equity holders of the company;
 Other financial payables at amortised cost;
 Deferred acquisition costs;
 Assets arising from contracts with customers;
 Third-party interest in consolidated funds;
 Investment contracts at fair value through profit or loss;
 Other payables and provisions;
 Employee benefits; and
 Assets arising from reinsurance contracts held
which are included in the Interim Financial Information’s selected notes, and a Summary of material accounting policies (together the
“restated IFRS 17 and Other Presentation Changes and Restated Financial information”).
Directors’ Responsibility for the restated IFRS 17 and Other Presentation Changes and Restated
Financial information
The directors are responsible for the preparation and presentation of the restated IFRS 17 and Other Presentation Changes and Restated
Financial information in all material respects, in accordance with the principles of IAS 34: Interim Financial Reporting (IAS 34) , and for such
internal control as the directors determine is necessary to enable the preparation of the restated IFRS 17 and Other Presentation Changes
and Restated Financial information that is free from material misstatement, whether due to fraud or error.
E. 	REVIEW OPINION

-- 88 of 105 --

111
Auditors’ Responsibilities for the Review of the restated IFRS 17 and Other Presentation Changes and
Restated Financial information
Our responsibility is to express a conclusion on the restated IFRS 17 and Other Presentation Changes and Restated Financial information.
We conducted our review in accordance with International Standard on Review Engagements (ISRE) 2410, Review of Interim Financial
Information Performed by the Independent Auditor of the Entity, read together with ISA 805 (Revised), Special Considerations – Audits of
Single Financial Statements and Specific Elements, Accounts or Items of a Financial Statement. ISRE 2410 requires us to conclude whether
anything has come to our attention that causes us to believe that the restated IFRS 17 and Other Presentation Changes and Restated
Financial information is not prepared in all material respects in accordance with the principles of IAS 34. This Standard also requires
us to comply with relevant ethical requirements.
A review of the restated IFRS 17 and Other Presentation Changes and Restated financial information in accordance with ISRE 2410 is a limited
assurance engagement. We perform procedures, primarily consisting of making inquiries of management and others within the entity, as
appropriate, and applying analytical procedures, and evaluate the evidence obtained.
The procedures performed in a review are substantially less than and differ in nature from those performed in an audit conducted in
accordance with International Standards on Auditing. Accordingly, we do not express an audit opinion on the restated IFRS 17 and Other
Presentation Changes and Restated Financial information.
Conclusion
Based on our review, nothing has come to our attention that causes us to believe that the reviewed account balances as defined as restated
IFRS 17 and Other Presentation Changes and Restated Financial information in the opening paragraph, forming part of the Interim Financial
Information of Discovery Limited for the six months ended 31 December 2023, is not prepared, in all material respects, in accordance with
the principles of IAS 34.
KPMG Inc.
Registered Auditor
Per: Mark Danckwerts
Chartered Accountant (SA)
Registered Auditor
Director
85 Empire Road
Parktown
2193
South Africa
20 March 2024
Deloitte & Touche
Registered Auditors
Per: Stephen Munro
Chartered Accountant (SA)
Registered Auditor
Partner
5 Magwa Crescent
Waterfall City
Waterfall
2090
South Africa
20 March 2024

-- 89 of 105 --

112	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Embedded value
statement
Table 2: Value of in-force covered business
Table 1: Group embedded value
Table 3: Group embedded value earnings
Table 4: Components of Group embedded value earnings
Table 5: Experience variances
Table 6: Methodology and assumption changes
Table 7: Embedded value of new business
Table 9: Embedded value sensitivity
Table 8: Embedded value economic assumptions
Table 10: Value of new business sensitivity

-- 90 of 105 --

113
Embedded value statement
for the six months ended 31 December 2023
The embedded value of the Discovery Group consists of the following components:
 the adjusted net worth attributed to the business at the valuation date;
 plus: the present value of expected future shareholder cash flows from the in-force covered business;
 less: the cost of required capital.
The present value of future shareholder cash flows from the in-force covered business is calculated as the value of projected future after-tax
shareholder cash flows of the business in-force at the valuation date, discounted at the risk discount rate.
The required capital are the assets attributed to the covered business above the amount required to back covered business liabilities, whose
distribution to shareholders is restricted as they are allocated to cover regulatory and internal capital requirements.
The value of new business is the present value, at the point of sale, of the projected future after-tax shareholder cash flows of the new
business written by the Discovery Group, discounted at the risk discount rate, less an allowance for the reserving strain, initial expenses and
cost of required capital. The value of new business is calculated using the current reporting date assumptions.
The embedded value includes the insurance and administration profits of the covered business in the Discovery Group. Covered business
includes business written in South Africa through Discovery Life (“Life”), Discovery Invest (“Invest”), Discovery Health (“Health”) and Discovery
Vitality (“Vitality”), and in the United Kingdom through VitalityLife and VitalityHealth. For Vitality Group, Ping An Health Insurance, Discovery
Insure, Discovery Bank and Umbrella Funds, no published value has been placed on the current in-force business.
In August 2011, the Discovery Group raised R800 million through the issue of non-cumulative, non-participating, non-convertible preference
shares. For embedded value purposes this capital, net of share issue expenses, has been excluded from the adjusted net worth.
IFRS 17 Insurance Contracts became effective for the Discovery Group from 1 July 2023, with comparative restatement of the preceding year,
namely the financial year ended 30 June 2023, including a restatement of the opening Group statement of financial position as at 1 July 2022.
The change in the accounting standard does not have a material impact on the embedded value for covered businesses. In respect of non-
covered businesses which were impacted by the transition to IFRS 17, such as Discovery Insure and Ping An Health Insurance, the transitional
impacts to the Group’s shareholder funds were experienced which would serve to change previously disclosed embedded values. These
changes are immaterial in aggregate, and so the disclosure of prior periods in the embedded value statement have not been restated. The
cumulative effect of the changes were recognised in the period for the six months ended 31 December 2023.
TABLE 1: GROUP EMBEDDED VALUE
R million
31 December
2023
31 December
2022
%
change
30 June
2023
Shareholders’ funds1 	52 206 	57 184 	(9) 	63 974
Adjustment to shareholders’ funds from published basis2 	(33 141) 	(41 885) 	(21) 	(45 688)
Adjusted net worth3 	19 065 	15 299 	25 	18 286
Value of in-force covered business before cost of required capital 	87 915 	80 678 	9 	83 906
Cost of required capital 	(3 500) 	(3 518) 	(1) 	(4 016)
Discovery Group embedded value 	103 480 	92 459 	12 	98 176
Number of shares (millions) 	662.1 	658.4 	658.4
Embedded value per share 	R156.29 	R140.43 	11 	R149.11
Diluted number of shares (millions) 	663.7 	667.0 	661.3
Diluted embedded value per share4 	R155.92 	R138.63 	12 	R148.45
1 Shareholders’ funds and the adjustment to shareholders’ funds from the published basis for the comparative periods are on an IFRS 4 basis. The key
differences in the adjustment to shareholders’ funds from the published basis between an IFRS 17 and IFRS 4 basis include the change to the net assets
under insurance contracts for Life and VitalityLife and the recapture of the FinRe Liability and allowance for a deferred acquisition cost asset for
VitalityHealth.
2 A breakdown of the adjustment to shareholders’ funds is shown in the table below. Note that where relevant, adjustments have been converted using the
closing exchange rate of R23.57/GBP (June 2023: R23.99/GBP; December 2022: R20.45/GBP).
R million
31 December
2023
31 December
2022
30 June
2023
Life net assets under insurance contracts 	(17 225) 	(25 721) 	(25 491)
Vitality Life Limited net assets under insurance contracts 	(8 739) 	(9 415) 	(12 051)
VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax) 	(4 162) 	(3 848) 	(5 001)
VitalityLife receivable relating to the Unemployment Cover benefit (net of deferred tax) 	(12) 	(10) 	(13)
Goodwill relating to the acquisition of Standard Life Healthcare and the PAC joint venture 	(2 916) 	(2 531) 	(2 969)
Intangible assets (net of deferred tax) in covered businesses 	(820) 	(867) 	(893)
Net preference share capital 	(779) 	(779) 	(779)
Reversal of 1 Discovery Place IFRS 16 financial lease accounting 	1 406 	1 260 	1 333
Equity settled share based payment mark-to-market adjustment 	106 	26 	176
(33 141) 	(41 885) 	(45 688)
In respect to the table directly above:
• Prior to 31 December 2023, the adjustment for “VitalityHealth and Vitality Health Insurance Limited deferred acquisition costs (net of deferred tax)” also
included the adjustment for the FinRe Liability which has since been recaptured.
• The “equity settled share based payment mark-to-market adjustment” reflects the difference between the provision in the IFRS equity and the mark-to-
market value of the equity settled share based payments.

-- 91 of 105 --

114	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
3 The following table sets out the capital position of the covered businesses with the required capital on a consistent basis to that used in the embedded value:
R million
31 December
2023
31 December
2022
30 June
2023
Shareholders’ funds 	52 206 	57 184 	63 974
Adjustment to shareholders’ funds 	(33 141) 	(41 885) 	(45 688)
Adjusted net worth 	19 065 	15 299 	18 286
Excess of available capital over adjusted net worth 	45 771 	36 860 	40 336
Available capital 	64 836 	52 159 	58 622
Required capital 	43 197 	39 272 	41 987
Excess available capital 	21 639 	12 887 	16 635
The excess of available capital over adjusted net worth reflects the difference between the adjusted net worth for embedded value purposes and the available
capital on a statutory solvency basis for covered business. This includes:
– The net preference share capital of R779 million which is included as available capital.
– The difference between Vitality Life Limited’s Solvency II Pillar 1 Own Funds and its adjusted net worth.
– The difference between Life’s Pillar 1 Own Funds and its adjusted net worth.
The following table sets out the required capital for each of the covered businesses:
R million
31 December
2023
31 December
2022
30 June
2023
Health and Vitality 	1 159 	1 067 	1 108
Life and Invest 	27 716 	25 872 	26 011
VitalityHealth 	4 312 	3 235 	4 238
VitalityLife 	10 010 	9 098 	10 630
Total required capital 	43 197 	39 272 	41 987
– For Health and Vitality, the required capital was set equal to two times the monthly renewal expense and Vitality benefit cost.
– For Life and Invest, the required capital was set equal to 1.25 times the SAM Pillar 1 Solvency Capital Requirement.
– For VitalityHealth, the required capital amount was set equal to 1.35 times the Solvency II Pillar 1 Solvency Capital Requirement.
– For the VitalityLife business on the PAC licence, prior to 31 December 2023, the required capital was set equal to 1.5 times the UK Solvency I long-term
insurance capital requirement as per the agreement with PAC following the long-term delay of the Part VII transfer. From 31 December 2023 the VitalityLife
business on the PAC license is classified as an insurance contract under IFRS 17. In line with the terms of the contract, the 1.5 times the UK Solvency I
long-term insurance capital requirement is now reserved for. As a result, this amount no longer contributes to Required Capital in the embedded value,
reducing the cost of capital, and the release of the reserve is included in the value of in-force. For the business sold on the Vitality Life Limited licence, the
required capital was set equal to 1.4 times the Solvency II Pillar 1 Solvency Capital Requirement.
4 The diluted embedded value per share adjusts for the effect of vested treasury shares, share options exercised, and vesting of share awards where the
impact is dilutive. This adjustment has been aligned to the diluted number of shares shown elsewhere in the financial statements. Disclosure of prior periods
in the embedded value statement have been restated accordingly.
Embedded value statement continued
for the six months ended 31 December 2023

-- 92 of 105 --

115
TABLE 2: VALUE OF IN-FORCE COVERED BUSINESS
R million
Value before cost of
required capital
Cost of required
capital
Value after cost of
required capital
at 31 December 2023
Health and Vitality 	26 268 	(516) 	25 752
Life and Invest1 	35 051 	(1 763) 	33 288
VitalityHealth 2 	13 964 	(750) 	13 214
VitalityLife 2 	12 632 	(471) 	12 161
Total 	87 915 	(3 500) 	84 415
at 31 December 2022
Health and Vitality 	26 406 	(493) 	25 913
Life and Invest1 	34 164 	(1 510) 	32 654
VitalityHealth 2 	10 586 	(569) 	10 017
VitalityLife2 	9 522 	(946) 	8 576
Total 	80 678 	(3 518) 	77 160
at 30 June 2023
Health and Vitality 	25 985 	(512) 	25 473
Life and Invest1 	33 301 	(1 665) 	31 636
VitalityHealth2 	12 797 	(698) 	12 099
VitalityLife2 	11 823 	(1 141) 	10 682
Total 	83 906 	(4 016) 	79 890
1 Included in the Life and Invest value of in-force covered business is R2 080 million (June 2023: R2 005 million; December 2022: R1 889 million) in respect of
investment management services provided on off balance sheet investment business. The net assets of the investment service provider are included in the
adjusted net worth.
2 The value of in-force has been converted using the closing exchange rate of R23.57/GBP (June 2023: R23.99/GBP; December 2022: R20.45/GBP).

-- 93 of 105 --

116	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Embedded value statement continued
for the six months ended 31 December 2023
TABLE 3: GROUP EMBEDDED VALUE EARNINGS
Six months ended 	Year ended
R million
31 December
2023
31 December
2022
30 June
2023
Embedded value at end of period 	103 480 	92 459 	98 176
Less: embedded value at beginning of period 	(98 176) 	(86 258) 	(86 258)
Increase in embedded value 	5 304 	6 201 	11 918
Dividends paid 	783 	31 	69
Transfer to hedging reserve 	70 	(32) 	(76)
Employee share option schemes 	(306) 	(178) 	(553)
IFRS 17 impact on non-covered businesses1 	(79) 	– 	–
Acquisition of subsidiaries with non-controlling interest 	– 	(1) 	(6)
Embedded value earnings 	5 772 	6 021 	11 352
Annualised return on opening embedded value 	12.1% 	14.4% 	13.2%
1 The embedded value for prior periods has not been restated for the transition to IFRS 17. This item represents the difference between IFRS 4 and IFRS 17
equity on non-covered business, such as Discovery Insure (decrease in equity at 30 June 2023) and Ping An Health Insurance (increase in equity at
30 June 2023), and an opening IFRS balance sheet restatement as a result of prior period errors (decrease in equity at 30 June 2023). These impacts largely
offset as at 30 June 2023. These impacts have not been included in the embedded value earnings and so a minor adjustment is required to reconcile the
change from the embedded value at the beginning of the period.
TABLE 4: COMPONENTS OF GROUP EMBEDDED VALUE EARNINGS
Six months ended 31 December 2023
Six months
ended
31 December
2022
Year
ended
30 June
2023
R million
Net
worth
Cost of
required
capital
Value of
in-force
covered
business
Embedded
value
Embedded
value
Embedded
value
Total profit from new business
(at point of sale) 	(2 512) 	(154) 	3 350 	684 	940 	1 440
Profit from existing business
– 	Expected return 	3 695 	(39) 	1 369 	5 025 	3 965 	8 589
– 	Change in methodology and assumptions1 	965 	626 	(925) 	666 	(237) 	(4 854)
– 	Experience variances 	208 	55 	616 	879 	2 073 	3 204
Impairment, amortisation and fair value
adjustment2 	(30) 	– 	– 	(30) 	(29) 	(67)
Increase in goodwill and intangibles 	(110) 	– 	– 	(110) 	(151) 	(263)
Other initiatives3 	78 	– 	11 	89 	(220) 	24
Non-recurring expenses 	(159) 	– 	– 	(159) 	(106) 	(193)
Acquisition costs4 	(17) 	– 	(2) 	(19) 	(20) 	(48)
Finance costs 5 	(1 662) 	– 	– 	(1 662) 	(1 324) 	(2 848)
Foreign exchange rate movements 6 	(96) 	24 	(406) 	(478) 	599 	5 070
Other7 	(6) 	– 	– 	(6) 	(5) 	90
Return on shareholders’ funds5, 8 	893 	– 	– 	893 	536 	1 208
Embedded value earnings 	1 247 	512 	4 013 	5 772 	6 021 	11 352
1 The changes in methodology and assumptions will vary over time to reflect adjustments to the model and assumptions as a result of changes to the
operating and economic environment. The current period’s changes are described in detail in Table 6 below (for previous periods refer to previous embedded
value statements).
2 This item reflects the amortisation of the intangible assets reflecting the banking costs, Cambridge Mobile Telematics system spend and capital expenditure
in Discovery Group Europe Limited.
3 This item includes the profits of non-covered businesses (including Discovery Insure, Vitality Group and Ping An Health Insurance) and costs of start-up
businesses (including Discovery Bank, a commercial offering in Discovery Insure, and an Umbrella Fund offering in Invest). Head office costs which relate to
non-covered business are included in this item, as well as cR77 million of expenses which are currently incurred by the covered businesses but will be met by
non-covered businesses in due course, and hence have not been included in the relevant covered businesses’ embedded value expense analysis.
4 Acquisition costs relate to commission paid on the Life and Invest business and expenses incurred in writing Health and Vitality business that has been
written over the period but will only be activated and on risk after the valuation date. These policies are not included in the embedded value or the value of
new business and therefore the costs are not deducted from the value of new business.
5 Finance costs and return on shareholders’ funds are shown gross of intercompany charges (R781 million at 31 December 2023, R538 million at
31 December 2022 and R1 198 million at 30 June 2023).
6 This item includes foreign exchange gains/(losses) emerging through the income statement, in addition to translation impacts on the cost of required capital
and value of in-force.
7 This item includes, among other items, the tangible tax impact from movements in covered business intangible assets, which are excluded from the net worth.
8 The return on shareholders’ funds is shown net of tax and management charges.

-- 94 of 105 --

117
TABLE 5: EXPERIENCE VARIANCES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Renewal expenses 	68 	– 	11 	(2) 	(55) 	– 	1 	– 	23
Lapses and surrenders 1, 2 	(2) 	(133) 	19 	99 	– 	235 	(95) 	137 	260
Mortality and morbidity 	– 	– 	(22) 	(10) 	(71) 	– 	72 	– 	(31)
Policy alterations2 	– 	(10) 	(323) 	28 	– 	– 	(1) 	(41) 	(347)
Backdated cancellations 	– 	– 	– 	– 	– 	– 	– 	– 	–
Premium and fee income 3 	73 	– 	(49) 	201 	63 	– 	(34) 	(51) 	203
Inflation-linked indexation 	– 	– 	(3) 	(82) 	– 	– 	– 	218 	133
Economic 4 	– 	– 	37 	(84) 	100 	– 	– 	– 	53
Commission 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 5 	50 	– 	75 	(69) 	3 	– 	37 	– 	96
Reinsurance6 	– 	– 	– 	– 	(1) 	– 	(51) 	(60) 	(112)
Maintain modelling term7 	– 	160 	– 	55 	– 	48 	– 	– 	263
Vitality benefits 	41 	– 	– 	– 	– 	– 	4 	– 	45
Other8 	53 	(1) 	36 	33 	92 	– 	80 	– 	293
Total 	283 	16 	(219) 	169 	131 	283 	13 	203 	879
1 For VitalityHealth, the lapse and surrender experience reflect improved retention rates from strong premium increases and expansion of existing schemes.
For Health & Vitality, the lapse and surrender experience was driven by an increase in the number of employer groups who have widened the eligible
schemes that employees can join beyond the Discovery Health Medical Scheme. Better than expected lapse experience has been observed for the other
covered businesses.
2 For Life and Invest, the policy alterations experience relates mainly to persistent pressures within the economic environment. This is partially offset by positive
experience on lapses.
3 Other than higher than expected premium and fee income, this experience variance item includes the impact of positive integration experience for individual
life business in Life.
4 For Life and Invest, the experience includes lower than expected growth in asset values in the Invest business. For VitalityHealth, investment return continued
to contribute to profitability as interest rates in the UK remain high.
5 The tax variance arises due to the timing difference between the expected tax payments and actual payments.
6 For VitalityLife, the reinsurance experience includes an increase in reinsurance premium provisions related to prior periods, and the greater than expected
cost of financing reinsurance.
7 For Health and Vitality, Life and Invest, and VitalityHealth, the projection term is rebased at each year-end. Therefore, an experience variance arises because
the total term of the in-force covered business is effectively increased by six months.
8 The key Other experience relates to cash flow timing variances in Life and Invest and profits / losses from companies within the Health, VitalityHealth and
VitalityLife segments which are not part of covered business.

-- 95 of 105 --

118	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Embedded value statement continued
for the six months ended 31 December 2023
TABLE 6: METHODOLOGY AND ASSUMPTION CHANGES
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
R million
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force
Net
worth
Value of
in-force 	Total
Modelling changes 1 	– 	– 	12 	(98) 	– 	– 	– 	241 	155
Expenses 	– 	– 	– 	– 	– 	– 	– 	– 	–
Lapses 	– 	– 	– 	– 	– 	– 	– 	– 	–
Mortality and morbidity 	– 	– 	– 	– 	– 	– 	– 	– 	–
Benefit changes 	– 	– 	– 	– 	– 	– 	– 	– 	–
Vitality 	– 	– 	– 	– 	– 	– 	– 	– 	–
Tax 	– 	– 	– 	– 	– 	– 	– 	– 	–
Economic assumptions 2 	– 	(840) 	20 	(668) 	– 	643 	– 	971 	126
Premium and fee income 	– 	84 	– 	– 	– 	– 	– 	– 	84
Reinsurance and financing3 	– 	– 	693 	(638) 	– 	– 	– 	9 	64
Other 4 	– 	– 	324 	216 	– 	– 	(84) 	(219) 	237
Total 	– 	(756) 	1 049 	(1 188) 	– 	643 	(84) 	1 002 	666
1 For Life and Invest, the item reflects refinements to the data and models. For VitalityLife, the item reflects the reduction in cost of capital due to the
implementation of the Solvency UK Risk Margin Reforms.
2 For Health and Vitality, and Life and Invest, the economic assumptions were updated in line with observed market nominal and real yield risk-free curves at
31 December 2023. For VitalityLife, the item includes the impact of updating the assumptions relative to the Solvency II yield curves and the IFRS interest
rates. Note that for VitalityLife, following the implementation of IFRS 17, the risk-free rate assumption is based on the Solvency II yield curves instead of a
single interest rate derived from the curves. For VitalityHealth, the impact of updating the assumptions relative to the Solvency II yield curves results in an
increase to the annuity factor.
3 For Life and Invest, the reinsurance and financing item primarily relates to the impact of financing arrangements, where the future expected cash flows
arising from part of the negative reserves are monetised to match other positive policy liabilities.
4 The Other item includes, among other things, second order impacts relating to the adoption of IFRS 17 for covered business, which have not been captured
as part of the opening IFRS equity restatement, such as taxation phasing and reallocations identified as part of the transition.

-- 96 of 105 --

119
TABLE 7: EMBEDDED VALUE OF NEW BUSINESS
Six months ended 	Year ended
R million
31 December
2023
31 December
2022
%
Change
30 June
2023
Health and Vitality
Present value of future profits from new business (at point of sale) 	406 	531 	954
Cost of required capital 	(21) 	(20) 	(39)
Present value of future profits from new business (at point of sale)
after cost of required capital 	385 	511 	(25) 	915
New business annualised premium income1 	2 200 	2 238 	(2) 	4 959
Life and Invest
Present value of future profits from new business (at point of sale)2 	287 	377 	516
Cost of required capital 	(45) 	(48) 	(87)
Present value of future profits from new business (at point of sale)
after cost of required capital 	242 	329 	(26) 	429
New business annualised premium income3 	1 576 	1 496 	5 	2 965
Annualised profit margin4 	2.0% 	2.8% 	1.8%
Annualised profit margin excluding Invest business 	4.3% 	4.5% 	2.5%
VitalityHealth 5
Present value of future profits from new business (at point of sale) 	245 	80 	269
Cost of required capital 	(53) 	(38) 	(87)
Present value of future profits from new business (at point of sale)
after cost of required capital 	192 	42 	357 	182
New business annualised premium income6 	1 190 	884 	35 	2 001
Annualised profit margin4 	2.5% 	0.7% 	1.4%
VitalityLife 7
Present value of future profits from new business (at point of sale) 	(100) 	104 	3
Cost of required capital 	(35) 	(46) 	(89)
Present value of future profits from new business (at point of sale)
after cost of required capital 	(135) 	58 	(333) 	(86)
New business annualised premium income 	667 	540 	24 	1 124
Annualised profit margin4 	(2.8%) 	1.4% 	(1.0%)
1 Health new business annualised premium income is the gross contribution to the medical schemes. The new business annualised premium income shown
above excludes premiums in respect of members who join an existing employer where the member has no choice of medical scheme, as well as premiums in
respect of new business written during the period but only activated after 31 December 2023.
The total Health and Vitality new business annualised premium income written over the period, inclusive of Sasolmed, was R7 052 million (June 2023:
R9 051 million; December 2022: R4 604 million).
2 Included in the Life and Invest embedded value of new business is -R3 million (June 2023: R21 million; December 2022: R7 million) in respect of investment
management services provided on off balance sheet investment business.
Risk business written prior to the valuation date allows certain Invest business to be written at financially advantageous terms, the impact of which has been
recognised in the value of new business.
3 Life new business is defined as Life policies to which Life became contractually bound during the reporting period, including policies whose first premium is
due after the valuation date. Invest new business is defined as business where at least one premium has been received and which has not been refunded
after receipt. Invest new business also includes Discovery Retirement Optimiser policies to which Life and Invest became contractually bound during the
reporting period, including policies whose first premium is due after the valuation date.
The new business annualised premium income of R1 576 million (June 2023: R2 965 million; December 2022: R1 496 million) (single premium APE:
R741 million (June 2023: R1 430 million; December 2022: R674 million)) shown above excludes automatic premium increases and servicing increases in
respect of existing business. The total new business annualised premium income written over the period, including automatic premium increases of
R1 184 million (June 2023: R2 208 million; December 2022: R1 130 million) and servicing increases of R387 million (June 2023: R716 million;
December 2022: R363 million), was R3 147 million (June 2023: R5 889 million; December 2022: R2 990 million) (single premium APE: R778 million
(June 2023: R1 499 million; December 2022: R708 million)). Single premium business is included at 10% of the value of the single premium.
Policy alterations and internal replacement policies, including Discovery Retirement Optimisers added to existing Life Plans are shown in Table 5 as
experience variances and not included as new business. Term extensions on existing contracts are not included as new business.
4 The annualised profit margin is the value of new business expressed as a percentage of the present value of future premiums.
5 The VitalityHealth value of new business is calculated as the value at point of sale of the new business written premium in-force at the valuation date
multiplied by the Margin multiplied by the Annuity Factor less the new business cash flows from point of sale to the valuation date. The assumptions for the
Margin and Annuity Factor are shown in Table 8.
6 VitalityHealth new business is defined as individuals and employer groups which incepted during the reporting period. The new business annualised
premium income shown above has been adjusted to exclude premiums in respect of members who join an existing employer group after the first month, as
well as premiums in respect of new business written during the period but only activated after 31 December 2023.
7 VitalityLife new business is defined as policies to which VitalityLife became contractually bound during the reporting period, including policies whose first
premium is due after the valuation date.

-- 97 of 105 --

120	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Embedded value statement continued
for the six months ended 31 December 2023
Basis of preparation
TABLE 8: EMBEDDED VALUE ECONOMIC ASSUMPTIONS
31 December
2023
31 December
2022
30 June
2023
Beta coefficient 	0.75 	0.75 	0.75
Equity risk premium (%) 	3.5 	3.5 	3.5
Risk discount rate (%)
– 	Health and Vitality1 	15.125 	14.375 	15.125
– 	Life and Invest1 	15.625 	14.375 	15.875
– 	VitalityHealth 	5.992 	6.365 	7.000
– 	VitalityLife 	5.975 	6.399 	7.042
Rand/GBP exchange rate
Closing 	23.57 	20.45 	23.99
Average 	23.43 	20.38 	21.43
Margin over Expense inflation to derive Medical inflation (%)
South Africa 	3.00 	3.00 	3.00
Expense inflation (%)2
South Africa 	– 	Health and Vitality 	7.16 	7.82 	7.96
– 	Life and Invest 	7.72 	7.36 	8.13
United Kingdom 	3.65 	3.75 	3.75
Pre-tax investment return (%)
South Africa 	– 	Cash1 	11.50 	10.25 	11.75
– 	Life and Invest bonds3 	13.00 	11.75 	13.25
– 	Health and Vitality bonds3 	12.50 	11.75 	12.50
– 	Equity1 	16.50 	15.25 	16.75
United Kingdom 	– 	VitalityHealth risk-free rate 	3.37 	3.74 	4.38
– 	VitalityLife risk-free rate 	3.35 	3.77 	4.42
– 	VitalityLife IFRS interest rate 	3.35 	4.24 	3.98
– 	VitalityLife investment return 	4.70 	3.25 	4.31
Long-term corporation tax rate (%)
South Africa 	27 	27 	27
United Kingdom 	25 	25 	25
VitalityHealth Assumptions
– 	Margin (net of tax and cost of capital) (%) 	12.07 	12.00 	12.05
– 	Annuity Factor 	6.63 	6.49 	6.28
Projection term
– 	Health and Vitality 	20 years 	20 years 	20 years
– 	Discovery Life – VIF 	40 years 	40 years 	40 years
– 	Group Life 	20 years 	20 years 	20 years
– 	VitalityLife 	No cap 	No cap 	No cap
– 	VitalityHealth4 	20 years 	20 years 	20 years
1 Derived as a margin over (or below for cash) the respective pre-tax investment return for bonds.
2 The inflation assumption is derived as the difference between the nominal and real yield curve at each duration. As an indication, the cash flow weighted
average inflation is shown in the table. For the United Kingdom, the expense inflation assumption is aligned with the long-term market view of inflation.
3 As indications, the cash flow weighted averages derived from the relevant yield curve(s) are shown.
4 The VitalityHealth projection term of 20 years is used in the derivation of the Annuity Factor.

-- 98 of 105 --

121
The Discovery Group embedded value is calculated based on a risk discount rate using the Capital Asset Pricing Model (CAPM) approach with
specific reference to the Discovery Group beta coefficient. The assumed beta is fixed at 0.75. This has been set such that the risk discount
rate proxies the result of a Weighted Average Cost of Capital approach with reference to the capital structure of the Group and the observed
beta calculated using daily returns over a long time period. The observed beta is calculated with reference to the ALSI. The assumed beta
will only change if the capital structure of the Group and/or the observed beta calculated using daily returns over a long time period suggest
the beta assumption should depart significantly from the assumption at the financial year-end. As beta values reflect the historic
performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors may
want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly.
Life and Invest mortality, morbidity and lapse and surrender assumptions were derived from internal experience, where available,
augmented by reinsurance and industry information.
The Health and Vitality lapse assumptions were derived from the results of recent experience investigations.
The VitalityHealth assumptions were derived from internal experience.
VitalityLife assumptions were derived from internal experience, where available, augmented by reinsurance, industry and Discovery Group
information.
Renewal expense assumptions were based on the results of the latest expense and budget information.
The initial expenses included in the calculation of the embedded value of new business are the actual costs incurred excluding expenses of
an exceptional or non-recurring nature.
The South African investment return assumptions for Life, Invest, Health and Vitality were set relative to the publicly available JSE risk-free
nominal yield curve.
The current and projected tax position of the policyholder funds within the Life company has been taken into account in determining the
net investment return assumption.
The risk-free rate assumption for VitalityHealth was based on the single interest rate derived from the Prudential Regulatory Authority yield
curve. VitalityLife has transitioned to the use of full yield curves to represent its risk-free rate assumption following the implementation of
IFRS 17. The inflation rate is consistent with the long-term market view of inflation.
From 30 June 2018, VitalityHealth calculate the value of in-force at the valuation date as the in-force written premium multiplied by the
Margin multiplied by the Annuity Factor, as set out in the table above. The Annuity Factor assumption is derived from assumed future lapse
rates and premium increases. The Margin assumption reflects assumed profit margins after tax and Cost of Capital. The assumptions
underlying the Annuity Factor and Margin are set taking into account the current experience in the business at different durations.
The cost of required capital is calculated using the difference between the risk discount rate and the net of tax asset return on tangible
assets. The Vitality Life Limited required capital amount is assumed to earn the investment return assumption, which is set based on the
return on a portfolio of government and corporate bonds assumed to back the required capital. The Life and Invest cost of required capital
is calculated assuming shareholder cash flow is limited to the cash flow available after having met both the required capital amount and an
internally defined liquidity target capital requirement of tangible assets.
The embedded value has been calculated in accordance with the Actuarial Society of South Africa’s Advisory Practice Note (“APN”) 107:
Embedded Value Reporting, except the recommended disclosure of Free Surplus and Required Capital has been adjusted to take into
account the nature of the capital requirements in the covered businesses, as can be seen in Table 1 note 3.

-- 99 of 105 --

122	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023	 	123
Sensitivity to the embedded value assumptions
The risk discount rate uses the CAPM approach with specific reference to the Discovery Group beta coefficient. As beta values reflect the
historic performance of share prices relative to the market, they may not allow fully for non-market related and non-financial risk. Investors
may want to form their own view on an appropriate allowance for these risks which have not been modelled explicitly. The sensitivity of the
embedded value and the embedded value of new business at 31 December 2023 to changes in the risk discount rate is included in the tables
below.
For each sensitivity illustrated below, all other assumptions have been left unchanged. No allowance has been made for management action
such as risk premium increases where future experience is worse than the base assumptions.
TABLE 9: EMBEDDED VALUE SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Embedded
value
%
change	R million
Adjusted
net worth
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Value
of
in-force
Cost of
required
capital
Base 	19 065 	26 268 	(516) 	35 051 	(1 763) 	13 964 	(750) 	12 632 	(471) 	103 480
Impact of:
Risk discount rate + 1% 	19 065 	24 836 	(557) 	32 071 	(1 838) 	13 235 	(982) 	11 719 	(531) 	97 018 	(6)
Risk discount rate – 1% 	19 065 	27 848 	(471) 	38 560 	(1 653) 	14 771 	(491) 	13 689 	(371) 	110 947 	7
Lapses – 10% 	19 065 	27 113 	(541) 	37 976 	(1 861) 	16 460 	(884) 	13 319 	(568) 	110 079 	6
Interest rates – 1%1 	19 065 	26 404 	(498) 	35 611 	(1 736) 	14 771 	(793) 	12 362 	(621) 	104 565 	1
Equity and property market value – 10% 	19 025 	26 268 	(516) 	34 312 	(1 758) 	13 964 	(750) 	12 632 	(471) 	102 706 	(1)
Equity and property return + 1% 	19 065 	26 268 	(516) 	35 410 	(1 766) 	13 964 	(750) 	12 632 	(471) 	103 836 	–
Renewal expenses – 10% 	19 065 	28 903 	(478) 	35 740 	(1 736) 	15 031 	(750) 	12 886 	(448) 	108 213 	5
Mortality and morbidity – 5% 	19 065 	26 268 	(516) 	37 309 	(1 674) 	16 310 	(750) 	13 045 	(459) 	108 598 	5
Projection term + 1 year 	19 065 	26 571 	(521) 	35 134 	(1 769) 	14 079 	(756) 	12 632 	(471) 	103 964 	–
1 All economic assumptions were reduced by 1%.
The following table shows the effect of using different assumptions on the embedded value of new business.
TABLE 10: VALUE OF NEW BUSINESS SENSITIVITY
Health and Vitality 	Life and Invest 	VitalityHealth 	VitalityLife
Value of
new
business
%
change	R million
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Value of
new
business
Cost of
required
capital
Base 	406 	(21) 	287 	(45) 	245 	(53) 	(100) 	(35) 	684
Impact of:
Risk discount rate + 1% 	370 	(23) 	200 	(47) 	190 	(69) 	(153) 	(39) 	429 	(37)
Risk discount rate – 1% 	445 	(19) 	386 	(42) 	307 	(35) 	(39) 	(28) 	975 	43
Lapses - 10% 	434 	(23) 	385 	(48) 	411 	(62) 	538 	(41) 	1 594 	133
Interest rates – 1% 1 	412 	(20) 	287 	(44) 	307 	(56) 	(69) 	(47) 	770 	13
Equity and property return + 1% 	406 	(21) 	299 	(45) 	245 	(53) 	(100) 	(35) 	696 	2
Renewal expense – 10% 	469 	(20) 	312 	(44) 	317 	(53) 	(79) 	(33) 	869 	27
Mortality and morbidity – 5% 	406 	(21) 	331 	(43) 	403 	(53) 	(80) 	(34) 	909 	33
Projection term + 1 year 	413 	(21) 	289 	(45) 	254 	(53) 	(100) 	(35) 	702 	3
Acquisition costs – 10% 	424 	(21) 	365 	(45) 	245 	(53) 	10 	(35) 	890 	30
1 All economic assumptions were reduced by 1%.
Embedded value statement continued
for the six months ended 31 December 2023

-- 100 of 105 --

124	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
Annexure A
Income from non-insurance business lines
New business annualised premium income

-- 101 of 105 --

125
Annexure A
This Annexure does not form part of the IFRS results. Discovery assesses its performance using alternative non-IFRS profit and income
measures. These measures enhance the comparability and understanding of the financial performance of the Group.
NEW BUSINESS ANNUALISED PREMIUM INCOME
for the six months ended 31 December 2023
The new business annualised premium income (API) set out below provides a view of the scale of new business across all operations of the
Group and does not necessarily reflect the new business attributable to the legal entities within the Group. For instance, DHMS new business
is attributable to the medical scheme but is under the administration and marketing of Discovery Health which earns a fee in respect of such
services.
Core business API, increased by 28% for the six months ended 31 December 2023 when compared to the corresponding prior period.
R million
Group
December
2023
Unaudited
Group
December
2022
Unaudited
%
Change
Discovery Health1 	6 835 	4 487 	52
Discovery Life 	1 519 	1 485 	2
Individual Life 	1 444 	1 355 	7
Group Life 	75 	130 	(42)
Discovery Invest 	1 629 	1 505 	8
Discovery Insure 	666 	616 	8
Discovery Vitality 	217 	162 	34
Other initiatives2 	234 	356 	(34)
Total new business API from SA Composite 	11 100 	8 611 	29
VitalityHealth 	1 135 	890 	28
VitalityLife 	935 	801 	17
Total new business API from UK Composite 	2 070 	1 691 	22
Total new business API from VG Composite: Ping An Health Insurance (PAHI)
own license 	1 027 	804 	28
New business API of Group 	14 197 	11 106 	28
1 New business API for Discovery Health includes new business API for all businesses administered by Discovery Health, including DHMS, Closed Schemes and
offerings such as GAP cover, FlexiCare cover and African Health (prior year number restated for Africa Health).
2 Other new businesses include the Umbrella Fund and Discovery Insure commercial.
Calculation of New business API
New business API is calculated at 12 times the monthly premium for new recurring premium policies and 10% of the value of new single
premium policies It also includes both automatic premium increases and servicing increases on existing long-term insurance policies. The
amounts exclude indirect taxes.
The new business API in the table above differs from the new business API disclosed in the embedded value largely as a results of:
 The timing of inclusion of the policyholders in the calculation of new business API – in the embedded value, new business is included
from the earlier of the date that the first premium has been received or when the policy is on risk, whereas in table above, new business
is included when the policy has been contractually committed.
 ❚Inclusion of automatic premium increases and servicing increases on existing life policies – these are included in the table above but
excluded in the embedded value API values disclosed.
Refer to the footnotes to Table 7: Embedded Value of New Business for a more detailed description of the differences in new business
disclosures between the embedded value and the table above. 	.

-- 102 of 105 --

126	DISCOVERY UNAUDITED INTERIM RESULTS FOR THE SIX MONTHS ENDED 31 DECEMBER 2023
INCOME FROM NON-INSURANCE BUSINESS LINES
for the six months ended 31 December 2023
(not included in new business API definition above)
R million
Group
December
2023
Unaudited
Group
December
2022
Unaudited 	Change %
Discovery Health – Income excluded from API measure 	592 	575 	3
Discovery Bank 	933 	706 	32
Discovery Bank – Net banking fee and commission income (NIR) 	567 	438 	29
Discovery Bank – Net bank interest and similar income (NII) 	366 	268 	37
Vitality Global income1 	1 417 	1 273 	11
Vitality Network 	942 	754 	25
Vitality Health International (excluding PAHI) 	475 	519 	(8)
Total income from non-insurance business lines 	2 942 	2 554 	15
1 Vitality Global income includes gross recurring and lump sum revenues earned by Vitality Group and solution revenue from external clients, while that from
internal clients and rewards is specifically excluded.

-- 103 of 105 --

Transfer secretaries Computershare Investor Services (Pty) Limited
(Registration number: 2004/003647/07)
Rosebank Towers, 15 Biermann Avenue, Rosebank, 2196
Private Bag X9000, Saxonwold, 2132
Sponsors and debt sponsors Rand Merchant Bank (a division of FirstRand Bank Limited)
Secretary and registered office A Ceba, Discovery Limited
(Incorporated in the Republic of South Africa)
(Registration number: 1999/007789/06)
Company tax reference number: 9652/003/71/7
JSE share code: 	DSY ISIN: ZAE000022331
JSE share code: 	DSBP ISIN: ZAE000158564
JSE company code: 	DSYI
1 Discovery Place, Sandton, 2196
PO Box 786722, Sandton, 2146
Tel: (011) 529 2888 Fax: (011) 539 8003
Directors ME Tucker (UK) (Chairperson), A Gore* (Group Chief Executive), L Chiume1, R Farber, WM Hlahla, FN Khanyile, D Macready,
Dr TV Maphai2, T Mboweni, KC Ramon1, M Schreuder, B Swartzberg*, B van Kralingen, DM Viljoen* (Group Chief Financial Officer), SV Zilwa2.
* Executive.
1 Appointed effective 18 September 2023.
2 Retired effective 16 November 2023.
Debt officer DM Viljoen
Interim financial results
– prepared by G Pieterse CA(SA), J Symons CA(SA)
– supervised by DM Viljoen CA(SA)
Embedded value statement
– prepared by P Bolink FASSA
– supervised by A Rayner FASSA, FIA
Administration

-- 104 of 105 --

Discovery Limited | +27 11 529 2888 | askthecfo@discovery.co.za | www.discovery.co.za
Copyright 2021. Discovery Ltd is the licensed controlling company of the designated Discovery Insurance Group.
Registration number: 1999/007789/06. Companies in the Group are licensed insurers and authorised financial services providers.

-- 105 of 105 --